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Due to the disease burden of influenza virus types A and B, vaccines, which are 
manufactured as formalin-inactivated killed virus (KV) and live-attenuated virus 
(LAIV), are produced to provide coverage against currently circulating influenza A 
(IAV) and B (IBV) viruses. Although the licensed LAIV vaccine provides enhanced 
coverage over the KV vaccine, it is only licensed for immunocompetent individuals 
ages 2-49 years without pre-existing conditions, so individuals who are most at risk 
cannot receive it. Previously, our lab showed that incorporation of an 8 amino acid 
HA tag in frame at the C-terminus of the PB1 open-reading frame (ORF) in addition 
to the mutations found in the PB2 and PB1 segments of the licensed LAIV vaccine 
yielded a stable, efficacious alternative LAIV vaccine for IAV; however, to develop a 
complete vaccine, a corresponding IBV candidate is required. Towards this goal, a 
contemporary IBV strain, B/Brisbane/60/2008, was cloned and recovered by reverse 
genetics (RG-B/Bris).  Subsequently, it was demonstrated that the parental and RG-
  
B/Bris show similar growth kinetics in vitro.  An initial vaccine attempt, which 
combined PB2 cap-binding mutants with the HA tag in PB1, was made but led to the 
realization of the PB2 cap-binding mutations, PB2 W359F and F406Y, as virulence 
factors. In a subsequent vaccine attempt, mutations analogous to those found only in 
segment 2 of the A/Ann Arbor/6/60 cold-adapted LAIV backbone were introduced 
into the homologous segment of RG-B/Bris. The following mutations were 
introduced into the PB1 gene segment of RG-B/Bris, either in the presence or absence 
of a C-terminal HA tag: K391E, E580G, and S660A. Two viruses were rescued, 
referred to as RG-B/Bris ts and RG-B/Bris att, both containing the set of three amino 
acid mutations but differing in the absence or presence of the HA tag, respectively. 
Both viruses showed ideal attenuation, safety, and immunogenicity in DBA/2 mice 
and conferred protection against lethal IBV challenge. More importantly, RG-B/Bris 
att, but not RG-B/Bris ts, showed ideal stability with no reverting mutations over 8 
passages in eggs. Taken together, a stable, immunogenic, and live attenuated virus 
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Chapter 1: Introduction to Influenza B, Reverse Genetics and 
LAIV Vaccines 
 
1.1. General Introduction to Orthomyxoviridae 
 
Influenza B virus (IBV) causes respiratory disease in humans and belongs to 
the Orthomyxiviridae family of viruses (3, 4). As part of group V in the Baltimore 
scheme of virus classification, IBV has a negative-sense, single-stranded RNA 
genome (5). In addition to influenza B, there are five other virus types belonging to 
this family: influenza A virus, influenza C virus, Thogotovirus, Isavirus and 
Quaranjavirus (3, 6-9). All virus types within the family Orthomyxoviridae possess 
segmented genomes, each gene segment encoding at least 1 protein; influenza A 
virus, influenza B virus, and Isavirus have 8 RNA gene segments, while the influenza 
C virus genome has only 7 segments (3, 6, 10). Thogotovirus and Quaranjavirus 
possess even fewer segments, having just 6 RNA gene segments (8, 9). The 
segmented nature of the genome enables rapid divergence of each virus type through 
the swapping of virus segments amongst like virus types, and by increasing diversity 
of the virus genome, virus host range may also increase.  
 Orthmyxoviruses infect a wide host range, from oviparous animals to 
mammals, and all orthomyxoviruses, excepting Isavirus, cause disease in humans. 




among orthomyxoviruses in that they may use insect vectors. Influenza C virus 
infects humans but is not considered a major human pathogen, as it causes mild 
infection only in young children, and children beyond age 6 typically have protective 
antibodies against influenza C (11-13). Influenza A has the broadest host range of all 
orthomyxoviruses. The influenza A virus (IAV) reservoir is thought to be waterfowl, 
but it is also known to infect dogs, horses, swine, and bats among other species (14-
17). Both IAV and IBV are considered major human pathogens; furthermore, 
although influenza B has been isolated in birds and seals, the IBV host range is 
thought to be limited primarily to humans (18-23). Indeed, vaccines are manufactured 
each year to protect against IAV and IBV illness in humans (24, 25).  
 




 IBV is most closely related to influenza A and C viruses within the 
Orthomyxoviridae family, and IAV and IBV are more closely related. The IAV and 
IBV major antigenic surface gene, hemagglutinin (HA), diverged 4,000 years ago 
while the major antigenic surface gene of influenza C, hemagglutinin-esterase (HE), 
diverged 8,000 years ago (26). These divergence times are earlier than previous 
estimates but have high bootstrap values indicating that these values are reliable (27). 
IBV is one of the major causes of respiratory illness in humans. Symptoms 
associated with IBV infection are fever, cough, muscle aches, malaise, congestion 
and sore throat (28, 29). The incidence of IBV-related illness varies seasonally, as 




31). Each year, the significant morbidity and mortality influenza B causes is 
profound, particularly in infants and the elderly. For example, in the U.S. from 2004-
2011 (excluding the 2009-10 influenza A pandemic), 22-44% of all pediatric 
influenza-related deaths were IBV-related (28). Additionally, hospitalization rates due 
to influenza B illness from 1979/80-2000/01 occurred at a rate of 83.4/100,000 cases, 
making IBV hospitalization rates during this period higher than seasonal influenza A 
H1N1 virus but lower than influenza A H3N2 virus (4).  
 The prevalence of IBV virus tends to be lower than that of IAV; however, this 
does not diminish its impact on human health. Indeed, every 3 years influenza B is 
actually more prevalent than influenza A (32). Even during years when influenza B is 
less prevalent, it has been documented to account for a disproportionately large 
number of pediatric fatalities. For example, during the 2010-11 influenza season, IBV 
accounted for 38% of all influenza-associated pediatric deaths despite accounting for 
only 26% of all circulating influenza viruses (33). For this reason, regardless of the 
prevalence of influenza B in a given year, it is represented in the seasonal influenza 
vaccine (24). 
 IBV vaccine manufacture is complicated by the fact that the virus has an 
error-prone RNA polymerase with no proofreading capabilities, as well as a 
segmented genome. These features generate diversity by the accumulation of 
mutations, antigenic drift, and the exchange of viral RNA (vRNA) segments, 
reassortment (34). Multiple strains of IBV circulate throughout the year, leading to 




Due to the high mutability of these viruses, virus surveillance is carried out 
throughout the year to determine the most prevalent strains of IBV in circulation (35). 
Each fall, the World Health Organization (WHO) makes recommendations as to 
which viruses should be included in the seasonal influenza vaccine, which is 
comprised of 2 strains of IAV and 2 strains of IBV (35-37). Vaccines are produced in 
two primary formulations, formalin-treated inactivated/killed virus (KV) and live-






1.3. Genomic organization and encoded proteins of influenza B 
 
 1.3.1. Genomic organization 
 
 The IBV genome is 14.548 kb in length, making it the largest viral genome of 
the influenza virus types (38). The 8 segments of its genome are numbered 1-8 based 
on the movement of each RNA segment in a polyacrylamide gel (39, 40). Segments 
1-8 correspond to the PB1, PB2, PA, HA, NP, NA, M and NS segments, respectively 
(39, 40)(Fig. 1.1). Segments 1-3, the PB1, PB2 and PA genes, correspond to the viral 
RNA-dependent RNA polymerase (RdRp) (41, 42). Segments 4 and 6 correspond to 
the HA and NA surface genes, respectively; segment 6 also encodes NB, an ion 
channel protein (43-45). NP, the nucleoprotein that coats and stabilizes the vRNA 
segments, is encoded by segment 5 (46). Segment 7, the M gene, encodes BM1 and 
BM2 by a stop-start translation mechanism (47). The eighth and final segment, NS, 
encodes BNS1, an antagonist of the innate immune response, and BNS2 (also known 
as NEP), the nuclear export protein, by a post-transcriptional splicing mechanism (48-
50).  
Each of the 8 vRNA gene segments consists of a coding region flanked by 5’ 
and 3’ untranslated regions (UTRs). The first 9 nucleotides at the 3’ end UTR of the 
vRNA of all IBV gene segments are highly conserved, as are the extreme termini of 
the 5’ end of the vRNA (2, 51-53). These conserved 5’ and 3’ ends have partial 
inverted complementarity and have been shown to interact (51, 54). The interaction of 




forming a panhandle structure (54-56). It has been proposed that IBV may also 
assume a corkscrew structure; this is based on studies demonstrating that IAV, which 
has similar partial inverted complementarity of its UTRs, forms both panhandle and 
corkscrew structures (39, 51, 56, 57).  
IBV 5’ and 3’ UTRs are unique in length, being on average longer than those 
of IAV, a feature that may affect transcription. Indeed, mutational analyses of the 
influenza B panhandle region have shown that IBV tolerates greater variability in 
sequence than has been shown for IAV without any detrimental affects on 
transcription (53, 55).  






Figure 1.1. Influenza Genome. All 8 RNA segments and the encoded 
proteins are shown. Segments are 1, 2, 3, 4, 5, 6, 7, and 8 (from top to 




1.3.2. Influenza B encoded proteins 
 
  
The 8 vRNA segments of influenza B virus encode 11 proteins. Each gene 
segment encodes at least 1 protein with 3 segments encoding 2 proteins each (40, 44, 
47, 48). The gene segments can be divided into backbone genes (PB1, PB2, PA, HA, 
NP, M and NS) and surface genes (HA and NA).   
PB1, polymerase basic protein 1, contains the polymerase active site and 
catalyzes cRNA, vRNA and mRNA transcription (41, 58, 59). PB1 works 
synergistically with PB2, polymerase basic protein 2, and PA, polymerase acidic 
protein, to perform these functions. PB2 is responsible for binding the host 5’ pre- 
mRNA cap, which is a crucial step for viral mRNA transcription as the cap acts as a 
primer for extension (60, 61). Once PB2 binds the cap, PA, an endonuclease, cleaves 
the cap, and then, PB1 initiates transcription (41, 58, 59, 62). Together, PB1, PB2 and 
PA form the RdRp which is bound to every vRNA segment, and the RdRp interacts 
with NP, a nucleoprotein that coats and stabilizes each segment, to form the viral 
ribonucleoprotein complex (vRNP)(63-66). 
The remaining segments of the virus backbone, M and NS, encode 2 proteins 
each. The M segment encodes BM1 and BM2 via a stop-start translation mechanism, 
in which the start signal of BM2 overlaps the stop signal of BM1 (47). BM1 is a 
matrix protein that provides structure to the influenza B virion but is also involved in 
nuclear import and export (49, 67, 68). BM2, in contrast, is an integral membrane ion 
channel protein whose primary function is the acidification of the influenza B virion 




BNS2/NEP, nuclear export protein, via a post-transcriptional splicing mechanism 
(48-50, 71). The splicing mechanism functions such that BNS1 and BNS2 share a 5’ 
leader sequence in the mRNA that is 75 nucleotides in length. The remainder of 
BNS2 is translated by a +1 frame shift in the BNS1 open reading frame, and then the 
BNS2 transcript is spliced at the 5’ and 3’ ends to yield a smaller product than BNS1  
(ORF)(48, 72).  
Segment 4 is a surface gene that encodes just one protein, hemagglutinin (HA) 
(40). HA is a major antigenic protein and is also responsible for binding the host cell 
receptor, alpha 2,6 sialic acid on the surface of host respiratory epithelial cells (43, 
73, 74). In the 1980s, the antigenicity of the HA of influenza B virus diverged into 
two lineages (75). This divergence led to the categorization of IBV strains based on 
the sequence homology and antigenicity of the HA to either B/Yamagata/16/88 or 
B/Victoria/2/87, the prototypical strains of the B/Yamagata-like and B/Victoria-like 
lineages, respectively (75). As the major antigenic protein, HA is key in vaccine 
development; nevertheless, due to the lack of cross-reactivity between these lineages, 
a vaccine with an HA mismatched to the currently circulating strain will not protect 
vaccinees (28, 76, 77).  
The two remaining IBV proteins, NA and NB, are encoded from segment 6. 
NA, neuraminidase, is a surface protein which is responsible for cleaving sialic acid 
moieties from glycoproteins that coat the surface of the host cell releasing newly 
budded virions (78-80). In addition to being a sialidase, NA is immunogenic, 
although it is not considered to be a major antigenic protein (81, 82). Unlike NA, NB, 




channel protein (44, 83, 84). Although the function of NB within the viral life cycle 
has not been elucidated, the structure of NB is similar to BM2, so it is speculated that 






1.4. Influenza B virus life cycle and immune response to infection 
 
1.4.1. Virus attachment and entry 
 
 The IBV life cycle begins with the attachment of the HA homotrimer to the 
host cell surface (Fig. 1.2) (43). In order to be infectious, however, HA must first be 
cleaved by trypsin-like proteases located in the human upper respiratory tract; 
consequently, prior to attachment, HA0 is cleaved into the HA1 globular head and 
HA2 stalk region, which remain bound by disulfide bonds (86-91). Attachment 
occurs via HA recognition of the terminal alpha 2,6 sialic acid bound to glycoproteins 
of human respiratory epithelial cells. Mutations in the HA sialic acid binding sites 
alter the HA preference for sialic acid from alpha 2,6 to alpha 2,3 sialic acid (the 
receptor for avian IAV); regions identified as important for receptor binding are 
located in the HA1 globular head, particularly in the 120, 150 and 160 loops and the 
190 helix region (92, 93). Although influenza B virus is known to bind primarily to 
alpha 2,6 sialic acids, it should be noted that B/Victoria-like viruses, in particular, are 
capable of naturally binding alpha 2,3 and alpha 2,6 sialic linkages (74). Despite 
some variability in sialic acid preference, the base of the receptor binding site is 
highly conserved at 4 amino acids in all IBV strains: F95, Y158, H191 and Y202 
(92).    
 Entry of the influenza B virion is thought to occur via receptor-mediated 
endocytosis (89-91, 94). Upon HA binding with sialic acid on the surface of the host 




dependent, as IAV entry has been shown to be clathrin-mediated and all known 
mechanisms of IBV entry are also found in influenza A (86, 94-98). Upon 
endocytosis of the virion, the successful trafficking of the endosome requires protein 
kinase C (PKC), which has been shown to regulate the function of the late endosome 
(99). Indeed, inhibition of PKC inhibits IBV entry (98). As the endosome matures 
into the low pH environment of the late endosome (pH 5.5), a conformational change 
is triggered in the HA protein in which the fusion peptide present in the HA2 stalk 
region becomes exposed and inserts itself into the endosomal membrane (94, 95, 97). 
Fusion of the viral and the endosomal membranes exposes the contents of the virion, 
the vRNPs, to the cytoplasm (95, 100). During this process, proton pumps, BM2 and 
likely also NB, pump protons into the virion, acidifying it and causing the release of 
the vRNPs by BM1 (45, 69, 85, 101-103). At this stage, the contents of the virion are 







Figure 1.2. Influenza B virus life cycle. HA of influenza B binds to sialic acid, 
and the virus particle is endocytosed. The endosome matures and acidifies. Then, 
BM2 and NB pump protons into the influenza virion, and acidification causes a 
conformational change in the HA. Next, the HA2 fusion peptide fuses the 
endosomal and the viral membranes, exposing the vRNPs to the cytoplasm. BM1 
releases the vRNPs into the cytoplasm. Then, NP and BM1 facilitate the import 
of vRNPs into the nucleus using a series of host proteins. Once in the nucleus, 
the viral RdRp, snatches the host pre-mRNA caps, and viral mRNAs are 
transcribed. vRNA is also synthesized. Next, viral mRNA and vRNPs are 
exported from the nucleus. vRNPs are exported through an association with 
BM1 and NEP, and NEP interacts with CRM1 to export the vRNPs out of the 
nucleus. Viral mRNAs are translated using host machinery at the ER and are 
subsequently packaged in the Golgi and sent to the plasma membrane (HA, NA, 




1.4.2. Nuclear import 
 
 The IBV life cycle relies on host cell machinery in the nucleus, thus nuclear 
import of viral proteins and vRNA is required. Indeed, NP, BM1, and the polymerase 
proteins of influenza B virus have all been shown to enter the nucleus (68, 104, 105).  
Localization to the nucleus requires nuclear localization signals (NLS). The 
nuclear localization signals of NP and BM1 have recently been defined, and while 
nuclear localization signals for PB2, PB1 and PA remain undefined, these polymerase 
proteins have been shown to localize to the nucleus in binary complexes PA-PB1, 
PA-PB2 and PB1-PB2 (68, 104, 105). Interestingly, although PB2 localizes 
exclusively to the nucleus, PA and PB1 have been identified in the cytoplasm (105). 
The elucidation of host and viral proteins involved in mediating nuclear 
import of influenza B vRNP complexes requires further study; however, BM1 seems 
to play an important role. It has been shown to interact with host protein, importin α, 
part of the nuclear import machinery, and has also been shown to be a nuclear shuttle 
protein, having been identified moving back and forth between the cytoplasm and the 
nucleus during the early stages of viral replication (68). Based on influenza A 
research, in which importin α recognizes the NLS on the vRNP complex and interacts 
with importin β to shuttle the vRNPs across the nuclear pores of the nuclear envelope 
into the nucleus, it is possible that BM1 mediates the interaction between the vRNP 
complex and importin α through its NLS which would be consistent with BM1 acting 
as a shuttle protein (68, 106, 107). In this way, BM1 may transport the complex into 
the nucleus before releasing the vRNP only to move back to the cytoplasm and 




through an interaction with importin α as has been shown in influenza A. Once the 
vRNP complexes have entered the nucleus, viral transcription and replication can 
begin.  
 
1.4.3. Transcription, replication and translation 
 
 Once in the nucleus, IBV must produce viral mRNA, cRNA and vRNA in 
order to produce progeny virion. Viral mRNA is produced first, and its transcription 
is initiated by the viral RdRp. Transcription of the viral genome begins with PB2 cap-
binding to the host 5’ pre-mRNA cap and cleavage of the cap by PA as described 
previously (60-62). IBV cleaves methylated and unmethylated 5’ caps, m7 GpppG-
RNA and GpppG-RNA, respectively (61). The cap acts at a primer for transcription 
and is also required for the viral transcripts to be translated by host ribosomes. In 
addition to possessing a cap, all viral mRNA transcripts are polyadenylated by a 
stuttering mechanism in which the polymerase moves back and forth over a stretch of 
uracils generating a Poly-A tract at the 3’ end of each mRNA transcript (108, 109). 
Viral mRNA transcripts are then either further processed by the spliceosome, as in the 
case of segment 8, or immediately exported out of the nucleus to be translated by the 
ribosome (48). 
 Transcription of cRNA and vRNA occurs after viral mRNA transcription, 
although it is unclear how the transition occurs. It has been hypothesized that NP may 
play a role in switching from mRNA transcription to cRNA transcription, as NP has 




cRNA transcripts are transcribed to serve as templates for the production of vRNA 
but are not incorporated into the virion; only vRNA transcripts become incorporated 
into the virion (112). During cRNA and vRNA transcription, neither transcripts are 
capped or polyadenylated. Given the absence of a cap, the promoter region for cRNA 
and vRNA synthesis is the binding region of the 5’ and 3’ ends of the UTRs of each 
gene segment, although the cRNA promoter is complementary, not identical, to the 
vRNA promoter (51, 55, 113, 114). After the vRNA segments are transcribed, vRNP 
complexes are exported out of the nucleus (115).  
 
1.4.4. Nuclear export 
 
 Much like nuclear import, the IBV nuclear export process relies on host 
proteins. The vRNPs are exported from the nucleus using the CRM1 nuclear export 
pathway (49). NEP interacts with CRM1 and nucleoporins to export the vRNP 
complexes out of the nucleus (49). Although NEP is capable of directly interacting 
with vRNP complexes, the interaction of NEP with the nuclear export machinery is 
typically mediated by BM1 (116). The BM1 nuclear export signals (NES) have 
recently been defined, and it is thought that at least 1 of the 2 NESs in BM1 is CRM1 
dependent, although this has not been shown definitively (68). Export of the vRNP 
complexes has also been shown to utilize the Ref/MEK/ERK signaling cascade (117). 
Inhibition of MEK interferes with nuclear export, but the mechanism of action has not 




 Exported viral mRNA transcripts HA, NA, BM2 and NB are translated by the 
ribosome at the endoplasmic reticulum (ER) (118-121). Following translation, the 
proteins are folded and then sent to the Golgi apparatus for further modification (118, 
119, 121). While in the Golgi, HA is glycosylated and its signal peptide is cleaved; 
furthermore, new evidence has suggested that HA0 is cleaved by proteases within the 
Golgi into HA1 and HA2 (122-124). NB is also modified in the Golgi through the 
addition of fatty acids to cysteine residues in a process known as palmitoylation, and 
these modifications are required for proper trafficking of NB to the cell membrane 
(118). All of these proteins, HA, NA, BM2 and NB, are targeted for the apical side of 
the cell membrane of polarized epithelial cells where they accumulate at lipid raft 
regions to form a platform for budding viral progeny (125). 
 
1.4.5. Virus assembly and budding 
 
 Assembly and budding of viral progeny occurs at lipid rafts where HA, NA, 
BM2 and NB have incorporated into the cell membrane. Viral proteins and vRNPs 
must then be recruited to the site of assembly. For example, BM2 is known to recruit 
BM1 to the plasma membrane and to enhance BM1 association with the plasma 
membrane (103, 126). Additionally, BM2, through interactions with BM1-vRNP 
complexes, facilitates the assembly of the vRNP complexes into the viral bud (127).  
There are likely two types of BM1 that assemble into the virion, BM1 with 
and without vRNP (127). There is evidence to suggest that BM1 without vRNP 




based on findings which show that a deletion of the HA cytoplasmic tail that disrupts 
HA incorporation can be compensated with mutations in BM1 (128). Such mutations 
may restore the HA-BM1 interaction (129).  
Assembly and packaging of the vRNP complexes has been the subject of 
extensive research seeking to determine whether or not the vRNPs are assembled 
specifically or randomly into the budding virion. Each vRNA gene segment contains 
packaging signals at the 5’ and 3’ ends, and although IBV packaging signals have not 
been defined, IAV packaging signals are known and have been conclusively shown to 
employ specific incorporation (130-134). Given the similarity of the influenza A and 
B vRNP and RNA structures, it is likely that packaging of influenza B vRNP 
complexes is also specific (46, 51, 58, 135). 
Once the virion has been assembled, budding occurs. The viral bud forms with 
the aid of at least NA and BM1, although HA may be involved as in influenza A 
virus; nonetheless, the primary protein involved in bud formation and virion 
morphology is BM1(136-139). Once the bud has formed, it is excised and released 
from the cell surface by NA sialidase activity (78, 82).  
   
 
1.4.6. Host immune response to infection 
 
 
Entry of influenza into a host cell stimulates an immune response, as host 
proteins sense a foreign presence in the cell via pathogen recognition receptors 




a foreign body (140, 141). The resultant immune response can be broken down into 
two branches, innate and adaptive, which differ in the time required to mount a 
response and the specificity of the response. The innate immune response uses PRRs 
to recognize PAMPs, and thus acts as the host’s first line of defense against infection 
(141). The adaptive immune response is stimulated by the innate response but relies 
on T cells and B cells to mount a specific immune response against a particular 
pathogen primarily via CTL (cytotoxic T lymphocyte) and antibody production, a 
process that can take weeks to develop (142). 
 Influenza virus stimulates a robust innate immune response. PRRs of the 
innate immune system recognize single-stranded and double-stranded RNA as 
PAMPs. These PRRs include toll-like receptors (TLRs), retinoic acid inducible gene-I 
(RIG-I) and NOD-like receptors (143). Each PRR recognizes a distinct feature of 
influenza virus. For example, TLR7 recognizes single-stranded RNA while TLR3 and 
RIG-I recognize double-stranded RNA generated transiently during the virus life 
cycle. Recognition of the foreign RNA by PRRs leads to stimulation of pro-
inflammatory cytokines as well as type I interferon (IFN) (144-146). IFN stimulation 
then leads to expression of a plethora of other genes with antiviral activity. 
As IFN has strong antiviral activity and can control gene expression, it is key 
in stimulating the expression of other antiviral genes and even immune cells. 
Induction of interferon-stimulated genes (ISGs) by IFN occurs via the JAK/STAT 
pathway (147). An important ISG induced via this pathway is the Mx (myxovirus) 
gene, which encodes MxA, a protein that is capable of inhibiting influenza virus 




In addition to stimulating ISGs, IFN stimulates cell types of the innate 
immune system such as macrophages and dendritic cells. When alveolar macrophages 
become activated, they phagocytose infected cells; however, macrophages can also 
produce NOX2 (nitric oxide synthase 2) and TNF alpha (tumor necrosis factor alpha) 
when they become infected, contributing to influenza-induced pathology (150-154). 
In contrast, stimulation of dendritic cells by IFN leads to the stimulation of adaptive 
immune pathways as dendritic cells present influenza virus antigen to CD4+ and 
CD8+ T cells, ultimately leading to antibody production (155, 156).  
The adaptive immune response can be divided into cell-mediated and humoral 
branches, which are governed by T cells and B cells, respectively. The humoral 
branch leads to the production of antibodies by B cells, while the cell-mediated 
branch utilizes T cells that are virus-specific and remain present even after the 
clearance of viral infection. CD4+ and CD8+ T cells are both activated by the 
presentation of virus antigens from antigen presenting cells (primarily dendritic cells) 
but have different functions (155, 156). CD8+ T cells are directly cytolytic and 
capable of killing virally infected cells (157). While CD4+ T cells have some 
cytolytic activity, they function primarily as T helper cells (Th), with Th1 and Th2 
cells being of particular importance after virus infection (158). Th1 cells produce IFN 
gamma and IL-2 to control macrophage and CD8+ T cell responses to infection (159). 
Th2 cells, in contrast, produce IL-4 (IL, interleukin), IL-5 and IL-6, which stimulate 
the proliferation and differentiation of B cells into plasma cells (159, 160).  
The primary immunoglobulins produced after influenza virus infection are 




enter the respiratory tract). IgM is present in the circulatory system and is capable of 
mediating neutralization of influenza virus infection via the complement pathway 
(161-165). Influenza virus-specific antibody responses are produced primarily against 
the HA and NA surface glycoproteins. Indeed, the presence of HA specific antibodies 
against a particular influenza virus has historically been used as a correlate of 
protection against re-infection with the same or similar virus at a later date (166-168). 
Traditionally, influenza vaccines have been produced in a KV vaccine formulation 
known to generate IgG primarily against the globular head of the HA protein. More 
recently, live-attenuated vaccines have been made available and these vaccines 
produce a broader immune response, inducing IgA and IgG responses to vaccination 
as well as an increased IFN and T cell responses (169, 170). 
Influenza viruses have evolved mechanisms to evade the host innate immune 
responses discussed above. IBV BNS1 protein is one such adaptation, as it possesses 
a variety of different functions related to the evasion of the innate immune response. 
BNS1 has been shown to antagonize ISG15, which is involved in the activation of an 
antiviral state within the host cell, and interact with dsRNA at its N-terminus. It also 
prevents activation of host proteins, protein kinase R (PKR) and interferon regulatory 
factor-3 (IRF-3) (50, 171-173). Finally, it is crucial for the down-regulation of 
interferon beta (IFN-β). Given its ability to bind dsRNA, it would seem that BNS1 
regulatory functions are carried out via RNA binding and sequestration; however, this 
is not always the case. While BNS1 dsRNA binding and sequestration results in the 
down-regulation of PKR, BNS1 down-regulation of IFN occurs independent of 




Regardless of the means by which BNS1 regulates gene expression of the host 
innate immune response, regulation is crucial to the completion of the IBV life cycle. 
For instance, by sequestering RNA from PKR, BNS1 prevents PKR from carrying out 
its function (174). Without intervention by BNS1, PKR would be activated by the 
presence of dsRNA and would halt viral protein synthesis by phosphorylating eIF2, a 
translation initiation factor (174). In summary, without BNS1, IBV is unable to use 
the host translation machinery to translate its genome. In addition, BNS1 inhibits 
activation of IRF-3. IRF-3 is an interferon regulatory transcription factor which, when 
activated, translocates to the nucleus from the cytoplasm and initiates transcription of 
antiviral cytokines. The inhibition of IRF-3 prevents these cytokines from being 
produced; conversely, without BNS1, the host cell is better able to mount an immune 
response (175). Indeed, the degree of virus attenuation has been shown to correlate 
with the length of BNS1, and BNS1 truncated viruses have been shown 






1.5. Influenza B host-range, evolution and restriction 
 
1.5.1. Host range  
 
IBV has a narrow host-range that is thought to be limited primarily to humans. 
Although these viruses have been isolated in seals and pheasants, these hosts are not 
believed to be natural reservoirs (18-23, 178). Interestingly, IBV strains that have 
been repeatedly isolated from seals in the Dutch coastal regions are distinct from 
those virus strains circulating in the surrounding humans populations, suggesting that 
some other reservoir exists for these viruses (19, 20). Harbor porpoises residing near 
these seals were initially suspected to be the reservoir of these influenza B viruses; 
nonetheless, recent research has confirmed that there is no serological evidence of 




Novel influenza viruses can arise by either antigenic shift or antigenic drift. 
The emergence of a novel influenza virus by antigenic shift occurs through the 
exchange (or reassortment) of influenza virus gene segments after the infection of a 
single host cell with 2 or more viruses (179). Through reassortment, viruses can 
evolve more rapidly than by antigenic drift, the accumulation of mutations over 




reassortment of influenza B strains has been linked to the emergence of new epidemic 
strains (180-185). For example, outbreaks of the same antigenic lineage reported in 
the same geographic region over a short span of years were initially puzzling because 
protection against infection is thought to be based primarily on the HA protein; 
however, phylogenetic analyses in these cases revealed the cause to be a reassortant 
virus carrying an NA from a virus of the opposite lineage (180). Importantly, 
influenza viruses can only reassort with like virus types conceivably due to 
differences in packaging signal requirements; therefore, IBV strains only reassort 
with other strains of IBV (34, 186-188).  
Influenza B, due to an error-prone viral RNA polymerase, also evolves readily 
by antigenic drift. Antigenic drift differs from antigenic shift in that it occurs over 
many cycles of viral replication, whereas antigenic shift can occur after a single cycle 
of replication. The rate of antigenic drift is determined by selective pressures exerted 
on each gene segment and the mutation rate of the viral RdRp. IBV has a mutation 
rate of .6x10-6/replication cycle (189). Additionally, influenza B evolution is not 
governed by antigenic changes on HA or NA, as none of the gene segments 
experience positive selection (189-191). The percentage of mutations (regardless of 
the mutation rate) resulting in nonsynonymous mutations in influenza B HA and NA 
proteins is much lower than, for instance, human influenza A, a virus that experiences 
positive selection on the HA (189, 192, 193). In fact, it has been shown that only 30% 
of mutations in HA and NA of IBV result in amino acid changes which is in stark 
contrast to the 50% seen in human IAV (190). This finding is reasonable if one again 




viruses do not switch from one host species to another (like influenza A), changes in 
highly mutable regions like the receptor binding region of HA are less likely to occur, 
as influenza B viruses already posses the ability to bind well to the human influenza 
virus receptor, alpha 2,6 sialic acid.  
 
1.5.3. Host restriction of influenza B 
 
 
Influenza B host restriction is due to virus preference for and recognition of 
human specific proteins. One major factor recently elucidated is the specificity of 
BNS1 for human and non-human primate ISG15 mentioned previously (194, 195). 
BNS1 protein evades the host innate immune response during infection by binding 
directly to ISG15, thereby interfering with the establishment of an antiviral state in 
the host cell (50, 194, 196-198). BNS1 binds specifically to five amino acid residues 
present in the hinge region of ISG15 (194). In a pull-down assay of BNS1 and 
human, mouse, canine and monkey ISG15, only human and monkey BNS1/ISG15 
complexes were detected. Further, mutating the canine and mouse ISG15 to carry the 
5 amino acid human hinge region resulted in BNS1/ISG15 complexes for both canine 
and mouse ISG15 mutants (194). Thus, the species specificity of this reaction relies 
on the sequence of the 5 amino acid hinge.  
Although ISG15 is the only host factor that has clearly been determined to 
have a species-specific interaction with IBV, there are other host proteins that could 




known to interact with human Hsp40 (heat shock protein 40), a chaperone protein, 
through its C-terminal domain (199). Hsp40 is a regulator of PKR (protein kinase R), 
which, as has been previously described, is crucial in the host response to infection 
(174). Other proteins of the host innate immune response, such as RIG-I and MDA5 
(melanoma differentiation-associated gene), have been shown to differ among 
species. Interactions between these proteins and IBV may offer additional 
opportunities for species-specific interactions (200-202).  
A recent study has suggested that influenza B host restriction is related to the 
low binding affinity of the HA to the sialic acid receptor. Compared to IAV, IBV has 
lower overall receptor-binding affinity (203). This may be due to a conserved 
phenylalanine residue at position 95 of the influenza B HA (95). When this position is 
mutated to a tyrosine, receptor binding to synthetic glycans dramatically increases 
(204). Interestingly, when a tyrosine at an analogous residue of influenza A HA 
(amino acid residue 98) is mutated to a phenylalanine, receptor-binding affinity 
decreases (205). These findings suggest an association between the presence of 
tyrosine at position 95/98 resulting in enhanced receptor binding and a broad host 






1.6. Introduction to Influenza B Reverse Genetics  
 
The development of a reverse genetics system for IBV has been a boon for 
influenza B research. It has allowed for the easy manipulation and engineering of 
viruses with mutant or wild-type genomes to facilitate functional studies of any gene 
segment, as well as the recovery of virus for a vaccine seed stock. The first reverse 
genetics systems for influenza B, a 12-plasmid system for B/Beijing/1/87 and an 8-
plasmid system for B/Yamagata/166/98, were published in 2002 (2, 52). Since this 
time, other reverse genetics viruses have been produced including B/Yamagata/1/73 
and B/Lee/40 (127, 206, 207). Importantly, a reverse genetics system for B/Ann 
Arbor/1/66 cold-adapted, the licensed LAIV vaccine backbone, has also been 
generated, although this was done primarily to determine the role of each mutation 
present in the cold-adapted vaccine backbone (208).  
Both the 8-plasmid and 12-plasmid reverse genetics systems rely on the RNA 
Pol I and RNA Pol II polymerases present in the host cell. Within a normal host cell, 
RNA Pol I transcribes ribosomal RNA (rRNA), which is not capped or 
polyadenylated, making RNA Pol I ideal for transcribing vRNA from plasmids (209). 
Similarly, the use of RNA Pol II, which transcribes pre-mRNA transcripts in a normal 
host cell, is ideal for the transcription of viral mRNA from plasmids, as RNA Pol II 
transcripts are capped and polyadenylated (210).  
In both reverse genetics systems, all 8 influenza B gene segments were cloned 
into bidirectional plasmids containing Pol I and Pol II promoter sequences, allowing 




upon transfection (2, 52). Plasmids are designed such that human Pol I and Pol II 
promoters as well as a corresponding t1 terminator (for Pol I) and a poly A signal (for 
Pol II) flank each gene segment (Fig. 1.3A and B). In the case of the 12-plasmid 
system, four expression plasmids each possessing only one promoter, Pol II, and one 
influenza B gene segment corresponding to one of the vRNP complex genes were 
also transfected (52). The expression plasmids ensure that host RNA Pol II 
transcribes the viral polymerase genes, enhancing the probability that the viral 
polymerase will be present to initiate viral transcription. Alternatively, the 8-plasmid 
system must rely solely on the transfected bidirectional polymerase plasmids for 
transcription of all gene segments (2). Plasmids are typically transfected into 
293T/MDCK (Madin-Darby Canine Kidney) cell co-culture; 293T cells are readily 
transfectable and can be used to infect the MDCK cells, which are not as easily 
transfected but propagate virus well (Fig.  1.3A).  
Through the use of reverse genetics (RG), we have gained invaluable insight 
in areas such as viral protein function, host-virus interaction and novel vaccines. 
Although our knowledge of influenza B still lags behind that of influenza A, research 
progress has been expedited in the last 11 years due to the advent of a reliable reverse 
genetics system. Below is a segment-by-segment review of many of the most notable 
reverse genetics achievements in influenza B research as they pertain to vaccine 






    
Figure 1.3. 8-plasmid reverse genetics. The transfection of 8 
bidirectional plasmids in a 293T/MDCK cell co-culture is shown (A). 
The plasmids transfect the 293T cells (1), which produce virus that 
infects the MDCK cells (2). The MDCK cells propagate the infection. 
A schematic of a bidirectional plasmid is shown (B). Orange: Pol II 
promoter, Red: Pol I promoter, Yellow rectangle: 293T cells, Gray 






1.6.1. HA receptor binding, egg-adapted mutations and the significance of the 
HA cytoplasmic tail 
 
Not surprisingly, much research on influenza B has focused on the HA gene, 
as it is encodes the primary antigenic protein. Although much was known about the 
HA of influenza B prior to the advent of reverse genetics, reverse genetics enabled 
several important discoveries. These include the determination of receptor binding 
sites responsible for receptor preference switching between alpha 2,6 and alpha 2,3 
sialic acids as well as the sites responsible for increasing virus yield in eggs (211-
214). As will be shown below, these studies are important for vaccine development. 
Influenza vaccine candidates are typically grown in eggs. Viruses that do not 
initially grow well in eggs must be egg-adapted to improve vaccine yields; however, 
egg-adaptation generates mutations in the HA gene which can lead to antigenic drift, 
lowering vaccine efficacy (215). In order to determine which mutations enhance 
vaccine growth in eggs without altering antigenicity, numerous egg-adaptation studies 
have been carried out (211, 213). The first of these studies identified mutations 
associated with an egg-adapted B/Victoria/504/2000 and then introduced different 
combinations of these mutations into reverse genetics plasmids. The rescued viruses 
were assessed for virus growth in eggs and for antigenicity to the wild-type (WT) 
B/Victoria/504/2000 virus using hemagglutination inhibition (HI) assays (213). 
Several combinations (R162M/ D196Y and G141E/R162M/D196Y) of egg-adapted 
mutations were shown to enhance viral growth in eggs; however, only one mutation, 




the egg-adaption studies, B/Victoria/504/2000 HA plasmid constructs carrying 
different combinations of the mutations identified to enhance growth in eggs, G141E, 
R162M and D196Y, were designed and evaluated to determine whether these 
mutations altered receptor binding preference for alpha 2,6 sialic acid (213). 
Interestingly, the G141E mutation was determined to be key in shifting sialic acid 
preference from 2,6 to 2,3. The generated RG virus carrying only G141E showed 
strong preference for alpha 2,3 sialic acids, while viruses carrying the R162M and 
D196Y mutations showed preference for alpha 2,6 sialic acid (213). 
Glycosylation sites on receptor binding regions have been shown to affect 
antigenicity of influenza viruses; therefore, in order to maintain antigenicity of a virus 
through egg passaging, stable glycosylation sites are necessary (216-218). Research 
by Chen et al. identified stabilizing mutations that allow for the maintenance of 
glycosylation sites at the receptor binding regions of HA in influenza B while 
maintaining high growth in eggs (219). In this study, B/Victoria-like and 
B/Yamagata-like surfaces on the B/Ann Arbor/1/66 cold-adapted vaccine backbone 
were rescued by 8 plasmid reverse genetics to compare egg-adapted strains and 
MDCK cell-grown strains with the WT progenitor strains. The B/Ann Arbor/1/66 
cold-adapted backbone was selected to simulate egg-adaptation during vaccine 
production (220, 221). Results showed that the glycosylation sites at 196/197 
(B/Victoria-like and B/Yamagata-like viruses, respectively) present in progenitor 
strains were lost after egg-adaptation (219, 220, 222, 223). Despite this finding, a 
G141R mutation was found to stabilize the glycosylation sites at 196/197 without any 




receptor-binding preference, as described above. When the 141R mutation was 
incorporated into the HA segment of viruses previously shown to undergo antigenic 
drift after egg passaging, the presence of the 141R mutation prevented antigenic drift 
(219).  
 
1.6.2. Antiviral resistance of NA and the role of NB 
 
Segment 6 encodes two proteins, NA and NB, which are targets of viral 
inhibitors. As a sialidase, NA has been the target of antivirals known as 
neuraminidase (NA) inhibitors (82, 224). With the increasing use of these inhibitors, 
drug-resistance has become a concern, stimulating research on resistance markers 
(225). The NB ion channel, in contrast, is amantadine-susceptible; however, little is 
known about the significance of NB within the virus life cycle, although research is 
ongoing (226). 
All NA inhibitors were similarly designed based on the crystal structure of 
NA as well as the structure of sialic acid, as sialic acid is itself a mild inhibitor of NA. 
Each inhibitor blocks the active site of NA, although by different means. Zanamivir 
was designed to bind the active site based on charge (227). The NA active site has a 
negatively charged region where it binds sialic acid, thus a molecule similar to sialic 
acid, but with a greater positive charge, was designed to bind more tightly to the NA 
active site (227).  
Recently, the effectiveness of NA inhibitors outside the laboratory setting has 




side effects (228, 229). With the frequent use of NA inhibitors such as zanamivir, 
oseltamivir and peramivir, the lack of effectiveness in clinical trials could be due to 
resistance mutations.  
In order to determine molecular markers of influenza B NA inhibitor 
resistance, Jackson et al. used reverse genetics to introduce mutations into IBV and 
test susceptibility of mutant viruses to NA inhibitors (52). One of the first NA 
inhibitor resistance-associated mutations identified for influenza B was E116G (230, 
231). By introducing the E116G mutation into NA, Jackson et al. showed that IBV 
shifted from being zanamivir-susceptible to zanamivir-resistant (52). The group also 
demonstrated that resistance markers identified in IAV were conserved in IBV. Each 
mutant virus was then evaluated for neuraminidase activity in the presence of 
neuraminidase inhibitors as well as viral growth, protein stability and protein 
expression. The results of these assays indicated that the NA inhibitor resistance 
mutations caused attenuation, by either decreasing NA stability or NA expression 
depending on the mutation (232).  
While NB is sensitive to amantadine, an ion channel blocker, the utility of this 
sensitivity cannot be completely understood until more is known about the role of NB 
within the virus life cycle (226). Through the reverse genetics rescue of NB knockout 
viruses, researchers determined that, while required for efficient replication in mice, 
NB was not required for replication in vitro (in MDCK cells) (233). Thus, NB may 
not be as critical for influenza virus replication as BM2, which has been shown to be 
crucial for the production of infectious virus (103). By extension, amantadine 




1.6.3. Transcription of BM1 and BM2 and implications for vaccine 
development and experimentation 
 
The manner in which IBV segment 7 encodes BM1 and BM2 has been the 
subject of extensive research, as it is done by a unique mechanism of translational 
regulation that could potentially be manipulated for vaccine development (47). In 
order to manipulate its unique translational mechanism and modify it for potential use 
as a vaccine, a clear understanding of how it works and the function of its protein 
products are required. Reverse genetics has been key in determining both the 
mechanism as well as protein functions of BM1 and BM2. This research may allow 
for the modification of segment 7 for the generation of experimental LAIV vaccine 
candidates and has already generated a tool to facilitate the evaluation of vaccine 
candidates and pathogenesis of IBV in mice (234). 
As previously described, the M segment of influenza B encodes BM1 and 
BM2 by a stop-start translation termination-initiation pentanucleotide (UAAUG) 
mechanism in which the stop codon of BM1 overlaps the start codon of BM2 (47, 
235). The region primarily responsible for the expression of BM2 is the 45-nucleotide 
sequence upstream of the stop-start region (or the terminal 45 nucleotides of the 3’ 
end of BM1 mRNA) (235, 236). The importance of this region was determined by 
cloning a series of plasmids carrying various truncations in the coding region (mRNA 
sense) of the 3’ end of BM1 and inserting Gaussia Luciferase (GLuc) in place of 
BM2. The precise region of the M gene responsible for BM2 expression was 




Using a similar method, expression of foreign genes cloned in place of BM1 and 
BM2 was demonstrated, although expression of the foreign gene cloned in place of 
BM2 was dependent on the proportion of BM1 upstream of the stop-start signal. The 
most robust expression of the downstream foreign gene was achieved when BM1 was 
present in its entirety (235).  
Using reverse genetics, BM2 was determined to be a requirement for viral 
replication and also necessary for incorporation of the vRNP complexes into the 
budding virion (127, 237). In both studies, a series of BM2 mutant plasmids were 
constructed including a full BM2 knockout, BM2 cytoplasmic tail mutants and 
various partial BM2 knockouts. The full BM2 knockout virus was not amplifiable, 
suggesting that BM2 is required for the generation of infectious virus (237). When 
BM2 knockout virus plasmids were transfected into cells stably expressing BM2, 
virus rescue was achieved. Further analysis of the growth of the BM2 mutant viruses 
showed that the cytoplasmic tail is specifically required for rescue (237). In a related 
study, the cytoplasmic tail was shown to be important for virus replication because it 
interacts with BM1 and BM1-vRNP complexes to promote assembly (103). 
The translational control mechanisms and functional studies of BM2 have 
clear implications for vaccine development. First, the studies show that the stop-start 
translation mechanism can be utilized for the expression of foreign genes, suggesting 
that IBV could be used as a vector to carry immune-modulators to enhance the 
immune response to vaccination, or other genes. Indeed, the stop-start mechanism has 
been utilized in the NS segment of influenza A to express IL-2 in the context of an 




cytoplasmic tail plays in the production of infectious virus, it could be a viable 
candidate for modification to produce a LAIV vaccine. This has been demonstrated as 
an effective means of live-attenuation in the context of IAV, although M2 is 
expressed by a post-transcriptional splicing event, not a stop-start translation 
mechanism (239-241).  
Manipulation of the M segment has also resulted in the generation of research 
tools. McCullers et al. identified a mutation in BM1 that enhances morbidity in mice 
infected with the BM1 mutant influenza B virus. Avirulent B/Memphis/12/97 was 
passaged in BALB/c mice until enhanced morbidity was observed (234). A mutation 
in BM1, 221S, was consistently found in the isolates associated with enhanced 
morbidity (234). Subsequently, various strains of reverse genetics viruses carrying the 
serine mutation at position 221 were rescued and used to infect mice and infected 
mice showed morbidity indistinguishable from the passaged virus (234). This finding 
is particularly important given that mice are not readily susceptible to influenza B 
(242, 243). The limited susceptibility makes the evaluation of vaccine candidates 
difficult, as a lethal dose of challenge virus is required to perform a stringent test of a 
vaccine candidate as well as clearly show protection or the lack of protection 
conferred by a vaccine. Incorporating the BM1 221S mutation into a challenge virus 






1.6.4. BNS1 antagonism of the innate immune response 
 
NS, segment 8, has been the focus of manipulation via reverse genetics 
primarily due to interest in the evasion of the innate immune response by BNS1 (50, 
171, 172). Some of the primary functions and notable lack of functions related to 
BNS1 are: direct inhibition of ISG15, inability to inhibit host mRNA nuclear export, 
inability to activate phosphatidylinositol 3-kinase signaling (PI3K), inhibition of IFN 
stimulation, inhibition of PKR, inhibition of IRF-3 and interaction with nuclear 
speckle domains (50, 172, 194, 196, 244-247). The functions discovered via reverse 
genetics and their relevance to vaccine development are described below.  
In order to determine whether or not BNS1 down-regulates the expression of 
IFN, Dauber et al. generated a BNS1 knockout (206). This virus was severely 
attenuated in tissue culture. When the IFN induction of the knockout virus was 
compared to WT, there was significantly more IFN induced in cells infected with the 
knockout compared to the WT (206). Although this study did not determine the 
mechanism by which BNS1 down-regulates IFN, it conclusively proved that BNS1 
suppresses IFN expression.  
In a study similar to the one described above, the BNS1 knockout was utilized 
to demonstrate the inhibition of IRF-3 nuclear translocation by the N-terminal and C-
terminal regions of BNS1 (171). Cells were transfected with a green fluorescent 
protein (GPF)-IRF-3 fusion expression plasmid and then infected with either the 
BNS1 knockout or WT virus. Results showed that significantly more IRF-3 




(171). Then, by separately knocking out the N-terminal and C-terminal regions of 
BNS1 to generate two expression plasmids and then transfecting these plasmids 
individually with the GFP-IRF-3 expression plasmid, the group showed that both the 
C-terminal and N-terminal regions of BNS1 are capable of inhibiting IRF-3 
translocation (171).  
In another study by Dauber et al., the role of dsRNA binding by BNS1 in 
down-regulating IFN and inhibiting PKR activation was investigated. The group 
cloned a series of BNS1 truncation mutants including a full BNS1 knockout, a BNS1 
C-terminal knockout and many BNS1 mutants containing point mutations (172). Each 
of the mutant viruses recovered differed in the ability to bind dsRNA. The study 
concluded that dsRNA binding is not essential for IRF-3 or IFN inhibition, as BNS1 
mutants lacking the ability to bind dsRNA were still able to inhibit IRF-3 and IFN 
(172). Despite these findings, PKR inhibition was found to be dependent on dsRNA 
binding. Indeed, the N-terminal region and the degree to which it binds dsRNA were 
indispensible for PKR inhibition (172).  
Given the critical role that BNS1 plays in antagonizing the host innate 
immune response, it is not surprising that BNS1 mutant viruses are attenuated. As the 
collection of data above suggests, the absence or decrease in BNS1 expression leaves 
the virus unable to evade the host immune response. Indeed, experimental vaccines 





1.7. Introduction to LAIV Vaccines 
 
Each fall, both KV and LAIV vaccines are manufactured to protect against the 
current circulating strains of influenza. The strains incorporated into the seasonal 
vaccines are selected each year, and selected strains are determined by surveillance 
through the WHO Global Influenza Surveillance and Response System, GISRS (25). 
The GISRS functions such that National Influenza Centers of the GISRS carry out 
surveillance of influenza viruses throughout the year on a national level. Together, 
these centers test over 600,000 clinical samples annually. The National Influenza 
Centers then send representative samples to WHO Collaborating Centers for 
characterization (35). Once characterization is complete, representatives from the 
Collaborating Centers and other branches of WHO make recommendations regarding 
which viruses to incorporate into the seasonal vaccines for both the Northern and 
Southern Hemispheres based on the data gathered by the Collaborating Centers (35). 
Vaccines are manufactured in trivalent and quadrivalent formulations necessitating 
the selection of 4 virus strains per hemisphere. The trivalent formulation carries 2 
strains of influenza A and 1 strain of influenza B (of either the B/Yamagata or 
B/Victoria lineage) while the quadrivalent formulation carries 2 strains of influenza A 
and 2 strains of influenza B (both B/Yamagata and B/Victoria lineages) (24). 
To generate a vaccine with a gene constellation consistent with the WHO 
recommendations, classical reassortment methods are commonly employed. This 
process involves co-infecting eggs with the appropriate influenza backbone virus and 




virus is egg-adapted B/Lee/40, and the influenza B LAIV backbone is B/Ann 
Arbor/1/66 cold-adapted (36, 220). Classical reassortment methods are sometimes 
difficult with IBV, as it is a human virus and, depending on the strain, may not grow 
well in eggs. Before FDA approval of reverse genetics for vaccine seed stock 
preparation and in cases where reassortment through co-infection of eggs is not 
feasible, whole influenza B seasonal virus is adapted to eggs (215). In cases when co-
infection and reassortment of eggs is possible, infection is followed by plaque 
isolation and genotyping to identify the desired virus isolate. This process is long, and 
reverse genetics could be employed to hasten production time of vaccines. Recently, 
many have called for such a switch to the reverse genetics system (249-252). Indeed, 
Medimmune, manufacturer of the licensed LAIV vaccine, received FDA approval for 
this technology in 2006 (253). The broad implementation of reverse genetics would 
allow for rescue of a vaccine seed virus by specifically transfecting DNA plasmids 
carrying the surface genes of the seasonal virulent virus along with the LAIV or KV 
backbone genes. No selection or genotyping would be required (254, 255). Today, 
though, classical reassortment methods are still widely used, although reverse 
genetics methods are utilized. 
Aside from the difference in vaccine backbones distinguishing the KV vaccine 
from the LAIV vaccine, the KV formulation differs from the LAIV in its inactivation 
by formalin treatment and the immune response it generates. Traditionally, the KV 
vaccine has been administered in the form of an intramuscular injection, and given 
the route of administration and its non-replicative nature, the vaccine stimulates a 




stimulate cell-mediated immunity (T cell memory) (256). Although it only stimulates 
a humoral immune response, the KV vaccine can be administered to a broad range of 
individuals and is recommended for individuals 6 months of age and older (24). 
The LAIV backbone is replication-impaired due to mutations rather than a 
chemical treatment as is the case of the replication-incompetent KV vaccine. It is also 
distinct from the KV formulation in its route of administration and the immune 
response it generates. The mutations present in the influenza B LAIV vaccine were 
generated from the successive passaging of B/Ann Arbor/1/66 at progressively lower 
temperatures until the virus grew well at 25°C in Chicken Embryo Kidney cells 
(CEK) (220, 221, 223, 257, 258). In all, serial passaging generated 7 mutations, 
primarily located in the vRNP complex, and the resultant virus was dubbed B/Ann 
Arbor cold-adapted (ca) (208, 221, 259-262). In addition to being cold-adapted, it is 
also temperature sensitive, as it grows poorly, if at all, at 37°C, the temperature of the 
lower respiratory tract (257). Such cold-adaptation and temperature sensitivity 
restricts virus growth to the upper respiratory tract (33°C), allowing for safe 
immunization by preventing a lower respiratory tract infection while stimulating both 
humoral and cell-mediated immune responses (220, 221, 223, 257, 258, 263). While 
the LAIV vaccine stimulates a broader immune response and has been shown to be 
safe, it is only recommended for ages 2-49 (24). In addition to age limitations, it is 
not recommended for those who are ill, those who have pre-existing conditions (such 
as asthma), those who are immune-compromised or women who are pregnant.  
The combination of both the LAIV and the KV vaccines provides coverage to 




(24). Both vaccines are grown in eggs; although cell-grown vaccines are approved, 
they are not widely used, and thus vaccination of individuals with allergies to egg 
proteins remains an issue (24)(Hasan et al. 2013). Further, the KV vaccine has been 
reported to cause Vaccine Associated Enhanced Respiratory Disease (VAERD) 
which is a phenomenon that is generated by exposure to a virus post-vaccination 
containing an HA of the same type as the vaccine, but with antigenic drift, such that 
antibodies cross-react with the HA but cannot neutralize it (264-266). Finally, 
although studies have shown the LAIV vaccine to be safe in high-risk groups, 
inherent risk in vaccinating immune-compromised individuals with a replication-
competent vaccine limits use of the LAIV formulation in those individuals who could 
most benefit from its more robust immune response (267, 268). For all of these 
reasons, researchers have developed numerous alternative LAIV strategies. While the 
majority of these strategies have been developed for influenza A, several influenza B 
strategies have also been developed. In addition to a discussion on the B/Ann Arbor 








1.7.1. Review of the B/Ann Arbor ca vaccine backbone 
 
 1.7.1.1. In vitro and in vivo characterization 
 
Early studies with the B/Ann Arbor ca backbone showed that the virus is cold-
adapted, temperature sensitive and attenuated. Cold-adaptation has been demonstrated 
by comparing virus plaque titers; titers at 25°C of the B/Ann Arbor/1/66 ca are high 
(example, 2x108 Plaque forming units (Pfu)/mL) while the WT virus does not form 
clear plaques at this temperature. The temperature sensitive phenotype has been 
confirmed at 37°C, as this is the viral growth shutoff temperature (263). Finally, the 
attenuation phenotype, defined as restricted growth in the lungs, was shown in ferrets. 
In ferrets, the B/Ann Arbor ca backbone has been shown to cause mild pathology in 
the upper respiratory tract and little to no pathology in the lower respiratory tract; 
thus, this virus is also attenuated (263).  
These growth phenotypes are not only found in the wholly B/Ann Arbor ca 
virus, but are also found in reassortant viruses carrying different (recombinant) 
surface genes on the B/Ann Arbor ca backbone (263, 269). The ability of these 
phenotypes to be conferred to other viruses makes the backbone an ideal vaccine 
candidate, as the surface can be changed to match the WHO recommended strains 
without having to reformulate the entire vaccine. Another key feature of the B/Ann 
Arbor ca backbone growth phenotypes is that they are stable in vivo (270). To 
evaluate in vivo stability, a reassortant virus possessing the cold-adapted backbone 




for a prolonged period (6-15 days). Virus was then isolated and tested for temperature 
sensitivity and attenuated properties both in vitro and in immunocompetent hamsters, 
and both phenotypes were maintained (270). 
Reverse genetics has allowed for careful study of the mutations present in the 
B/Ann Arbor ca backbone. These studies have resulted in the mapping of the 
temperature sensitive, cold-adapted and attenuated phenotypes to specific mutations 
(208, 259, 260). The mutations identified in the B/Ann Arbor ca backbone are PB2 
630R and PA 431M as well as NP 114A, 410H and 509T. Mutations in BM1 have 
also been identified, 159Q and 183V (208, 259). Of these loci, 5 have been shown to 
confer the cold-adapted phenotype, and these include the three mutations in NP as 
well as the PA 431M and PB2 630R mutations (259). The temperature sensitive 
phenotype has been mapped to NP 114A, NP 410H, and PA 431M while the 
mutations in BM1 have been shown to enhance this phenotype (208, 260). Finally, 
the loci responsible for the attenuation phenotype are NP 114A, NP H410, PA 431M, 
M 159Q and M 183V (208).  
 
1.7.1.2. Small-scale clinical trials: B/Ann Arbor ca monovalent vaccines 
 
 The first clinical trials to evaluate the safety and efficacy of the B/Ann Arbor 
ca backbone were done decades before it was licensed in 2003 (263, 267, 269, 271, 
272). Monto et al. showed that the B/Ann Arbor ca backbone with a recombinant 
surface was safe in college age adults. In comparison to the placebo control group, the 




throat (263). Of the vaccinated group, 37.3% of these individuals had increased 
antibody titers to the virus that they were vaccinated against compared to pre-
vaccination titers. Virus was detected in 8 vaccinees on day 2 post-vaccination with 
the B/Ann Arbor ca backbone. Following detection of shed virus, samples were 
evaluated, and shed virus was determined to have maintained its temperature sensitive 
properties demonstrating stability (263).  
 In another clinical trial, Keitel et al. showed that individuals vaccinated with a 
B/Ann Arbor ca backbone virus and recombinant surface genes (distinct from the 
surface described in Monto et al.) developed mild upper respiratory, cold-like 
symptoms (269). In this study, participants ages 18-35 were vaccinated with 
increasing doses of the cold-adapted vaccine. Cold-like symptoms were associated 
with high vaccination doses. Consistent with Monto et al., some vaccinees did shed 
virus, although shedding was dose dependent. Additionally, 25% of vaccinated 
individuals were shown to have increased IgA responses against homologous virus 
compared to pre-vaccination titers. These data were compared to a group of 
volunteers who were similarly inoculated with increasing doses of the WT virus 
represented in the surface genes of the vaccine. The symptoms and viral shedding 
generated from inoculation with the WT virus were significantly higher than with the 
recombinant vaccine, although they were also dose-dependent (269).  
 Clinical trails with the B/Ann Arbor ca backbone have also been completed in 
children (271, 272). In one study, seropositive and seronegative infants and children 
ages 6 months to 9 years old showed a similar safety profile to that seen in adults 




individuals, although there were differences in immunogenicity. A greater number of 
seronegative individuals experienced an increase in antibody titers post-vaccination 
than seropositive individuals. Differences in shedding among seropositive and 
seronegative individuals were also found, and although both groups shed virus, peak 
viral titers were lower in seropositive individuals than in seronegative (271). The shed 
virus was evaluated for temperature sensitivity and, consistent with other studies, it 
was shown to maintain its temperature sensitive phenotype. Importantly, despite viral 
shedding, this study found that the vaccine virus was not readily transmissible to 
naïve children who were in close contact with vaccinated individuals, evidenced by a 
lack of antibody titers and viral shedding detected in unvaccinated children who were 
in close contact with vaccinated children (271). Interestingly, seronegative children 
were shown to shed the vaccine virus for an average of 9 days, longer than both 
adults (6 days) and seropositive children (5 days) (271, 273). Another study in 
children ages 8 months to 14 years made similar findings (272). Additionally, this 
study quantified the amount of virus required to infect 50% of seronegative children 
at 104.5 TCID50, which was consistent with data from previous studies (272).  
  Finally, the B/Ann Arbor ca backbone has been tested in 
immunocompromised and elderly individuals. While these groups tolerate 
vaccination with the B/Ann Arbor ca backbone similarly to healthy individuals, the 
vaccine has shown less immunogenicity. Overall, the results have shown a poor 
immune response to vaccination in comparison to younger, healthy individuals (267). 
Although some antibody responses are generated in these individuals post-




Interestingly, elderly individuals shed lower titer virus and were less likely to shed 
virus than younger, healthy individuals post-vaccination, suggesting that there is a 
lower rate of infectivity in elderly individuals which may be due to the immune 
history of older individuals, having likely been exposed to influenza virus infection a 
greater number of times than younger individuals (267). 
 
1.7.1.3. Clinical trials and licensing  
 
Large-scale clinical trials (typically including over 1,000 individuals per trial) 
were completed with the trivalent formulation of the LAIV vaccine to assess safety 
and efficacy in children and adults before it was licensed in 2003 (274-276). This 
formulation contains both the A/Ann Arbor and B/Ann Arbor ca backbones as well as 
surface genes corresponding to H1 and H3 strains of influenza A and one strain of 
influenza B (24). In a study of children 15-71 months of age, adverse vaccine side 
effects included mild respiratory tract infection and, in some cases, fever (274). Each 
of the vaccine components proved immunogenic in this age group. Consistent with 
the small-scale clinical trails described above, antibody responses post-vaccination 
were higher in seronegative individuals. Importantly, in a healthy adult challenge 
trial, the trivalent LAIV vaccine efficacy was compared to a trivalent inactivated 
vaccine. The estimated efficacy post-challenge in this study for all three components 
of the vaccine combined was 85% for the LAIV vaccine compared to 71% for the 
inactivated trivalent vaccine (277). Notably, in a working adult clinical trial, the 




absenteeism from work among the vaccinated group (278). In total, 16 clinical trials 
were completed in ages ranging from 1-81, which lead to the licensing of the trivalent 
LAIV vaccine, and study cohorts included healthy and high-risk groups (275). Data 
obtained from these studies were consistent with the findings described in the smaller 
scale human studies (1.6.1.2).  
 
Note: the following section is based on “Design of Alternative Live Attenuated 
Influenza Virus Vaccines”, a chapter written for Current Opinions in Microbiology 
and Immunology by Finch et al.  
 
 
1.7.2. Modifying the NS Gene Segment 
 
Considerable effort has been placed in modifying the influenza NS gene as a 
means of creating a safer alternative to the current LAIV vaccine strategy (40). The 
strategy relies on BNS1 antagonism of the innate immune response, as viruses 
containing BNS1 knockouts and truncations are attenuated (50, 171, 172, 206). Here, 
Influenza B BNS1 truncation mutants that have been shown to be efficacious 
vaccines in the mouse model are discussed (176, 177). 
A series of Influenza B BNS1 truncated viruses have been generated and 
rescued via reverse genetics. A number of truncations were made in the C-terminus of 
BNS1: BNS1 1-14, BNS1 1-38, BNS1 B1-57 and BNS1 1-80 (Wressnigg et al. 




are approved for vaccine production. While all of these truncated viruses are 
attenuated, the degree of attenuation corresponds to the length of the truncation; 
however, even BNS1 1-80 is insufficient to block IFN and induces an IgG response 
greater than that produced by the WT virus (Wressnigg et al. 2009). When mice were 
vaccinated with these mutants, they were fully protected after just one immunization 
(at 5x105 tissue culture infectious dose 50, TCID50) against 5x105 TCID50 
homologous virus challenge. Viral titers of lung homogenates revealed that none of 
the mice immunized with a BNS1 mutant had detectable virus titers in the lungs after 
lethal challenge (177).  In a similar study, BNS1 1-80 and BNS1 1-110 truncations 
were cloned, and the rescued viruses were used to vaccinate mice (176). Both viruses 
provided protection against homologous, 5x105 Pfu, challenge in mice (176). 
The NS1 truncation vaccine strategy has been extensively studied in the 
context of influenza A and has shown efficacy in multiple animal models and in 
humans (248, 279-281). As both the NS1 and BNS1 truncation strategies revealed 
similar results in mice, it is likely that the BNS1 truncation strategy could be 
extended to other animal models and humans (279). 
 
1.7.3. Modifications in the HA Cleavage Site 
 
HA has been another target of manipulation for LAIV vaccine development, 
particularly at the monobasic cleavage site (40). As previously described, monobasic 
cleavage sites, like those found in influenza B, are cleaved by trypsin-like proteases 




(97). This contributes to the restriction of influenza B viruses to the upper respiratory 
tract, as trypsin-like proteases are located in this region (122, 282, 283). It follows 
then that altering the enzyme specificity of the cleavage site may be a means of 
attenuating the virus by restricting virus growth under specific conditions. Indeed, 
this has been shown to be an effective mean of generating a LAIV vaccine as is 
described below (284, 285). 
Stech et al. modified the HA cleavage site of B/Lee/40 to recognize elastase, a 
porcine pancreatic enzyme. Two viruses were generated after mutating the cleavage 
site: B/Lee/40-Val (arginine to valine at position 361) and B/Lee/40-Ala (arginine to 
alanine at 361). In the presence of elastase, each vaccine candidate grew to WT levels 
in MDCK cells, although B/Lee/40-Val grew to slightly lower titers. Since B/Lee/40-
Ala grew well and did not cause weight loss in mice, the vaccine study was 
completed using B/Lee/40-Ala. After lethal challenge of WT B/Lee/40 at 106 Pfu, no 
virus was detected in the lungs of mice immunized with at least 104 Pfu of B/Lee/40-
Ala on day 3 post-challenge. Mice immunized with these doses maintained weight 
post-challenge and survived. In contrast, mice immunized with B/Lee/40-Ala 
formalin-treated KV vaccine had high viral titers detectable in the lungs on day 3 
post-challenge, and weight loss was recorded (285).  
This cleavage modification strategy presents major advantages. For instance, 
elastase vaccines can be grown to WT levels in approved cell lines while providing 
adequate protection with just one dose; however, this strategy is prone to reversion 




strategy with another, such as the B/Ann Arbor cold-adapted mutations, may be 
necessary (220, 222, 223, 257, 258).  
 
1.7.4. Conclusions and Commentary: LAIV vaccines 
 
 While the currently licensed B/Ann Arbor ca backbone is safe, stable, 
immunogenic and effective, there are disadvantages and drawbacks to this strategy, 
particularly in coverage provided to high-risk groups. Although it has been shown to 
be safe in these groups, there is always a higher inherent risk in vaccinating these 
individuals. Additionally, the immune response in the elderly to the LAIV vaccine is 
poor, possibly as a result of the immune history of these individuals (267).  
Despite a plethora of available experimental LAIV vaccine strategies, there 
are far fewer experimental vaccines available for IBV than are available for IAV. The 
elastase and the BNS1 truncation strategies are potentially viable candidates as 
alternative strategies to the B/Ann Arbor ca backbone; in fact, the influenza A NS1 
truncation strategy has been shown to be efficacious and immunogenic in an aged 
mouse model and could be a potential alternative strategy for influenza B, as well 
(248). Nonetheless, there is still need for alternative influenza B vaccination 






1.8. Summary of Research Objectives  
  
The primary goal of this dissertation was to develop an alternative LAIV 
vaccine strategy for influenza B that complements our lab’s patented influenza A 
strategy using a contemporary influenza B virus. A contemporary influenza B virus 
was chosen for incorporation into an IBV vaccine strategy principally to provide 
better immune stimulation in elderly individuals. To this end, B/Brisbane/60/2008 
was selected, and an RT-PCR system was designed to clone it. Initial attempts to 
develop a LAIV vaccine involving PB2 cap-binding mutants led to the identification 
of these mutations as virulence factors in mice; however, a subsequent attempt to 
develop an alternative LAIV vaccine for influenza B succeeded.  
Two alternative LAIV B/Brisbane/60/2008 vaccines that are safe, 
immunogenic and confer full protection against lethal homologous challenge in mice 
were developed. Each vaccine virus contained the following mutations in PB1: 
K391E, E580G and S660A. Additionally, one virus also possessed an 8 amino acid 
HA tag at the C-terminus of PB1. The tag-less virus was named B/Brisbane/60/2008 
ts, while the tagged virus was named B/Brisbane/60/2008 att. The reverse-genetics 
system, virulence factors and vaccines will aid in the future study of influenza B 
viruses as well as the future development of an alternative LAIV influenza 






1.8.1. Dissertation outline 
 
• Development of a Contemporary B/Brisbane/60/2008 Reverse Genetics 
System 
o Two-step RT-PCR cloning strategy 
o Design of reporter system 
o In vitro characterization of RG-B/Brisbane/60/2008 
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Chapter 2: Development of a Contemporary 
B/Brisbane/60/2008 Reverse Genetics System 
 
2.1. Abstract 
Although there are two influenza B HA antigenic lineages, both relevant to 
human disease, B/Victoria-like and B/Yamagata-like, there are no contemporary 
reverse genetics systems available for either lineage. Reverse genetics viruses 
B/Yamanashi/166/98, a B/Yamagata-like virus, and B/Lee/40, the first influenza B 
virus isolate, are widely used for both vaccine development and functional studies of 
the influenza B genome, but neither virus is closely related to contemporary strains of 
either lineage. Here, a “universal” RT primer set was designed for a 2-step RT-PCR 
approach to clone B/Brisbane/60/2008 in a strategy modeled after influenza A. 
Reverse genetics B/Brisbane/60/2008 (RG-B/Bris), a contemporary B/Victoria-like 
virus, was successfully cloned and rescued. This virus grew to similar viral titers as 
the WT and was virulent in mice. To our knowledge, this is the most contemporary 
reverse genetics system for the B/Victoria lineage. The RG-B/Bris strain was further 
















Influenza B virus (IBV) belongs to the Orthomyxoviridae family of viruses 
and is one of three types of influenza viruses: A, B, and C. IBV has a negative-sense, 
single-stranded, segmented RNA genome (3). Its genome consists of 8 RNA 
segments and can be divided into backbone genes and surface genes (3, 44, 47, 48). 
Segments 1-3, 5, 7 and 8, which correspond to the PB1, PB2, PA, NP, M, and NS 
genes, respectively, are backbone genes that encode proteins present within the virion 
(39, 40). Segments 4, HA, and 6, NA, are surface genes that encode immunogenic 
surface proteins (39, 40, 73, 81, 162). 
Although it has been isolated in seals and birds, IBV circulates annually as a 
primarily human pathogen, causing respiratory disease (18, 19, 21-23, 178). 
Infections occur throughout the year but peak during the winter months due to drier, 
colder conditions known to enhance transmission of influenza (30, 31). Individuals of 
all ages are susceptible to infection with symptoms including fever, muscle aches, 
anorexia and nasal discharge; nonetheless, the most severe cases in the U.S. have 
generally been reported in the young and elderly (4, 28). The same age-related 
severity has not been reported in other countries; however, this may be due to 
insufficient data (28).  
IBV is generally less prevalent than influenza A virus (IAV); however, IBV 
still has a substantial impact on public health. Roughly every 3 years, an IBV is the 
dominant circulating influenza virus (32). Additionally, even in years when IBV has 




disease. For example, during the 2010-11 U.S. influenza season, IBV accounted for 
only 26% of all circulating influenza viruses, yet it accounted for 38% of all pediatric 
influenza-associated deaths (33). In fact, IBV has contributed heavily to influenza-
associated mortality of all ages. For instance, 25% of all influenza-associated 
mortality in the U.S. from 1976/77-1998/99 was IBV-associated (28). Finally, IBV 
has a well-documented history of causing epidemics, despite having no history of 
causing pandemics (76, 180, 286, 287).  
Influenza B strains cannot be categorized into subtypes, but instead, they are 
categorized based on antigenic lineage. There are two IBV antigenic lineages, 
B/Victoria/2/87-like (B/Victoria-like) and B/Yamagata/16/88-like (B/Yamagata-like), 
where B/Victoria/2/87 and B/Yamagata/16/88 are the prototypical strains of each 
lineage, respectively (75). These lineages were designated in the 1980s after strains of 
IBV with little to no cross-reactivity were detected (75, 77). Lineage designations are 
made based on sequence homology and antigenicity to the HA1 region of segment 4, 
hemagglutinin (HA), the major antigenic surface gene of IBV (40, 73, 75).  
Prior to the 1980s, a monovalent IBV-component vaccine was sufficient to 
protect against most illness due to the circulation of antigenically similar viruses; 
however, with the divergence of IBVs into two distinct lineages, as described above, 
the production of IBV vaccines has become more complicated, particularly since the 
new millennium. For instance, B/Yamagata-like viruses dominated in the 1990s, but 
in the 2000s, B/Victoria-like viruses re-emerged (217). Since this time, B/Yamagata-
like and B/Victoria-like viruses have co-circulated which has led to a trend of IBV 




mismatch between the dominant circulating IBV strain and the vaccine strain (76). 
Recently, both B/Victoria-like and B/Yamagata-like HA antigenic lineages were 
incorporated into the seasonal influenza vaccine in an effort to provide better vaccine 
coverage (24, 77). 
The specific virus strains selected for incorporation into the seasonal vaccines 
are recommended by the World Health Organization (WHO) Collaborating Centers 
based on surveillance of virus samples carried out by National Influenza Centers (35). 
As protection against the HA and, to a lesser extent, NA antigens is sufficient to 
provide neutralizing immunity, vaccines are manufactured with surface genes that 
correspond antigenically to the currently circulating IAV and IBV strains 
recommended for inclusion; however, the same backbone genes are incorporated into 
the seasonal vaccines each year (25, 37). Two primary formulations of the seasonal 
vaccine are manufactured, the killed virus (KV) and the live-attenuated influenza 
virus (LAIV) vaccines (24).  
The WHO recommended vaccine virus gene constellation can be generated by 
either classical reassortment, involving the co-infection of eggs with either the LAIV 
backbone or the KV backbone virus and the wild-type (WT) recommended virus 
followed by genotyping, or by reverse genetics (249, 250). For cases in which the 
surface genes on the egg-adapted backbone do not yield high titer virus, the vaccine 
strain is passaged in eggs until high titer virus is achieved (215). 
The KV vaccine is formalin-treated inactivated whole virus (25). Each year, 
the IBV-component is manufactured with a B/Lee/40 backbone, which was egg-




Once the vaccine strain stock is generated by the methods described above, it is 
treated with formalin, rendering it non-replicative, and as it is non-replicative vaccine, 
it generates a humoral immune response (170).  
Although the IBV-component of the seasonal LAIV virus vaccine is produced 
in a manner similar to the KV vaccine, either by classical reassortment or reverse 
genetics, it is replication impaired at high temperatures, rather than replication 
incompetent (263). The vaccine backbone was generated by serially passaging B/Ann 
Arbor/1/66 virus at progressively lower temperatures in Chicken Embryonic Kidney 
(CEK) cells until it grew well at 25°C (220). The mutations generated through serial 
passage rendered the virus cold-adapted and temperature sensitive restricting growth 
to the low temperatures of the upper respiratory tract and preventing severe infection 
associated with replication in the lower respiratory tract (223, 263, 270). 
Additionally, as a live-attenuated virus, the vaccine induces a broader immune 
response than the KV formulation, generating humoral and cell-mediated immunity 
as well as an enhanced innate immune response (170, 288).  
While the efficacy of the trivalent KV seasonal vaccine, which contains 2 IAV 
strains and 1 IBV strain, is estimated to be about 60% for ages 18-65 (averaged over 
the course of 12 seasons) and the trivalent LAIV vaccine has enhanced coverage to 
about 90% for ages 6 months to 7 years (averaged over the course of 12 seasons), 
improvements in efficacy, safety and coverage can still be made (289). This is 
particularly true when one considers vaccine availability for the most at-risk 
populations. For instance, the elderly and those with pre-existing conditions are not 




Importantly, an elderly person’s immune system is not highly responsive to 
vaccination with the LAIV vaccine due to immunosenescence (290). Adjuvants and 
increased doses of HA have commonly been utilized, with some success, to enhance 
the immune response in this group (291). An alternative, though, to these methods 
could be the use of a different, more contemporary vaccine backbone.  
Since an elderly person’s immune system has been repeatedly exposed to the 
currently licensed vaccine backbone and it has been suggested that repeated exposure 
to the same virus strain provides a limited boost to the cellular and humoral immune 
response, a more contemporary backbone would likely provide greater stimulation of 
the immune system (292). An additional benefit to using a more contemporary 
backbone may also be increased heterologous immunity against currently circulating 
strains as heterologous protection is conferred by immunity against the backbone 
genes, and indeed, NP protein, encoded from segment 5, has been shown to be a 
major target of CD8+ T cells (293-297). Unfortunately, there are few, if any, reverse 
genetics (RG) viruses currently available for IBV with which to develop a more 
contemporary, more efficacious, safer vaccine. 
In 2002, two reverse genetics systems were published for influenza B, an 8-
plasmid and a 12-plasmid system, which described reverse genetics rescue of 
B/Yamanashi/166/98 and B/Beijing/1/87 viruses, respectively (2, 52). Since this time, 
other reverse genetics systems have been published for B/Lee/40, B/Ann Arbor/1/66 
and B/Yamagata/1/73 (2, 52, 127, 206-208). All of these viruses are distantly related 
to IBV strains circulating today. In fact, B/Lee/40 is the first ever-isolated IBV strain 




B/Lee/40 and B/Ann Arbor/1/66 backbones are incorporated into the seasonal 
influenza vaccine each year, as described above (37, 220).  
Since there are no contemporary influenza B reverse genetics viruses 
available, the design of an alternative vaccine on a contemporary backbone required 
the cloning of a new virus. In this vein, this study sought to clone and characterize a 
reverse genetics plasmid set of B/Brisbane/60/2008, a B/Victoria-like virus, with the 
ultimate goal of developing an alternative LAIV vaccine based on a more 
contemporary strain. The data show the successful cloning and rescue of reverse 
genetics B/Brisbane/60/2008 (RG-B/Bris) via the design of a 2-step RT-PCR system 
modeled after that of influenza A (298, 299). Additionally, the results demonstrate 
that this virus grows to high titers and is virulent in mice, making it a suitable 






2.3. Materials and Methods 
 
2.3.1. Maintenance of cells 
 
 Both Madin-Darby Canine Kidney cells (MDCK) and human 293T cells 
(293T) were maintained in Dulbecco’s Modification of Eagle’s Medium (DMEM) 
(Corning, Corning, NY) containing 10% Fetal Bovine Serum (FBS) (Sigma-Aldrich, 
St. Louis, MO), Antibiotic/Antimycotic (10mL/L, Sigma-Aldrich, St. Louis, MO), L-
Glutamine (2mM, Sigma-Aldrich, St. Louis, MO) and HEPES Buffer (.025M, Sigma-
Aldrich, St. Louis, MO). With each passage of the MDCK cells, the passage number 
was recorded. MDCK cells were not used beyond passage 60. Cells were maintained 
in T75 flasks (Greiner Bio-One, Monroe, North Carolina) in a C02 incubator at 37°C. 
 
2.3.2. Cloning and sequencing of B/Brisbane/60/2008  
 
All 8 genes of B/Brisbane/60/2008 (a gift from the CDC) were cloned into 
pDP2002, a bi-directional cloning vector (1). Segments 4, 5, 6 and 8 were cloned 
using a previously described strategy (2). To clone the remaining segments, reverse 
transcription (RT) primers were designed based on influenza B published UTRs 
described in Hoffman et al. and Jackson et al. (2, 52). Due to the inherent variability 
in influenza B UTRs, this resulted in 3 “universal” RT primers that are 11 nucleotides 




primers differs in the final 2 to 3 nucleotides. The first RT primer was designed to 
correspond to the UTR of segments 1, 2 and 3, the second RT primer was designed to 
correspond to the UTR of segments 5 and 7, and the final RT primer was designed to 
correspond to the UTR of segments 4, 6 and 8.  Then, unique cloning primers were 
designed for each segment (Table 2.2). Each of the cloning primers was designed 
with AarI cut sites.   
To begin cloning, AMV Reverse Transcriptase (Promega, Madison, WI), 
RNAsin (Promega, Madison, WI) and an RT primer were incorporated into a reverse 
transcription reaction according to the manufacturer’s recommendations. Then, using 
cloning primers unique to each gene, cDNA was amplified by PCR. PCR was 
performed with Expand High Fidelity Polymerase (Roche, Indianapolis, IN) 
according to the manufacturer’s recommendations, albeit with some modifications. 
The following parameters were employed:  95°C for 4 min (denaturation), 56°C for 
30 sec (annealing), 72°C for 5-7 min (extension), 72°C for 10 min (final extension). 
The annealing and extension steps were repeated for 30 cycles. Segment 4 PCR was 
done with an extension of 5 min. PCR reactions for segments 1-3 were done with an 
extension of 7 min. After PCR amplification of each gene, an AarI digest (Thermo 
Scientific, Waltham, MA) was then performed to digest the amplified B/Bris gene, 
while a BsmBI digest (New England Biolabs, Ipswich, MA) was employed to digest 
the pDP2002 vector. Digested PCR products were ligated into pDP2002 using 
QuikLigase (New England Biolabs, Ipswich, MA).  
Each plasmid and WT vRNA segments were also sequenced by Sanger 




using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, 
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Figure 2.1. B/Brisbane/60/2008 plasmid maps. All 8 genes were cloned 





Table 2.1. Universal primers for influenza B reverse transcription. 
Each primer corresponds to either 2 or 3 gene segments. The primer 
sequence matches the 5’ region of the cDNA. The first 9 nucleotides are 
identical in each primer.  
 
Table 2.2. Cloning primers for B/Brisbane/60/2008. Each primer 
contains an AarI cut site shown in bold. The sequences shown 
correspond to the cDNA. Sequences for only M, PA, PB1, and PB2 
are shown. Reverse primers are shown in italics. The primers used for 
amplification of the remaining segments are described in Hoffman et 





2.3.3. Cloning of a Gaussia Luciferase reporter construct 
 
 An NP Gaussia Luciferase (GLuc) (template: pGLuc Basic, New England 
Biolabs, Ipswich, MA) reporter plasmid was engineered from pDP-NP 
B/Brisbane/60/2008 (B/Bris). NP 5’ and 3’ UTRs were designed to flank the GLuc 
open reading frame (ORF). Cloning was done via overlapping PCR. First, 3 PCR 
fragments were generated corresponding to the 5’ NP UTR, the 3’ NP UTR and the 
GLuc ORF. PCR primers used to amplify each fragment had overhangs such that 
overlapping PCR with these fragments generated a NP 5’-GLuc-NP 3’ PCR product. 
This PCR product was cloned into pDP2002 using restriction sites present in the 
vector. Ligation was preformed using QuikLigase (New England Biolabs, Ipswich, 
MA). The generated clone was dubbed, pDP-NP-GLuc-NP (Fig. 2.2). 
Next, the pCMV (Pol II) promoter was removed. This was also done by 
overlapping PCR. The regions immediately upstream and immediately downstream of 
the pCMV sequence were amplified, generating 2 fragments. PCR primers were 
designed with overhangs such that overlapping PCR of these 2 fragments omitted 
pCMV. The resultant PCR product was digested with cut sites present in the pDP-NP-
GLuc-NP vector. Ligation was performed with QuikLigase (New England Biolabs, 
Ipswich, MA). The final reporter clone was called, pdelCMV-NP-GLuc-NP.  Sanger 
sequencing performed using the BigDye Terminator v3.1 kit (Life Technologies, 
Carlsbad, CA) on a 3500xL Genetic Analyzer (Applied Biosystems, Foster City, CA) 






Figure 2.2. Cloning a GLuc Reporter: steps 1-3.  Blue: NP B/Bris. 
Green: GLuc. Black: pCMV promoter. The primers used to amplify the 
UTR regions of NP had overhangs that corresponded to the GLuc ORF. 
Likewise, the primers used to amplify the GLuc ORF had overhangs 





Figure 2.3. Cloning of a GLuc reporter: steps 4-6. Blue: NP B/Bris. 
Green: GLuc. Black: pCMV promoter. Regions immediately upstream 
and downstream of the pCMV promoter were amplified. The reverse 
primer of fragment 1 had an overhang that corresponded to fragment 2 
(overhang is shown in red). Similarly, the forward primer for fragment 2 




2.3.4. Virus rescue  
 
The 8 plasmids described in 2.3.2, each carrying 1 of the 8 B/Bris genes, were 
transfected into a co-culture of 293T cells and MDCK cells. 1µg/mL of each plasmid 
was transfected into 8x105 293T cell/ 5x105 MDCK cell co-culture in a 6-well plate 
(Corning, Corning, NY).  
First, a master mix (master mix 1) containing all but one plasmid was mixed: 
10µL of each plasmid (100ng/µL) was used per reaction and added to the master mix. 
70µL of master mix 1 was aliquoted per reaction to each transfection reaction tube 
(1.5ml screwcap, USA Scientific, Orlando, FL) and mixed by vortexing. 10µL of EB 
buffer (QIAgen, Valencia, CA) was added to the negative control. A positive control 
containing all reverse genetics B/Bris plasmids was also prepared. In all, each 
transfection reaction contained 80µL of plasmids (or plasmids and EB, in the case of 
the negative control). 
Next, a second master mix was prepared containing [OPTI-MEM] I, FBS and 
Antibiotic/Antimycotic free, (Life Technologies, Carlsbad, CA) and Transit-LTI 
(Mirus Bio, Nutley, NJ). For every 1µg of plasmid, 2µL of Transit-LTI was used 
(16µL per one 8 plasmid transfection reaction) (Mirus Bio, Nutley, NJ). Transit-LTI 
and [OPTI-MEM] I, FBS and Antibiotic/Antimycotic free, (Life Technologies, 
Carlsbad, CA) were mixed up to 120µL per reaction (for each 8 plasmid reaction, 
104µL [OPTI-MEM] I was added). Then, master mix 2 was vortexed, and 120µL was 
aliquoted to each plasmid mixture. Each reaction was vortexed again briefly. 




of [OPTI-MEM] I (FBS free) (Life Technologies, Carlsbad, CA) containing 10mL/L 
Antibiotic/Antimycotic (Sigma-Aldrich, St. Louis, MO) was added slowly to each 
reaction.  
Finally, media was aspirated from the 6-well plate co-cultures (Corning, 
Corning, NY) with a Pasteur pipette (Fisher, Hampton, NH). The 1mL of each 
transfection reaction was then overlaid on the cells. Each transfection reaction was 
carefully and slowly overlaid on the cells with a pipette, but was not mixed by 
pipetting. Cells were then placed at 33°C. After 24 h, the media was changed. Old 
media was carefully aspirated with a 1000µL pipette. Then, 2mL [OPTI-MEM] I 
(FBS free) (Life Technologies, Carlsbad, CA) containing 10mL/L 
Antibiotic/Antimycotic (Sigma-Aldrich, St. Louis, MO) and 1µg/mL of TPCK-
trypsin (Worthington Biochemical, Lakewood, NJ) was gently overlaid on each well. 
 
2.3.5. Virus stocks and titration 
 
Following rescue of RG-B/Bris, transfection supernatant was collected 4-5 
days post-transfection and spun down at 1000xg for 10 min at 4°C and then was 
passed onto MDCK cells. After 4 days, the supernatant was harvested, spun down at 
1000xg for 10 min at 4°C and used to directly inoculate eggs. Eggs were also 
inoculated to grow a stock of WT B/Brisbane/60/2008.  
To grow stocks, 10-fold serial dilutions of virus were prepared. Pipette tips 




pathogen free (SPF) 9-day old hen eggs (B&E Eggs, York Springs, PA) were 
inoculated with 200μL. Three eggs were inoculated per dilution. Eggs were then 
incubated at 33°C for 72 h. After 3 days, allantoic fluid (AF) from each egg was 
harvested, and hemagglutination (HA) assays were performed to determine the HA 
titer of each egg.  
To perform the HA assays, 100μL of undiluted AF was added to the first well 
in a V-bottom 96-well plate (Corning, Corning, NY). The remaining wells were filled 
with 50μL of PBS per well. Then, a series of 2-fold dilutions were made within the 
plate beginning at the first well (A1-A12). Finally, 0.5% cRBC (chicken Red Blood 
Cells, Lampire Biological Laboratories, Pipersville, PA) was added to each well. 
Plates were incubated at room temperature for 45 min, and HA titers were read. Virus 
positive wells were those that showed hemagglutination. The egg with the highest HA 
titer at the highest dilution was harvested. AF was spun down at 1,000xg for 10 min 
at 4°C, aliquoted and placed at -80°C. Each stock was then titrated by both egg 
infectious dose 50 (EID50) and tissue culture infectious dose 50 (TCID50) at 33°C.   
TCID50 titrations were performed using MDCK cells cultured in 96-well 
plates (Greiner Bio-One, Monroe, North Carolina). MDCK cells (25,000/well) that 
were seeded in 100µL of FBS free [OPTI-MEM] I (Life Technologies, Carlsbad, CA) 
containing 10mL/L Antibiotic/Antimycotic (Sigma-Aldrich, St. Louis, MO) and 
incubated overnight at 37°C.  The following day in a new 96-well plate (Greiner Bio-
One, Monroe, North Carolina), 10-fold serial dilutions were prepared. The 10-fold 
serial dilutions of virus were prepared in FBS free [OPTI-MEM] I supplemented with 




plates with 216µL per well media and then adding 24µL of virus to the first well, a 
1/10 dilution of virus (8 replicates for virus stocks and 4 replicates for virus samples). 
Next, dilutions were prepared beginning at the first well containing the 1/10 virus 
dilution. Dilutions of virus stocks were prepared out to 10-12 while dilutions of virus 
samples were prepared out to 10-6. Tips were discarded between each dilution. After 
preparing the dilutions, media was removed from the MDCK cells. Then, cells were 
overlaid with 200µL of each dilution, being careful to transfer one column of 
dilutions at a time, beginning with the most dilute wells. The virus-overlaid cells were 
then incubated for 72 h at 33°C. After 72h, hemagglutination assays were performed. 
Wells that showed hemagglutination were considered virus positive, and the TCID50 
was determined by the Reed and Muench method (300). 
Stock titration for the mouse study was done by EID50 in 9-day old specific 
pathogen free (SPF) hen eggs (B&E Eggs, York Springs, PA). First, virus was 
serially diluted in 1.5mL tubes (USA Scientific, Orlando, FL), and tips were 
discarded between each dilution. After virus preparation, three eggs were inoculated 
per dilution (in the allantoic cavity), and each egg was inoculated with 200µL of virus 
dilution. Then, eggs were placed at either 33°C for 72 h post-inoculation. After 72 h, 
eggs were moved to 4°C overnight. The following day, each egg was harvested. 
Then, 100µL of allantoic fluid (AF) from each egg was placed in a 96-well V-bottom 
plate (Corning, Corning, NY). Empty wells were filled with 50µL of PBS, and AF 
was subsequently diluted to 2-3. Then, a hemmaglutination assay (HA assay) was 
performed by aliquoting 50µL of 0.5% cRBC (Lampire Biological Laboratories, 




Eggs with HA assays showing hemagglutination in every well were considered virus 
positive. The EID50 was determined by the Reed and Muench method (301). 
  
2.3. 6. Virus rescue over time 
 
Transfections were performed as described in 2.3.4 with some modifications. 
Assays were setup in 12-well plates (Corning, Corning, NY) that were seeded 1 day 
prior to transfection with a co-culture of 2.5x105 MDCK/4x105 293T cells/well. The 
following transfections were preformed: RG-B/Bris with TPCK-trypsin, RG-B/BRis 
without TPCK-trypsin, and 7 plasmid RG-B/Bris with TPCK-trypsin (without pDP-
HA B/Bris). Each transfection reaction contained .5μg/mL of each plasmid and was 
done at 35°C. Thus, instead of 80μL of plasmid in a single reaction, 40μL of plasmid 
(100ng/μL) was used. The volume of Transit-LTI (Mirus Bio, Madison, WI) was 
similarly adjusted to compensate for the altered plasmid concentration. Thus, 8μL 
Transit-LTI was incorporated. As before, the volume was added up to 200μL with 
FBS free [OPTI-MEM] I (Life Technologies, Carlsbad, CA) containing 
Antibiotic/Antimycotic (10mL/L, Sigma-Aldrich, St. Louis, MO). Transfection 
supernatant was collected at 6, 30, 54, 78, 102 h post-transfection. At each time point, 
120μL of supernatant was collected. After collection, media and TPCK-trypsin 
(1μg/mL, Worthington Biochemical, Lakewood, NJ) were replenished with FBS free 
[OPTI-MEM] I containing Antibiotic/Antimycotic (10mL/L, Sigma-Aldrich, St. 
Louis, MO). Samples were then titrated by TCID50 as described in 2.3.5. Titers were 




2.3.7. Mini-genome assays 
 
Transfections were setup similar to those described in 2.3.4; however, there 
were some key differences. .5μg/mL of each plasmid was transfected into human 
293T cells (1x106/well) in a 12-well plate (Corning, Corning, NY). The total 
transfection volume was maintained at 1mL, although the volume of total plasmids 
per reaction was adjusted to 30μL instead of 80μL (5μL of 100ng/μL working stocks 
of each plasmid per reaction). [OPTI-MEM] I (Life Technologies, Carlsbad, CA) was 
mixed with 2μL/μg of Transit-LTI (Mirus Bio, Nutley, NJ) up to 200μL per reaction. 
In the case of the controls, 5μL of EB (QIAgen, Valencia, CA) was added to the 
plasmid mixture to compensate for the omitted plasmid. After overlaying the 
transfection reaction on the 293T cells, cells were placed at 35°C. The media was not 
changed and TPCK-trypsin was not added post-transfection.  
The transfected plasmids were those of the vRNP complex of 
B/Brisbane/60/2008 (pDP-PB2, pDP-PB1, pDP-PA, and pDP-NP), the Gaussia 
Luciferase reporter plasmid described in 2.3.3 and a Secreted Alkaline Phosphatase 
(SEAP) expression plasmid (pCMV-SEAP). The SEAP expression plasmid was 
included to control for transfection efficiency, as it is expressed under the control of 
pCMV, a Pol II promoter (i.e. only host RNA polymerase can generate SEAP 
expression). Two negative controls were included: a no reporter control (containing 
pCMV-SEAP and all 4 RNP plasmids) and a partial vRNP complex control 
(containing the reporter and 3 of 4 vRNP plasmids, no NP). Each transfection 




 Gaussia Luciferase (GLuc) expression was measured as an indirect indicator 
of polymerase activity. Since both SEAP and GLuc are secreted proteins, supernatant 
was collected at different time points (8, 16 and 24 h post-transfection) for analysis of 
GLuc activity. At every time point, 20µL of supernatant was collected, placed 
directly in a 96-well white micro-titer plate (Corning, Corning, NY) and stored at  
-20°C. At 24 h, additional supernatant was collected for SEAP quantification and 
stored at -20°C.  
GLuc expression was quantified using a BioLux® Gaussia Luciferase Assay 
Kit (New England Biolabs, Ipswich, MA). Briefly, the Luciferase Substrate was 
prepared immediately prior to use by performing a 1/1000 dilution of the substrate 
into the Sample Buffer. Next, 50µL of diluted Luciferase Substrate in sample buffer 
was added to 20µL of sample in a flat-bottom 96-well white micro-titer plate 
(Corning, Corning, NY). Immediately after the addition of the substrate, the 
luminescence was measured over a 1- sec-integration time on a Victor X4 
Luminescence Plate Reader (Perkin Elmer, Waltham, MA).  
SEAP was measured utilizing the Phospha-Light System (Applied 
Biosystems, Foster City, CA) according to manufacturer recommendations. To 
perform this assay, Assay Buffer and Reaction Buffer were first equilibrated to room 
temperature. Then, a 1x dilution of 5x Dilution Buffer was prepared in water, 
preparing enough for 18.75µL /sample. To each sample of supernatant (6.75µL), 
18.75µL of 1x Dilution Buffer was added and incubated at 65°C for 30 min. Next, 
samples were cooled on ice and then transferred to a 96-well flat-bottom white micro-




samples were incubated at room temperature for 5 min (25µL Assay Buffer/sample). 
During this incubation, reaction buffer, consisting of CSPD and Diluent (1:20 ratio), 
was prepared. After the incubation, 25µL of reaction buffer was added to each 
sample. Samples were incubated at room temperature for 20 min. SEAP activity was 
read in the Victor X4 Luminescence Plate Reader (PerkinElmer, Waltham, MA). 
GLuc activity was normalized with SEAP activity by dividing the raw GLuc activity 
at each time point by the raw SEAP activity, divided by 10,000, at 24 h [GLuc at x 
hpt/(SEAP at 24 hpt/10,000), where x is the number of hours post-transfection]. 
These values were graphed. 
 
2.3.8. Growth kinetics  
 
Growth kinetics assays were performed with virus stocks at 35°C with 0.01 
multiplicity of infection, MOI, of virus. Roughly 24 h prior to infection, MDCK cells 
(5x105/well) were seeded in a 6-well plate (Corning, Corning, NY) prepared with 
FBS free [OPTI-MEM] I (Life Technologies, Carlsbad, CA) containing 10mL/L 
Antibiotic/Antimycotic (Sigma-Aldrich, St. Louis, MO). The following morning, 
viruses were thawed and dilutions were prepared. Each well was infected with 1mL 
of 0.01 MOI of virus diluted in PBS. Plates were then moved to 4°C for 15 min to 
synchronize the infection. After 15 min, cells were moved to 37°C and incubated for 
45 min to infect. After infecting the cells, each well was washed 3x with 1mL of 
sterile PBS, discarding tips between each well. Finally, [OPTI-MEM] I (FBS free) 




Biochemical, Lakewood, NJ) was prepared. Then, 2mL of the media preparation was 
overlaid on each well. Again, tips were changed between each well. Plates were then 
placed at the appropriate temperature, 35°C. Viral supernatant was collected at 6, 12, 
24, 48 and 72 h post-infection (hpi) (120µL/well), discarding tips between each well. 
After collecting each sample, the media was replenished with an equivalent volume 
of FBS free [OPTI-MEM] I (Life Technologies, Carlsbad, CA) and 1µg/µLTPCK-
trypsin (Worthington Biochemical, Lakewood, NJ). When sample collection was 
complete, the samples were placed at -80°C to await titration by TCID50. Each virus 
was assessed at least twice in triplicate. 
 
2.3.9. Mouse Lethal Dose 50 (MLD50)  
 
 RG-B/Bris MLD50 studies were performed under BSL-2 conditions. First, 
serial dilutions from 107-105 EID50/mL of the RG-B/Bris virus were prepared in PBS. 
Four mice were inoculated per virus dilution. Each mouse received 50µL of the virus 
inoculum intranasally, and all mice were weighed the day of inoculation and for 12 
days post-inoculation. Mice that scored a 3 or greater for disease signs (described in 
Table 2.3) or mice that lost 20% or more of the starting weight were humanely 
euthanized. Euthanasia was performed by first anesthetizing the mice with the 
VetEquip Mobile Euthanasia System (VetEquip, Pleasanton, CA), which releases a 
mixture of isoflurane (Isoflo®) and oxygen (1 liter per min) into a chamber, and then 
performing cervical dislocation. The University of Maryland, College Park IACUC 
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Table 2.3. Scoring explanations of signs and symptoms of disease in mice. This 
table describes how mice were scored. Any mouse scoring 3 or greater and/or 




2.3.10. Phylogenetic analysis of influenza B HA and NA 
 
Sequences were gathered through nucleotide searches of full-length sequences 
using the Influenza Research Database (IRD, 
http://www.fludb.org/brc/home.spg?decorator=influenza). HA and NA sequences 
were collected internationally: Africa, Asia, Europe, North America and Oceania. 
Several sequences were gathered from each year from each country (of those 
available) in each region. Unfortunately, there were limited sequences available 
depending on the region and year. Thus, the phylogenetic tree is limited to the 
constraints of a limited dataset in certain regions, Africa in particular. After gathering 
the sequences from the IRD, sequences were downloaded by searching for accession 
numbers using the NCBI influenza database. Full-length coding regions were 
downloaded, and all duplicate sequences were removed. Then, sequences were 
aligned using Muscle with default parameters (302).  
Next, phylogenetic inference was tested by distance and maximum likelihood. 
Trees were rooted using the maximum likelihood and 100 bootstrap replicates via 
RAxML v8.0.X (303) and under models of nucleotide substitution (GTR + Γ (HA, 
NA) and GTRCAT (HA, NA)).  
Nucleotide BLASTs (Basic Logical Alignment Search Tool) were performed 
with each of the full-length RG-B/Brisbane/60/2008 genes to determine the sequences 
most closely related to the entire RG-B/Bris genome. BLASTs were performed by 
using NCBI Influenza Virus Resource database 




the top results showing the highest percentages of sequence identity were recorded. 

















2.4.1. Polymerase activity shows that RG-Bris polymerase is functional 
 
 Mini-genome assays were performed to assess polymerase activity of the RG- 
B/Brisbane/60/2008 (RG-B/Bris) vRNP complex as well as confirm that the NP 
GLuc reporter plasmid functioned as desired. Bidirectional reverse genetic plasmids 
encoding the vRNP genes of B/Bris were transfected into 293T cells along with the 
GLuc vRNA reporter plasmid, and supernatant was harvested at time points up to 24 
hpt. Finally, normalized GLuc expression was evaluated, and the results showed that 
the RG-B/Bris polymerase complex expressed GLuc above baseline, which was 
established by SEAP expression, confirming that the RG-B/Bris polymerase complex 
is functional. Additionally, all negative control complexes showed lower GLuc 
activity than the full polymerase complex after normalization by 2 logs and greater, 
consistent with the removal of the Pol II promoter from the reporter plasmid (Fig. 
2.4).  
 
2.4.2. Virus rescue over time shows RG-B/Bris rescues efficiently 
 
To evaluate the efficiency of RG-B/Bris virus rescue, all 8 bi-directional RG-
B/Bris plasmids were transfected into an MDCK/293T cell co-culture at 35°C. 




TCID50 to determine viral rescue titers over time. By 54 h post-transfection (hpt), 
rescue titers of the RG-B/Bris virus were near 105 TCID50/mL (Fig. 2.5). By 102 h 
post-transfection, virus titers were greater than 106 TCID50/mL (Fig. 2.5). As 
expected, RG-B/Bris does not rescue without TPCK-trypsin, an enzyme required to 
cleave HA and generate infectious virus (89). Thus, RG-B/Bris rescues efficiently 
and grows well in MDCK cells.   
  
2.4.3. WT and RG-B/Bris grow to similar titers in tissue culture 
 
Although all future work to be done in the development of a LAIV influenza 
B vaccine will be done with the reverse genetics virus, growth of the WT and RG- 
B/Brisbane/60/2008 viruses was compared in vitro. Growth kinetics assays were 
performed with 0.01 MOI of virus at 35°C, and time points were collected at 6, 12, 
24, 48 and 72 h post-infection (hpi). The results showed that the WT and RG viruses 
replicate to similar titers, although at early time points (12 hpi) the WT virus may 
replicate better (Fig. 2.6). The difference seen at 12 hpi could be a result of a 
mutation, PB1 N635S, which was identified in the RG-B/Bris virus when compared 







2.4.4. RG-B/Bris is virulent in mice 
 
An egg-grown stock of RG-B/Bris was generated to determine whether or not 
this virus is virulent in mice. To this end, 5-6 week old female DBA/2 mice were 
intranasally inoculated with 50µL of 107, 106 or 105 EID50 of virus, and signs of 
disease were monitored for 12 days post-inoculation (dpi). The results showed that at 
107 and 106 EID50 RG-B/Bris caused 100% mortality (data not shown, Fig 2.7, 
respectively). At 105 EID50, only 1 of 4 mice succumbed to infection (Fig. 2.7). The 
results confirm that the RG-B/Bris virus is virulent and causes death in the DBA/2 





Figure 2.4. Polymerase activity of RG-B/Brisbane/60/2008 at 35°C. Plasmids 
were transfected. Supernatant was collected at 8, 16 and 24 hpt. Maroon: no 
reporter control. Teal: partial vRNP control. Red: 6-plasmid transfection including 
4 vRNP plasmids, the GLuc reporter plasmid and a SEAP expression plasmid. 
Figure 2.5. Virus rescue over time of RG-B/Brisbane/60/2008 at 35°C. 
Transfections were setup with and without TPCK-trypsin. Supernatant was 
collected at 6, 30, 54, 78 and 102 hpt. Pink: transfection of all 8 
B/Brisbane/60/200 plasmids without TPCK. Gray: transfection of 7 
plasmids, excluding the HA plasmid with TPCK.  Red: transfection of all 8 






Figure 2.6. Growth kinetics of WT vs. RG-B/Brisbane/60/2008 viruses at 
35°C. MDCK cells were infected with 0.01 MOI of each virus. Time points 
were collected at 6, 12, 24, 48 and 72hpi. Green: WT B/Brisbane/60/2008 







Figure 2.7. Survival of RG-B/Brisbane/60/2008 inoculated mice. Mice 
were inoculated with 50µL intranasally of RG-B/Brisbane/60/2008 at 
different doses. Results of the MLD50  are shown. Red: RG-
B/Brisbane/60/2008 inoculated mice. 106 EID50 inoculated mice (A). 105 




2.4.5. Phylogenetic analysis of RG-B/Bris shows it is a member of the most 
recent B/Victoria-like virus clade 
  
 The B/Brisbane/60/2008 isolation date indicates that it is a contemporary 
virus, more contemporary than B/Lee/40 (B/Lee) and B/Yamanashi/166/98 (B/Yam), 
the most widely used reverse genetics IBV strains. The isolation date, however, does 
not indicate relative relatedness to current IBV strains. To determine the phylogenetic 
distance and relatedness between RG-B/Bris and other current IBV strains, 
phylogenetic analyses were performed. Specifically, phylogenetic analyses were 
performed on IBV HA and NA sequences available in the database using the 
maximum likelihood model.  
The results confirm the distant relationship of B/Lee from all other isolates 
(Fig. 2.8A and B). Indeed, B/Lee/40 is the most appropriate root of both HA and NA 
phylogenetic trees, as it is related to all other viruses represented on the trees. 
Additionally, the highlighted regions of both the HA and NA phylogenetic trees 
comprise the sequences gathered from roughly the last decade (Fig. 2.8A and B). 
These highlighted regions clearly illustrate that RG-B/Bris shares a much closer 
relationship in the sequences of both HA and NA to the most contemporary strains of 
B/Victoria-like viruses than B/Yam does to the most contemporary B/Yamagata-like 
viruses. In fact, the trees show that sometime around the new millennium, the HA and 
NA sequences of both IBV lineages branched off into new clades of viruses. 
B/Yamanashi/166/98 does not belong to the newest clades of HA or NA B/Yamagata-




B/Victoria-like viruses (Fig. 2.8A and B). As expected, RG-B/Bris HA and NA 
sequences are also very distantly related to B/Yamagata/16/88 and B/Victoria/2/87, 
the prototypical strains of the B/Yamagata-like and B/Victoria-like HA lineages.  
BLASTs were performed with full-length RG-B/Bris genome sequences to 
determine the relatedness of its entire genome to other virus isolates. The top 4 most 
closely related sequences were recorded (Table 2.4). All gene segments are closely 
related to contemporary virus isolates with isolation dates of related viruses ranging 
from 2008-2011. Interestingly, several of the gene segments are closely related to 
viruses from countries other than Australia (the country of origin for B/Bris), 
emphasizing the role that human travel has on virus spread. This is true of the NS, 
NA, HA, PA and PB1 segments. Importantly, aside from offering further evidence 
that the RG-B/Bris surface genes are closely related to contemporary IBV strains, the 
results show that the backbone genes are closely related to modern IBV strains 
suggesting that RG-B/Bris could be used to generate cross-protection to modern IBV 


















































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.8. HA and NA phylogenetic trees. Each tree is rooted with 
B/Lee/40 shown in dark blue. HA (A) NA (B) Yellow highlighting: 
most contemporary clade of B/Yamagata-like viruses. Blue 
highlighting: most contemporary clade of B/Victoria-like viruses.  
Green: B/Victoria/2/87 Purple: B/Yamagata/16/88 Orange: 
B/Yamanashi/166/98. Tables of HA and NA accession numbers are 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.4. Blast results for B/Brisbane/60/2008 plasmid sequences. Nucleotide 
blasts were performed with full-length plasmids sequences of each gene. The top 4 
most closely related sequences are listed. Segments from top to bottom: 8, 7, 6, 5, 







 This study showed the successful cloning and rescue of a contemporary 
reverse genetics virus, RG-B/Brisbane/60/2008 (RG-B/Bris), for the study of 
influenza B, particularly the future development of an alternative LAIV vaccine 
strategy. Cloning was done by a two-step RT-PCR system modeled after that of 
influenza A (298, 299). The strategy utilizes “universal” RT primers each of which 
share 9 nucleotides in common, accounting for the conservation of the IBV 5’ cDNA 
UTR region (51).  
The results showed that RG-B/Bris rescues efficiently, grows to high titers 
and is virulent in mice. The virulence that RG-B/Bris displays in mice is particularly 
important for vaccine studies, as lethal challenge doses are required to stringently test 
vaccine candidates. Additionally, the results of the phylogenetic analyses performed 
demonstrated that RG-B/Bris is part of the most recent HA and NA clades of 
B/Victoria-like viruses.  
In support of the findings which show that RG-B/Bris is more closely related 
to the most recent clade of B/Victoria-like viruses than currently available RG viruses 
and the currently licensed cold-adapted B/Ann Arbor/1/66 backbone in terms of 
isolation date and phylogenetic relatedness, the WHO has selected 
B/Brisbane/60/2008 as a vaccine candidate virus several times since its isolation (25, 
37, 304). In fact, the B/Victoria-like virus selected for incorporated into the 2013-4 
seasonal vaccine was B/Brisbane/60/2008-like. Given these facts and the findings 




backbone, as it still bears strong antigenic relatedness to currently circulating strains 
and, given the BLAST results, also a high percentage of sequence relatedness in the 
backbone to isolates as recent as 2011. A more contemporary vaccine backbone, as 
discussed in the introduction, could provide better immune stimulation in the elderly, 
as well as provide greater cross-protection due to the close relatedness of the virus 
backbone to circulating strains.  
 These findings clearly demonstrate a system (RG-B/Bris and the GLuc 
reporter plasmid) by which vaccine candidates will be able to designed, characterized 
and tested in the mouse model. Finally, given relatedness of RG-B/Bris to 
contemporary viruses, vaccine candidates designed on this backbone also have the 
potential to confer greater cross-protection in all vaccinated individuals and a better 





Chapter 3:  Development of an Alternative Influenza B LAIV 




 Influenza B virus (IBV) causes significant respiratory disease in humans each 
year with symptoms ranging from fever, malaise, headaches, body aches and loss of 
appetite. Infections are not isolated to particular age groups, having been documented 
in all ages; however, in the U.S., the data suggests that severe infections are more 
common in infants, children and the elderly. The IBV-associated disease burden is 
great enough to warrant inclusion of IBV into both formulations of the seasonal 
influenza vaccine, killed virus (KV) and live-attenuated virus (LAIV). As the LAIV 
vaccine is known to induce a more robust immune response than KV vaccine, it is 
thought to confer better coverage. The LAIV vaccine platform carries mutations that 
map primarily to the vRNP complex and cause temperature sensitivity, cold-
adaptation and attenuation. Among these mutations is a cap-binding mutation, PB2 
N265S, which is part of the influenza A virus (IAV) component of the vaccine. IBV 
research has suggested that cap-binding mutations, specifically W359F and F406Y, 
may also be attenuating, as these mutations have been shown to decrease polymerase 
activity. Further, our lab has a patented strategy for an IAV vaccine platform in which 
the PB1 segment carries an HA tag at the C-terminus, and we have shown that this 
HA tag provides greater safety and stability to the other mutations present in the 




which the PB2 cap-binding mutations, W359F and F406Y, were separately combined 
with a C-terminal HA tag in PB1. The results show that this strategy is not suitable as 








 Influenza B virus (IBV) belongs to the Orthomyxoviridae family of viruses, 
which is characterized by having a negative-sense, single-stranded, segmented RNA 
genome (3, 47, 48, 73). Its genome is comprised of 8 RNA segments, numbered 1-8, 
which encode a total of 11 proteins (3, 47, 48, 73). Each of these segments encodes at 
least 1 protein.  
Segments 1-3 of IBV encode PB1, PB2 and PA, respectively (40). These 
proteins form a heterotrimeric polymerase complex, which binds to the vRNA for 
genomic replication and mRNA transcription (42). Host mRNA transcripts are bound 
through the 5’ cap structures by PB2 and are then cleaved by PA, an endonuclease, to 
form a capped primer (61, 62, 135). This primer is then used by PB1 to initiate 
transcription of the viral mRNA (41, 58, 59). The polymerase complex also interacts 
with the nucleoprotein (NP), segment 5, to form the vRNP complex. NP coats each of 
the vRNA segments, stabilizing the RNA, and interacting with the polymerase 
complex that is bound to the 3’ end of the vRNA in the virion (42, 57, 63, 64, 305). 
The remaining segments 4, 6, 7 and 8 encode the surface proteins HA and NA from 
segments 4 and 6, respectively, of which HA is the major antigenic protein, as well as 
ion channels, matrix protein, nuclear export protein and an antagonist of the innate 







IBV circulates in humans as a major respiratory pathogen with transmission 
peaking in the cold, dry conditions of the winter months; consequently, influenza B 
viruses are incorporated as components in the seasonal influenza vaccine each year 
(4, 28, 30, 31). The seasonal vaccine is manufactured in two formulations, killed virus 
(KV) and live-attenuated virus (LAIV); each confers protection to the same influenza 
virus strains and is typically grown in eggs (24, 170). Both have 2 influenza A virus 
(IAV) components and a least 1 IBV component which are updated as needed to 
ensure that they are good antigenic matches to the dominant circulating virus strains 
(24, 37). As the HA and, to a lesser extent, NA surface glycoproteins are generally 
sufficient to provide protection against infection, only these are updated while the 
internal genes for each vaccine component remain consistent (35, 81, 309).  
Each year the IBV-component of the KV vaccine is produced with an egg-
adapted B/Lee/40 backbone (35, 37). Once vaccine stocks are grown, the virus is 
formalin-treated, rendering the vaccine non-replicative (24). It is then administered 
via an intramuscular injection, generating an IgG antibody response post-vaccination 
(24, 170).  
The IBV-component of the LAIV vaccine is replication impaired and contains 
cold-adapted internal genes from B/Ann Arbor/1/66 (B/Ann Arbor cold-adapted), 
which have high growth capacity in eggs and restricted growth in the lower 
respiratory tract (roughly 37°C) ensuring vaccine safety (208, 220, 257, 263, 310, 
311). The B/Ann Arbor cold-adapted backbone is replication impaired due to 
mutations generated through the successive passaging of the virus at progressively 




virus replication in the upper respiratory tract, it generates IgG, IgA, T-cell and 
heightened innate immune responses to vaccination (170, 263, 269, 312).  
The LAIV vaccine formulation, given the broadened immune response it 
generates in comparison to the KV virus formulation, is considered to be an 
improvement. Indeed, in a clinical trial comparing efficacy of the trivalent KV and 
LAIV vaccine formulations, the LAIV vaccine had 85% efficacy while the KV 
vaccine had only 71% efficacy (277). Despite the increased efficacy of the LAIV 
vaccine, the vaccine is only licensed for individuals ages 2-49 years old who have no 
pre-existing conditions, who are not immunocompromised and women who are not 
pregnant (24). The inherent risk involved in administering a live virus to groups with 
altered immune status has prevented licensing to these groups; however, in the 
elderly, studies have shown that the vaccine is safe but has limited efficacy likely due 
to immune history and immunosenescence (267).  
An elderly person’s immune system is not highly responsive to vaccination, 
particularly to the LAIV vaccine formulations, partly due to immunosenescence, 
which involves a shift towards Th2 T cell responses over Th1 and leads to a decrease 
in the cytolytic T cell (CD8+ T cell) response as well as a decrease in naïve T cells 
(among other changes) (290). As has been described, one of the benefits of the LAIV 
vaccine is that it generates a cell-mediated immune response, so it follows that a less 
efficient T cell response in the elderly would decrease LAIV vaccine effectiveness in 
this group. Efforts to boost the elderly immune response to vaccination have typically 
involved the use of adjuvants or increased doses of HA protein, but an alternative to 




Since an elderly person’s immune system has likely been exposed to the 
vaccine backbones repeatedly over a long period of time and repeated vaccinations 
with the same vaccine has been shown to generate minimal boosting of the immune 
response, a contemporary backbone that has not been seen as frequently by the 
immune system would generate a more robust immune response (292, 312). 
Additionally, the T cell mediated immune response to vaccination is generated 
primarily against the backbone genes; therefore, using a more contemporary 
backbone would target the primary problem with vaccination of immunoscencent 
individuals, T cell immunity (293, 296, 297, 313). A more contemporary vaccine 
backbone, though, is just one component of improving vaccine efficacy, and it must 
be combined with an attenuation strategy.  
Our lab has developed an alternative vaccine strategy on an influenza A 
platform that includes the PB2 and PB1 mutations found in the IAV-component of 
the LAIV vaccine, the A/Ann Arbor cold-adapted (A/Ann Arbor/6/60 (H2N2) cold-
adapted) backbone, and an HA tag at the C-terminus of PB1 such that the tag is 
expressed from the PB1 ORF (310, 311, 314). We have shown the addition of the HA 
tag yields a safer, more efficacious vaccine than a similarly constructed vaccine 
lacking the HA tag and that this vaccine can also serve as a Differentiating Infected 
from Vaccinated Animal (DIVA) vaccine (1, 314-316). Further, we have 
demonstrated this strategy to be effective in multiple animal models, such as swine, 
mouse, chicken and ferret against many IAV virus strains, providing good 




An important feature of the A/Ann Arbor cold-adapted backbone that we 
incorporated in our vaccine strategy is the PB2 cap-binding mutation, N265S, which 
has been shown to contribute to temperature sensitivity, growth restriction at 37°C, an 
important growth phenotype for vaccine safety (310, 311, 314). Accordingly, the 
mutation of other residues in the cap-binding region may prove effective targets for 
the development of future vaccines, both IAV and IBV. In fact, other cap-binding 
mutations have been described for IBV as potentially having attenuating effects. For 
instance, Wakai et al. showed that cap-binding mutations, W359F and F406Y, caused 
decreased polymerase activity at 37°C and 24 h post-transfection (hpt) in the context 
of B/Shanghai/361/2012 (61).  
This study sought to design an IBV vaccine strategy that would complement 
our lab’s IAV HA tag strategy described above. This was done in a contemporary 
backbone, RG-B/Brisbane/60/2008 (RG-B/Bris), with the aim of generating a vaccine 
that might better stimulate an immune response in the elderly. Here, the hypothesis 
that combining cap-binding mutations in PB2, W359F and F406Y, with the HA tag 
would result in a safe influenza B vaccine was tested. The W359F and F406Y 
mutations were cloned into separate plasmids to generate two PB2/PB1 vaccine 
candidates, each carrying a cap-binding mutation and the HA tag. The results show 
that this strategy, despite what appeared to be some attenuation in vitro, is untenable 






3.3. Materials and Methods 
 
3.3.1. Cloning and confirmation of mutations  
 
Cloning of the PB2 cap-binding mutant plasmids was done using the 
bidirectional pDP-PB2 plasmid described in chapters 2. In order to clone pDP-
PB2_W359F and pDP-PB2_F406Y, site-directed mutagenesis was performed with 
the QuikChange II XL kit (Agilent, Santa Clara, CA). Site-directed mutagenesis 
primers were designed using the QuikChange Primer Design tool provided on the 
manufacturer’s website (Agilent, Santa Clara, CA).  
The HA tag was cloned into pDP-PB1 in-frame and at the C-terminus by 
inverse PCR, and cloning was modeled after the HA tag cloning procedure described 
in Song et al. (314). Primers were designed such that the original stop codon in PB1 
was mutated to an alanine (A) and a new one was introduced following the HA tag. 
Additionally, the final amino acid, Isoleucine (I), in the WT PB1 sequence was 
repeated just before the mutated stop codon (A), thus the entire amino acid sequence 
introduced into PB1 was IAYPYDVPDY, the final 8 amino acids being the HA tag 
(Fig. 3.1). The generated clone was named, pDP-PB1HA. PCR amplification was 
done using Pfu Ultra Polymerase AD (Agilent, Santa Clara, CA) following the 
cycling conditions described in the manufacturer’s instructions. The HA tag and the 
PB2 cap-binding mutations were confirmed by Sanger Sequencing on a Genetic 




Terminator sequencing kit and protocol (Life Technologies, Carlsbad, CA). No 









Figure 3.1. Diagram of the HA tag. The HA tag nucleotide and amino acid 
sequences are shown. Sequencing reads for pDP-PB1HA were compared to the 
pDP-PB1 B/Bris plasmid. The HA tag is: YPYDVPDY. Amino Acids occurring 
prior to the tag, I and A, were generated as a result of deliberately repeating the 
final amino acid is the PB1 sequence, I, and mutating the original stop codon, A. 




3.3.2. Virus rescue and stocks 
 
 Viruses were rescued using 8 plasmid reverse genetics as described in 2.3.4.  
Each PB2 mutant plasmid was paired with pDP-PB1HA, and two viruses were 
rescued, PB2_F406Y_PB1HA: B/Brisbane/60/2008 and PB2_W359F_PB1HA: 
B/Brisbane/60/2008. Briefly, 8 plasmids, 1µg each, corresponding to each virus were 
mixed. Then, FBS free [OPTI-MEM] I (Life Technologies, Carlsbad, CA) and 
Transit-LTI, 2µL/µg plasmid, (Mirus Bio, Madison, WI) were added up to 200µL. 
The reagents were mixed and incubated at room temperature for 45 min. Following 
incubation, 800µL FBS free [OPTI-MEM] I (Life Technologies, Carlsbad, CA) 
containing 10mL/L of Antibiotic/Antimycotic (Sigma-Aldrich, St. Louis, MO) was 
added gently to each tube and then overlaid on a 293T/MDCK cell (8x105/ 5x105) co-
culture in a 6-well plate (Corning, Corning, NY). The cells were placed at 33°C 
overnight. The following day, the media was changed, FBS free [OPTI-MEM] I (Life 
Technologies, Carlsbad, CA) with TPCK (1µg/mL, Worthington Biochemicals, 
Lakewood, NJ) and 10mL/L of Antibiotic/Antimycotic (Sigma-Aldrich, St. Louis, 
MO). 
After virus rescue, supernatant was serially diluted and used to inoculate T75 
flasks (Greiner Bio-One, Monroe, NC) seeded with MDCK cells at 33°C. After 4-5 
days at 33°C, tissue culture supernatant was harvested, and the flask with the highest 
HA titer at the highest dilution was used to inoculate eggs. Serial dilutions were made 
to inoculate 9-day old SPF hen eggs (B&E Eggs, York Springs, PA). Three eggs were 
inoculated per dilution, and 200µL of diluted supernatant was used to inoculate each 




were placed at 4°C. The following day AF was harvested from the eggs, and HA 
assays were preformed as described in 2.3.5. The AF with the highest HA titer at the 
highest dilution was harvested.  
 
3.3.3. Virus titrations 
 
Virus titrations were done by tissue culture infectious dose 50 (TCID50) and 
egg infectious dose 50 (EID50). Calculations for growth kinetics assays were done 
based on TCID50. Both TCID50 and EID50 protocols were carried out in the same 
manner as described in 2.3.5. Titers were calculated by the Reed and Muench method 
(301). 
 
3.3.4. Mini-genome assays 
 
Polymerase assays and transfections were carried out as described in 2.3.7; 
however, three distinct polymerase complexes were evaluated. The first complex 
tested was generated by transfecting pDP-NP and pDP-PA with pDP-PB2_F406Y 
and pDP-PB1HA. Separately, pDP-NP and pDP-PA, pDP-PB2_W359F and pDP-
PB1HA plasmids were also transfected. Both PB2/PB1 polymerase mutant complexes 
were compared to the wholly WT RG-B/Bris polymerase complex. The Gaussia 
Luciferase (Gluc) reporter plasmid (described in 2.3.3) and secreted alkaline 




described above. Two negative controls were included: a no reporter control 
(containing pCMV-SEAP and all 4 RNP plasmids) and a partial vRNP complex 
control (containing the reporter and 3 of 4 vRNP plasmids, no NP). Assays were 
performed at 33, 35, 37 and 39°C. Time points were collected at 6, 12, 24, 48 and 72 
h post-transfection (hpt).  
 
3.3.5. Growth kinetics 
 
Growth kinetics assays were carried out as described in 2.3.8. 
PB2_F406Y_PB1HA: B/Brisbane/60/2008, PB2_W359F_PB1HA: 
B/Brisbane/60/2008 and WT RG-B/Bris viruses were evaluated. These assays were 
completed by infecting MDCK cells with 0.01 MOI of each virus at all temperatures 
previously described: 33, 35, 37 and 39°C. Time points were collected at 6, 12, 24, 48 
and 72 h post-infection (hpi). After each sample was collected, the media was 
replenished, and the samples were placed at -80°C to await titration by TCID50. 
TCID50 titers were determined by the Reed and Muench method (301).  
 
3.3.6. Western blot 
 
MDCK cells were infected with 2 MOI (based on virus titers by TCID50) of 
each virus: mock [FBS free [OPTI-MEM] I (Life Technologies, Carlsbad, CA)], WT 




1malH7:WF10att (positive control virus, described in Song et al.) (317). Prior to 
infection, 1 well of MDCK cells was trypsinized and counted to determine the cell 
number per well that would then be incorporated into the calculation of MOI. Each 
well was infected with 500µL of 2 MOI virus. After overlaying MDCK cells with 
virus, cells were placed at 37°C for 1 h. Next, 1mL of serum-free [OPTI-MEM] I 
(Life Technologies, Carlsbad, CA) with of 1µg/mL TPCK-trypsin (Worthington 
Biochemical, Lakewood, NJ) was added to each well. The infected cells were then 
placed at 33°C for 24 h. At 24 h post-infection, tissue culture supernatant was 
aspirated and 150µL of Laemilli Buffer (Bio-Rad, Berkley, CA) and β-ME were 
added (10:1 ratio, Laemilli Buffer to β-ME) to each well, while gently swirling the 
pipette tip. Then, each sample was immediately heated for 10 min at 95°C to 
complete protein denaturation. Finally, all samples were placed at -20°C.  
In order to perform the western blot, a gradient SDS-PAGE gel (Bio-Rad, 
Berkley, CA) loaded with 5µL of protein ladder (Fermentas, Hanover, MD) and 25µL 
of each sample was placed in a Mini-Protean Tetra Cell electrophoresis chamber 
(Bio-Rad, Berkley, CA) and run for 1 h at 130V. The gel was then removed from the 
electrophoresis chamber and placed on nitrocellulose paper (Bio-Rad, Berkley, CA) 
and blotting paper in transfer buffer. Then, the nitrocellulose paper, blotting paper 
and gel were placed into a semi-dry transfer chamber at 22V for 1 h (Bio-Rad, 
Berkley, CA). After transfer, the nitrocellulose paper was blocked for 2 h at room 
temperature on a rocker with 5mL of molecular grade non-fat dry milk (NFDM) (Bio-
Rad, Berkley, CA) [(1g) dissolved in 5mL of TTBS (a mixture of Tris-buffered saline 




Each wash was 5 min in length at room temperature on a rocker. Finally, a 1:2000 
dilution of anti-HA-tag primary antibody (Cell Signaling Technologies, Beverley, 
MA) was prepared in 5mL of TTBS with 1g of dissolved NFDM and allowed to 
incubate on a rocker at 4°C overnight.  
The following day, the nitrocellulose paper was again washed with TTBS as 
described above. Then, goat anti-mouse secondary antibody (Southern Biotech, 
Birmingham, AL) was diluted 1:50000 in 5mL NFDM and TTBS and incubated at 
room temperature on a rocker for 1 h and 30 min. The nitrocellulose paper was again 
washed 3x with TTBS. Finally, Clarity Western ECL Substrate (Bio-Rad, Berkley, 
CA) chemiluminescent substrate was applied to the nitrocellulose paper according to 
the supplied protocol, and the film was developed after a 10-min exposure to the 
nitrocellulose paper in an exposure cassette.  
 
3.3.7. Mouse study 
 
A mouse study to test vaccine candidate safety was carried out by inoculating 
5-6 week old female DBA/2 mice intranasally with 50µL of 106 EID50 of virus. Virus 
groups included: PB2_F406Y_PB1HA: B/Bris, PB2_W359F_PB1HA: B/Bris, and 
PBS. Four mice were inoculated per group. Weight loss and disease signs were 
monitored (for 9 days and 12 days post-inoculation, respectively). The mouse study 
was approved under University of Maryland approved protocol, R-12-100. Any 
mouse that lost 20% of its starting weight or more or scored a 3 or more in signs of 




3.3.8. Experimental replication and statistical analyses 
 
All data analyses were performed using GraphPad Prism Software Version 
6.00 (GraphPad Software Inc., San Diego, CA), and all in vitro assays were 
performed a minimum of two times in triplicate. For multiple comparisons, two-way 
ANOVA was performed followed by a post-hoc Bonferroni test; p<0.05 was 








3.4.1. Similar GLuc expression of PB2/PB1 mutants compared to WT  
 
To begin the characterization of the PB2/PB1 mutant viruses, polymerase 
assays were performed. The polymerase genes of these complexes and the WT 
complex were transfected with the GLuc reporter (described in Chapter 2) in 293T 
cells, and experiments were setup at 33, 35, 37 and 39°C. Both PB2/PB1 mutant 
polymerase complexes were found to express GLuc at levels similar to WT at 33 and 
35°C (Fig. 3.2A and B). At 37°C, however, expression of GLuc from both PB2/PB1 
mutant polymerase complexes was found to be impaired compared to the WT 
complex, although the difference, at least for the PB2_F406Y_PB1HA: B/Bris 
complex, is only roughly 10 fold at late time points (Fig. 3.2C). After normalization, 
GLuc expression of all polymerase complexes tested was nearly undetectable at 39°C, 
as expected, given that influenza B is not known to replicate at such high 
temperatures (data not shown)(318). In all, these assays do not suggest any difference 
between the polymerase activity of PB2_W359F_PB1HA: B/Bris and 
PB2_F406Y_PB1HA: B/Bris, but the data does suggest that the PB2/PB1 mutant 







Figure 3.2. Polymerase activity of PB2/PB1 mutant complexes. GLuc 
expression normalized with SEAP is shown for the following polymerase 
complexes: PB2_F406Y_PB1HA: B/Bris, PB2_W359F_PB1HA: B/Bris 
and WT. Assays were completed at 33, 35 and 37°C (A, B, and C, 
respectively). Red: WT. Dashed gray: PB2_F406Y_PB1HA: B/Bris. Dark 
gray: PB2_W359F_PB1HA: B/Bris. Time points were collected at 6, 12, 
24, 48 and 72hpt. GLuc activity was measured using a Biolux Gaussia 





3.4.2. Growth curves of PB2/PB1 mutant viruses are similar to WT 
 
Growth kinetics of the PB2/PB1 mutant viruses was compared to that of the 
WT RG-B/Bris virus. MDCK cells were infected at 0.01 MOI, and assays were 
performed at 33, 35, 37 and 39°C. As with the polymerase assays, time points were 
collected at 6, 12, 24, 48 and 72 hpi. Finally, samples were titrated by TCID50 to 
determine the growth curves of each virus. 
 The results indicate that the PB2/PB1 mutant viruses replicate to titers similar 
to WT at 33 and 35°C, although at 35°C, the PB2_F406Y_PB1HA: B/Bris virus 
grows to significantly lower titers than the WT (Fig. 3.3A and B). In contrast, at 
37°C, the PB2/PB1 mutant viruses grow to significantly lower levels than the WT at 
24 and 48 hpi, but by 72 hpi, there is no difference (Fig. 3.3C). At 39°C, all viruses 
were similarly undetectable (data not shown). Overall, the results suggest that the 
PB2/PB1 mutant viruses may be attenuated in comparison to the WT virus at 37°C, at 






Figure 3.3. Growth kinetics of PB2/PB1 mutant viruses. Growth curves for the 
PB2_F406Y_PB1HA: B/Bris and PB2_W359F_PB1HA: B/Bris viruses are shown 
at 33, 35 and 37°C (A, B, and C, respectively). Red: WT. Dashed gray: 
PB2_F406Y_PB1HA: B/Bris. Dark gray: PB2_W359F_PB1HA: B/Bris. 0.01MOI 
of each virus was used for infection. Time points were collected at 6, 12, 24, 48 
and 72hpi. Titrations were done by TCID50. Asterisk indicates p<0.05, each 
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Figure 3.4. Expression of HA tag from PB2/PB1 mutant viruses. Using a mouse 
anti-HA-tag primary antibody, a western blot was performed to determine HA tag 
protein expression by both PB2_W359F_PB1HA: B/Bris, PB2_F406_PB1HA: B/Bris 
and 1malH7: WF10att. MDCK cells were infected with 2MOI of each virus at 33°C. 
After 24 h, supernatant was aspirated, and samples were prepared for western blot. 
Exposure time: 10 min. Lane 1: mock infected. Lane2: WT RG B/Bris infected. Lane 
3: PB2_W359F_PB1HA: B/Bris infected. Lane 4: PB2_F406Y_PB1HA: B/Bris 






3.4.3. PB2/PB1 mutant viruses express the HA tag from the PB1 ORF 
 
To complete the in vitro characterization of the PB2/PB1 mutant viruses, HA 
tag expression from the PB1 ORF was evaluated. A western blot was performed by 
first infecting MDCK cells with 2 MOI of the mutant viruses, the WT and a positive 
IAV control and then collecting a time point at 24 h post-infection (hpi). Following 
sample collection, a western blot was performed with an anti-HA tag primary 
antibody. 
The western blot results showed clear expression of the HA tag from both of 
the PB2/PB1 mutant viruses as well as the IAV positive control, consistent with the 
design of the pDP-PB1HA plasmid used to generate the mutant viruses. Both 
PB2/PB1 mutant virus PB1 proteins ran lower than that of the IAV control, as IBV 
PB1 encodes a shorter protein than influenza A (Fig. 3.4). As expected, no HA tag 
was detected in the mock or WT RG-B/Bris infected samples, although there was 
some non-specific binding likely due to the long exposure time.  
 
3.4.4. PB2/PB1 mutant viruses are lethal in mice at 106 EID50 
 
Safety of the PB2/PB1 mutant viruses was evaluated in mice by inoculating 
female DBA/2 mice with 50µL intranasally of PB2_W359F_PB1HA: B/Bris, 
PB2_F406Y _PB1HA: B/Bris and PBS at 106 EID50, a standard vaccination dose. The 
results showed that the PB2/PB1 mutant viruses were lethal in mice at this dose (Fig. 




mice did not lose weight (data note shown); therefore, it is unclear whether or not 








Figure 3.5. Survival of PB2/PB1 mutant inoculated mice at 106 EID50. 
Mice were inoculated with 50µL of 106 EID50/mL of virus or PBS, 
depending on the group. Dashed gray: PB2_F406Y_PB1HA: B/Bris. Dark 






This study described the development of two experimental LAIV vaccine 
candidates designed on an IBV platform in which both viruses generated contained a 
PB2 cap-binding mutation, either F406Y or W359F, and an HA epitope tag at the C-
terminus of PB1. These modifications showed some indications of attenuation in vitro 
at 37°C as the GLuc expression exhibited by the polymerase complexes and the viral 
titers at early time points post-infection were lower than WT. Given that temperature 
sensitivity at 37°C is a key growth phenotype of the licensed LAIV influenza vaccine 
which contributes to restriction of LAIV vaccine replication to the upper respiratory 
tract and helps to ensure vaccine safety, the PB2_W359F_PB1HA: B/Bris and 
PB2_F406Y_PB1HA: B/Bris viruses were tested for safety in mice at a standard 
vaccine dose of 106 EID50; however, contrary to the attenuation that the in vitro data 
seemed to suggest, both of these PB2/PB1 mutant viruses were lethal in vivo (220, 
260, 263). 
The mortality caused by the PB2/PB1 mutant viruses was surprising for 
several reasons aside from simply the in vitro data. First, previous work with our HA 
tag in the context of IAV indicated that the tag enhances safety, efficacy and stability 
(314). Second, the PB2 F406Y and W359F cap-binding mutations had been 
previously shown to decrease polymerase activity compared to WT in the context of 
B/Shanghai/361/2002 (61). Third, a PB2 cap-binding mutation is included in the 
IAV-component of the LAIV vaccine, suggesting that the cap-binding region is a 




tag and the cap-binding mutations would cause attenuation, but instead, the results 
show that the PB2/PB1 mutant viruses are, at best, as virulent as the WT virus (based 
on the MLD50 of the WT virus established in Chapter 2).  
 While cap-binding mutations, as has been described above, have been known 
to cause attenuation, the idea of cap-binding mutants and other mutations in PB2 
being virulence factors in specific hosts is not unprecedented (310, 319). For instance, 
a mutation at 357 (H to N) in PB2, which is analogous to position 359 of IBV, in the 
context of IAV pH1N1 is an established virulence factor in mice (320). Aside from 
the cap-binding mutation, other PB2 residues associated with mammalian host 
adaptation and virulence in IAV are 81, 199, 355, 627, 647, 667, 671 and 701 (321-
325). Indeed, the role of PB2 in IAV adaptation to mammalian hosts is well 
established, and considering the conservation of PB2 structure, sequence and function 
between IAV and IBV, it is conceivable that some PB2 IBV residues have 
implications for host adaptation as well as enhanced virulence (61, 326). 
The lethality of these PB2/PB1 mutant viruses necessitated a re-evaluation of 
potential vaccine strategies and a closer analysis of our successful IAV vaccine 
strategy in order to develop an effective IBV vaccine in mice. Additionally, the data 
presented here and other findings discussed above suggest that the PB2 F406Y and 
W359F mutations may be virulence factors in the context of RG-B/Bris. Thus, the 





Chapter 4: PB2 Cap-binding Mutants as Influenza B Virulence 
Factors in Mice 
 
4.1. Abstract 
Influenza A virus (IAV) and Influenza B virus (IBV) have a similar host 
mRNA cap-snatching mechanism which is a key and unique feature of the viral life 
cycle utilized during viral transcription, so it follows that any perturbation of this 
complex activity would likely result in attenuation of the virus. Indeed, a cap-binding 
mutation in IAV is included in the licensed seasonal live-attenuated virus (LAIV) 
vaccine. Additionally, IBV cap-binding mutations, PB2 F406Y and W359F, have 
been shown to decrease polymerase activity in B/Shanghai/361/2002. This study 
sought to characterize these cap-binding mutations in the context of 
B/Brisbane/60/2008 as potential virulence factors based on findings described in 
Chapter 3. The data presented here show that in the context of B/Brisbane/60/2008, 
cap-binding mutations, PB2 W359F and F406Y, were more virulent, as evidenced by 
increased weight loss and mortality in DBA/2 mice compared to wild-type (WT) RG-
B/Brisbane/60/2008 (RG-B/Bris). The results suggest that this increased virulence 
may at least be partially due to improved growth and polymerase activity of the cap-
binding mutants at 37°C early in infection. As IBV is not readily infectious in mice 
and the IBV cap-binding region is conserved, these mutations could serve as tools for 
future studies of IBV pathogenesis and vaccine efficacy in mice and possibly other 






Influenza B virus (IBV), a significant human respiratory virus, is part of the 
Orthomyxoviridae virus family which also includes influenza A virus (IAV) and 
influenza C virus (3, 28, 76, 180, 286, 287). The IBV genome consists of 8 segments 
of single-stranded, negative-sense RNA, where each segment encodes at least 1 
protein (3).  
Of the 8 IBV RNA segments, 4 are associated with the viral ribonucleoprotein 
complex (vRNP), which is comprised of the RNA dependent RNA polymerase 
complex proteins (RdRp) and the nucleoprotein, NP, bound to vRNA (57). Segments 
1-3 encode the PB1, PB2 and PA polymerase proteins, respectively, forming the 
RdRp (42). NP, encoded from segment 5, stabilizes each vRNA segment and interacts 
with the viral RdRp, which is bound to each segment (42, 65, 327). The interactions 
of the RdRp and NP proteins are required for the panhandle structure of the vRNA to 
be maintained, a necessary structure for successful transcription and replication (42, 
57, 327). Upon entry of the vRNP into the host cell nucleus, the RdRp functions 
synergistically to snatch the 5’ pre-mRNA cap of host mRNA in order to initiate viral 
mRNA transcription (61, 328). First, the PB2 protein binds the host pre-mRNA cap 
(60, 61). Then, PA, which encodes a 5’ to 3’ endonuclease, cleaves the cap (62, 135, 
329, 330). Finally, PB1 initiates viral mRNA transcription using the 5’ pre-mRNA 
cap as a primer (41, 58).  
The remaining gene segments, segments 4, 6, 7 and 8, code for hemagglutinin 




serves as the major antigenic protein and is responsible for binding the host cell 
receptor, alpha 2,6 sialic acid (203, 306, 309, 331). Although NA is a surface protein 
and does have antigenic properties, its primary function is as a sialidase that cleaves 
the sialic acid moiety off the host cell, releasing the mature virion during budding (78, 
81, 82). Segment 6 also encodes NB protein, an ion channel protein (44, 45). Segment 
7 encodes BM1, which serves as a matrix protein, while BM2, translated by a stop-
start mechanism following the BM1 open-reading frame (ORF), functions as an ion 
channel protein. The IBV ion channels are involved in acidification of the virion after 
entry; however, BM2 is also involved in viral assembly and packaging (103, 332). 
Finally, segment 8 encodes BNS1 and BNS2 by a post-transcriptional splicing event. 
BNS1, non-structural protein 1, is involved in inhibiting the host innate immune 
response, while BNS2 serves as a nuclear export protein (49, 50, 308). 
 Cap snatching is an essential feature of the influenza virus life cycle, as 
described above, so it is not surprising that IAV and IBV cap-binding mutants have 
been shown to cause attenuation. For example, the IAV-component of the live-
attenuated licensed seasonal vaccine contains a cap-binding mutation at position 265, 
asparagine to serine, in PB2 contributing to virus temperature sensitivity and 
attenuation (220, 221, 223, 310). In addition, many cap-binding mutations introduced 
into B/Shanghai/361/2002 have been shown to decrease polymerase activity 
compared to the wild-type (WT) polymerase complex in 293T cells (61). Wakai et al. 
identified various mutations at positions 359 and 406 of the PB2 
B/Shanghai/361/2002 polymerase gene including W359H, W359F and F406Y that 




mutations showed severe decreases in activity at 24 hpt when compared to WT, 
whereas the F406Y mutant complex showed a moderate decrease in activity 
compared to WT (61). Contrary to these findings, other reports suggest that some 
cap-binding mutants may be virulence factors in vivo depending on the virus strain 
into which the mutations are introduced. For instance, H357N in PB2 of influenza A 
pH1N1 has been shown to increase virulence and mortality in BALB/c mice as 
compared to the virus carrying the WT PB2 (320).  
 IBV strains are known to infect many genetic strains of mice, both with and 
without adaptation; nonetheless, productive infection of mice with IBV has been 
difficult due to reduced susceptibility (243). Susceptibility of mice to influenza is a 
complex issue. One factor is the role of Mx1 gene, an IFN regulated gene, which has 
been shown to dramatically decrease susceptibility to influenza; however, most 
inbred mice possess a defective Mx1 gene (243, 333, 334). Another factor is the 
distribution of alpha 2,6 sialic acid receptors recognized by IBV, as alpha 2,3 sialic 
acid receptors are more abundant in mouse airways than alpha 2,6 (243, 331).  
Despite factors hindering mouse susceptibility to IBV, some IBV strains are 
known to infect mice without prior adaptation, and B/Lee/40 and B/Victoria/16/88 are 
examples (242). These IBV strains have been shown to naturally infect DBA/2 and 
C57BL/6 mice, but for other IBV strains, adaptation has been shown to effectively 
increase susceptibility of mice (242). For example, with the introduction of a 
mutation in BM1, N221S, B/Yamagata/166/98 has been shown to infect BALB/c 
mice (234). Susceptibility of mice to IBV appears to be highly variable depending on 




 Given the findings described in Wakai et al. showing PB2 cap-binding 
mutants with decreased polymerase activity in the context of B/Shanghai/361/2002 
and the findings described in Chapter 3, this study sought to characterize cap-binding 
mutants of WT RG-B/Brisbane/60/2008 (WT RG-B/Bris), PB2 F406Y and PB2 
W359F, speculating that these mutations were the reason the PB2/PB1 viruses 
described Chapter 3 were lethal (61). It was hypothesized that the F406Y and W359F 
PB2 mutations would result in increased virulence in vivo but not in vitro, as both 
showed decreased polymerase activity at 24 hpt and 37°C in the context of 
B/Shanghai/361/2002 and the data presented in Chapter 3 show insignificant 
differences between viruses carrying these mutations and the WT (61). Here, the 
results show that the introduction of these cap-binding mutants into the PB2 of RG-
B/Bris increased both virulence and mortality in DBA/2 mice as compared to WT. 
The in vitro and in vivo data suggests this increased virulence may be, at least in part, 
due to enhanced replication of the PB2 F406Y and PB2 W359F mutant viruses at 
37°C compared to WT early during infection. Given these findings, these cap-binding 





4.3. Materials and Methods 
 
4.3.1. Cloning of cap-binding mutants by site-directed mutagenesis, virus 
rescue, and stocks 
 
 All 8 plasmids of RG-B/Brisbane/60/2008 (RG-B/Bris) described in Chapter 2 
were used in these studies; however, only the PB2 plasmid was modified. The cap-
binding mutants, PB2 F406Y and PB2 W359F, were cloned through site-directed 
mutagenesis using the QuickChange II XL kit (Agilent, Santa Clara, CA) and the 
pDP-PB2 B/Bris plasmid as a template. Primers were designed using the 
QuickChange® Primer Design Program (Agilent, Santa Clara, CA). The cloning 
procedure was performed as per the manufacturer’s recommendations, and two 
constructs were generated, pDP-PB2_F406Y and pDP-PB2_W359F. Each plasmid 
was subject to Sanger sequencing using methods described in Chapter 2 to the 
confirm sequences. 
Two viruses, PB2_F406Y: B/Bris and PB2_W359F: B/Bris, were rescued by 
8-plasmid reverse genetics in which 7 RG-B/Bris plasmids and 1 mutant PB2 plasmid 
containing a mutation at either position 359 or 406 were transfected. Transfections 
were performed as described in 2.3.4. Briefly, 1µg of each plasmid was mixed with 
Transit-LTI, 2µL/µg plasmid (Mirus, Madison, WI), and [OPTI-MEM] (Life 
Technologies, Carlsbad, CA) up to 200µL. The solution was vortexed and incubated 
at room temperature for 45 min. After a 45-min incubation, 800µL of [OPTI-MEM] 




then overlaid with the transfection solution, and cells were placed at 33°C overnight. 
The following day, the media was changed, 2mL of [OPTI-MEM] and TPCK-trypsin, 
1µg/mL (Worthington, Lakewood, NJ). Stocks were grown in MDCK cells in T75 
flasks (Greiner Bio-One, Monroe, NC) as described in 3.3.2. Whole genome 
sequencing was performed to ensure that virus stocks contained only the desired 
mutations. Sanger sequencing was carried out using the Big Dye Terminator kit 
(BigDye® Terminator v3.1 Cycle Sequencing Kit, Life Technologies) and run on 




To titrate stock viruses, cell culture supernatants, and tissue homogenates, 
TCID50 titrations were performed using MDCK cells cultured in 96-well plates 
(Greiner Bio-One, Monroe, NC). Titrations were performed as described in 2.3.5. 
Briefly, MDCK cells (25,000/well) were seeded in 100µL of [OPTI-MEM] (Life 
Technologies, Carlsbad, CA) and incubated overnight at 37°C.  Subsequently, 10-fold 
serial dilutions of virus samples were prepared in [OPTI-MEM] supplemented with 
1µg/mL TPCK-trypsin (Worthington, Lakewood, NJ).  After removing the media 
from the MDCK cells, 200µL of each dilution was overlaid on multiple wells per 
dilution. The virus-overlaid cells were then incubated for 3 days at 33°C. After 
incubation, HA assays were performed as described in 2.3.4. Briefly, 50µL of virus 




(Corning, Corning, NY). Next, 50µL of 0.5% chicken red blood cells (cRBC) in PBS 
was added to each well, and the plates were incubated for 45 min at room 
temperature. Finally, hemagglutination was recorded, and the 50% infectious dose 
titer was determined by the Reed and Muench method (300). 
 
4.3.3. Mini-genome assays 
 
Polymerase assays were performed using a mini-genome assay as described in 
2.3.7 with some modifications. Briefly, assays were performed in 12-well plates 
(Corning, Corning, NY) with 0.5µg of the GLuc reporter plasmid, each RG-B/Bris 
vRNP plasmid and a secreted alkaline phosphatase (SEAP) expression plasmid. All 6 
plasmids were transfected in 293T cells (1x106 cells/well) with 2µL/µg plasmid of 
Transit-LTI (Mirus, Madison, WI). Negative controls were also included: a no 
reporter control (polymerase genes only) and a no PB1 control (contained polymerase 
genes and reporter but lacked PB1). Following transfection, supernatant was collected 
at 6, 12, 24, 48 and 72 h post-transfection (hpt), and an additional sample was 
collected at 24 hpt for SEAP analysis. This procedure was carried out at 33, 35, 37 
and 39°C. SEAP assays were performed using the Tropix Phospha-Light SEAP 
Reporter Gene Assay System kit (Life Technologies, Carlsbad, CA) and protocol. 
GLuc expression was quantified using a BioLux® Gaussia Luciferase Assay Kit 
(New England Biolabs, Ipswich, MA). The luminescence for GLuc and SEAP assays 
was measured over a 1 sec integration time on a Victor X4 Luminescence Plate 




4.3.4. Growth kinetics 
 
Growth kinetics were performed in MDCK cells in 6-well plates using an 
MOI of 0.01 based on virus titers by TCID50 as described in 2.3.8 with some 
modifications. Time points were collected at 6, 12, 24, 48 and 72 h post-infection 
(hpi), and for each time point, 120µL of supernatant was collected on ice and frozen 
at -80°C until titration. After sample collection, the media was replenished by adding 
[OPTI-MEM] (Life Technologies, Carlsbad, CA) containing 1µg/mL of TPCK-
trypsin (Worthington, Lakewood, NJ)].  The same procedure was followed at each 
temperature, 33°C, 35°C, 37°C and 39°C. Then, samples were titrated by TCID50, and 
the viral titer was determined by the Reed and Muench method (301). 
 
 4.3.5. Mouse studies 
 
Six-week old female DBA/2 mice were purchased from Charles River, 
Frederick, MD. Animal experiments were performed under BSL-2 conditions under 
the approval of the University of Maryland Institutional Animal Care and Use 
Committee protocols R-12-100 and R-13-65. On day 0, mice were weighed and then 
inoculated with 50µL of 105 EID50/mL of virus intranasally. There were four groups 
of mice: PB2_F406Y: B/Bris, PB2_W359F: B/Bris, WT RG-B/Bris and PBS. In each 
group, there were ten mice, except for the PBS in which there were only 4 mice, 




additional mice were inoculated for tissue collection, but for the PBS group, only 3 
additional mice were inoculated for tissue collection. Mice were monitored 
throughout the experiment for weight loss and clinical signs until 12 days post-
infection (dpi) and mice exhibiting 20% weight loss or greater and/or a scoring of 3 
or more for clinical signs (described in 2.3.9) were humanely euthanized. On days 3, 
5 and 7 post-inoculation, 3 mice per virus group and 1 PBS mouse were humanely 




The right lung lobe and nasal turbinates were harvested for titration while the 
left lung lobe was collected in 10% formalin for histopathology. Tissues were 
homogenized using a QIAgen tissue lyser at 50Hz for 4 min and then clarified by 
centrifugation at 4°C for 10 min at 1,000xg (QIAgen, Valencia, CA).  
 Formalin fixed lung samples were embedded, sectioned and subjected to 
hematoxylin and eosin (H&E) staining. Tissue from days 3, 5 and 7 days post-
infection (dpi) were analyzed by a board certified veterinary pathologist. Scoring of 
the bronchi/bronchioles, pulmonary vasculature, alveoli and overall/extent lung was 
performed. Tissue damage was scored on a scale of 0-4, 0 being normal and 4 being 
severe. A total score/extent lung score of 4 indicates the involvement of the entire 
lung lobe. 




extracted from lung homogenate supernatant of 1 mouse per virus group on peak titer 
days. RNA extractions were performed using the QIAgen RNeasy mini-kit, following 
the provided protocol (QIAgen, Valencia, CA), and cDNA was prepared by the 2-step 
RT-PCR protocol described 2.3.2. Full-length sequence was obtained for the PB2 
gene of each mouse sample for sequencing. The PB2 F406Y and W359F mutations 
were confirmed by Sanger sequencing, and no unwanted mutations were detected. 
 
 4.3.7. Statistical analyses 
 
All data analyses were performed using GraphPad Prism Software Version 
6.00 (GraphPad Software Inc., San Diego, CA).  All assays were performed a 
minimum of two times in triplicate. For multiple comparisons, two-way ANOVA was 






4.4.1. Polymerase assays and growth kinetics of cap-binding mutants show 
trend towards increased activity and replication at 37°C  
 
Polymerase activity of the PB2 cap-binding mutants was assessed by 
performing mini-genome assays at 33, 35, 37 and 39°C. Samples were collected out 
to 72 hpt. Although normalized GLuc expression of the cap-binding mutant 
complexes was generally higher than the WT, these differences are not significant as 
all were less than 1 log; therefore, these assays showed that the PB2_F406Y and 
PB2_W359F polymerase complexes express similar levels of GLuc as the WT 
polymerase complex at all temperatures (Fig. 4.1A-C). Interestingly, at 37°C, the 
PB2_W359F cap-binding mutant had higher GLuc expression compared to the WT, 
although, again, the difference was less than 1 log (Fig. 4.1A-C). Despite the fact that 
the difference in PB2_W359F polymerase expression was not significant compared to 
WT, it was in contrast to the findings in Wakai et al., which showed decreased 
polymerase activity of this mutation in comparison to WT in the context of 
B/Shanghai/361/2002. The PB2_F406Y complex showed nearly identical GLuc 
expression to the WT at 37°C, and like the results for PB2_W359F, this finding 
contrasted the results in Wakai et al. which showed a mild decrease in polymerase 
activity with the introduction of this mutation in the B/Shanghai/361/2002 
polymerase complex (Fig. 4.1C) (61). Finally, at 39°C, normalized polymerase 




Viral replication of the cap-binging mutants relative to the WT RG-B/Bris 
virus was evaluated next by performing growth kinetics. As with luciferase activity, 
viral growth kinetics were evaluated at 33, 35, 37 and 39°C. Supernatant was 
collected up to 72 hpi and titrated by TCID50 to determine viral titers. At 33 and 
35°C, the WT virus grew to significantly higher titers compared to both the cap-
binding mutant viruses at late time points (Fig. 4.2A and B). Similar to the 
polymerase assays, the PB2_F406Y and PB2_W359F viruses showed slightly 
enhanced growth when compared to the WT RG-B/Bris virus at 37°C over the range 
of time points measured; however, the difference in viral titers between the 
PB2_W359F and WT RG-B/Bris virus was insignificant (Fig. 4C). At 39°C, virus 
growth was below the detectable limit for all three viruses (data not shown). Overall, 






Figure 4.1. Mini –genome assays of B/Brisbane/60/2008 cap-binding mutants. 
Plasmids carrying the influenza polymerase genes as well as Gaussia Luciferase 
and secreted alkaline phosphatase (SEAP) were used to transfect 293T cells. 
Assays were completed at 33°C (A), 35°C (B), and 37°C (C). Luciferase activity 
was normalized to SEAP activity at 24hpt. Supernatant was collected at 6, 12, 24, 
48 and 72hpt to assay for GLuc activity. The blue line represents the polymerase 
complex carrying the PB2_W359F mutation. The black line represents the 
polymerase complex carrying the PB2_F406Y mutation. The red line represents 












Figure 4.2. Viral growth kinetics of B/Brisbane/60/2008 cap-binding 
mutants. MDCK cells were infected with 0.01 MOI of each virus. Growth 
kinetics were assessed at 33°C (A), 35°C (B), and 37°C (C). Supernatant 
was collected at 6, 12, 24, 48 and 72hpi. Virus titers of collected 
supernatant were determined by TCID50. Red: WT RG-B/Bris, Black: 
PB2_F406Y: B/Bris, Blue: PB2_W359F: B/Bris. Asterisk indicates 




4.4.2. Increased weight loss and mortality with cap-binding mutant viruses in 
DBA/2 mice 
 
To determine whether the cap-binding mutations confer some advantage to the 
WT RG-B/Bris virus in vivo, DBA/2 mice were inoculated with 105 EID50/mL of 
virus and monitored for weight loss and clinical signs (242). The results showed a 
significant increase in weight loss with the introduction of the F406Y and W359F 
PB2 cap-binding mutations, and similar weight loss was seen in both cap-binding 
mutant virus inoculated mice groups compared to the WT (Fig. 4.3A). While weight 
loss in the WT RG-B/Bris group began on the same day as the weight loss in the cap-
binding mutant virus groups, overall weight loss seen in the WT inoculated mice was 
less severe, averaging roughly 10% of the starting weight (Fig. 4.3A).  
The contrast in survival rate of mice inoculated with the PB2 cap-binding 
mutant and WT viruses reflected the differences seen in weight loss. Most mice in the 
PB2_F406Y and PB2_W359F groups either succumbed to infection or had to be 
euthanized based on weight loss by 8 dpi, although all mice in both groups had to be 
euthanized or succumbed to infection, while only 3 mice in the WT RG-B/Bris group 
developed severe disease requiring euthanasia (Fig. 4.3B). Notably, these deaths 
occurred late during the time course of infection (Fig. 4.3B). The majority of mice in 







Figure 4.3. Weight loss and survival of cap-binding mutant infected mice. 
Each group was inoculated with 50µL intranasally of 105 EID50/mL of virus, 
either a B/Bris cap-binding mutant virus or the WT RG-B/Bris virus. Mice 
were weighed and monitored daily for 12 days post-infection. Weight loss (A) 
Survival (B). The asterisk indicates significance, and the color of the asterisk 
indicates which virus group lost significantly more weight in comparison to 
WT. P-values of <0.05 were considered significant. p < 0.05 (*), p <.001 (***) 
n=10 per group. Red: WT RG-B/Bris. Black: PB2_F406Y: B/Bris. Blue: 





4.4.3. Pulmonary virus titers early during infection trend toward increased 
replication of cap-binding mutants  
 
Next, the relationship of the observed morbidity and mortality with viral titers 
in the lungs and nasal turbinates was assessed. On days 3, 5 and 7 post-inoculation, 
lung and nasal turbinates from 3 mice/group were harvested, and each sample was 
titrated by TCID50. Results revealed that lung titers on days 5 and 7 post-inoculation 
were similar among all virus groups. On day 3, lung titers were greater in the 
PB2_F406Y and PB2_W359F inoculated mice; nevertheless, with only 3 samples per 
group and an outlier in the PB2 F406Y group, significance cannot be determined 
(Fig. 4.4A-C). Virus titers in the nasal turbinates (NT) were evaluated next, and the 
results suggest that the WT RG-B/Bris virus grows to similar titers in the nasal cavity 
as the PB2 mutant viruses. WT RG-B/Bris nasal turbinate titers, however, dropped 
off gradually, while NT titers in both PB2 F406Y and PB2 W359F mutant groups 
dropped off more rapidly, although more samples would be needed to confirm this 







Figure 4.4. Tissue titers of cap-binding mutant infected mice. Each group 
was inoculated with 50µL intranasally of 105 EID50/mL of either a B/Bris cap-
binding mutant virus or WT RG-B/Bris. Three DBA/2 mice per group were 
sacrificed on days 3, 5 and 7 post-infection. Lung and nasal turbinates were 
collected for tissue titration. The left lung lobe was harvested from each mouse 
for tissue while the remaining lobes were homogenized in 500µL of PBS for 
tissue titration (A-C). The nasal turbinates were harvested from each mouse and 
homogenized in 500µL of PBS for titration (D-F). Virus titers were determined 
by TCID50. n=3 per group. Red: WT RG-B/Bris. Black: PB2_F406Y: B/Bris. 





4.4.4. PB2 cap-binding mutant viruses show enhanced lung pathology 
 
Tissue pathology in the left lung lobe of mice from each group on days 3, 5 
and 7 post-inoculation was assessed. The results showed that severe pathology 
associated with the WT virus progressed/developed more slowly in comparison to the 
progression/development of pathology in the PB2 mutant groups. This was evident in 
the severity scores of both the total (extent) tissue pathology and the pulmonary 
vascular pathology on 3 and 5 dpi when severity scores were higher in mice 
inoculated with cap-binding mutant viruses than mice inoculated with WT virus (Fig. 
4.5B and D). By day 7, virus-related tissue pathology scores were similar among mice 
in all virus groups (Fig. 4.5A-D). Representative images of histopathology from each 
group further support these overall findings. On day 3 post-inoculation, the WT virus 
inoculated group is nearly indistinguishable from the PBS group. On day 5, the 
pathology observed in the WT image is clearly more severe but reduced relative to 
both the PB2_F406Y and PB2_W359F inoculated groups. By day 7, virus-associated 
pathology is nearly indistinguishable among all virus groups (Fig. 4.6). 
Most of the severe pathology observed in the virus-infected tissues was 
observed in the pulmonary vascular regions. The pathology seen in the vasculature 
consisted primarily of vasculitis as evidenced by perivascular cuffing, the 
accumulation of a dense mass of lymphocytes around the blood vessel. Infection of 
this region is associated with acute lung injury in both mice and humans, as this 
region is involved in gas exchange, and any damage to it would contribute to 




Less severe pathology was observed in the alveolar and bronchiolar tissues, 
although severity scores were higher in the alveolar than the bronchiolar tissues. The 
majority of necrosis and inflammation was seen in the alveoli. Normal to mild 
pathology was seen in the bronchi, and severity scores were similar amongst all virus 
groups. In all, similar manifestations of pathology were seen in mouse tissue from all 





Figure 4.5. Lung pathology of cap-binding mutant infected mice. Tissue 
pathology was assessed for 2 mice per virus group. Each group was inoculated 
with 50µL intranasally of 105 EID50/mL of either a B/Bris cap-binding mutant 
virus or WT RG-B/Bris. Tissue pathology was analyzed in the right lung lobe of 
each mouse on days 3, 5 and 7 dpi. Aveoli pathology (A), vascular pathology 
(B), bronchi pathology (C) and extent pathology (D) Red: WT RG-B/Bris. 
























Figure 4.6. Representative images of lung pathology of cap-binding 
mutant infected mice. Top left image: PBS negative control. First row 
of images, from left to right: PB2_F406Y, PB2_W359F and WT RG-
B/Bris on 3 dpi. Second row of images, from left to right: WT RG-
B/Bris, PB2_F406Y and PB2_W359F on 5 dpi. Third row of images, 







Here, PB2 cap-binding mutations, F406Y and W359F, originally described in 
B/Shanghai/361/2002 were characterized in the context of WT RG-
B/Brisbane/60/2008 to determine if the PB2 cap-binging mutations would be 
virulence factors in vivo but attenuated in vitro (61). In order to characterize these 
mutations, polymerase assays, growth kinetics and in vivo analyses of survival and 
pathology in a DBA/2 mouse model were performed.  
The in vitro data generated in this study showed few differences between the 
cap-binding mutant viruses and the WT virus, although the results did suggest that the 
cap-binding mutants may replicate to higher titers at 37°C. In contrast, the in vivo 
results showed some clear differences between the PB2 cap-binding mutant viruses 
and the WT virus indicating that the PB2 cap-binding mutants are virulence factors in 
mice. Viral titers in the lungs and nasal turbinates were similar among all virus 
groups; however, at 3dpi, lung titers were higher in both PB2 mutant infected mouse 
groups than in the WT infected group. Additionally, the pathology scores and images 
suggested that the development of severe pathology was slower in the WT virus 
infected group than the development of pathology seen in both PB2 cap-binding virus 
infected groups. The survival data, however, is the most compelling evidence of 
enhanced virulence of the cap-binding mutant viruses. Overall, 100% of the mice in 
both PB2_F406Y and PB2_W359F virus groups either succumbed to infection or had 
to be euthanized, while the same outcome occurred in only 30% of the mice in the 




and more virulent in the DBA/2 mouse model while expressing similar levels of 
GLuc and replicating to similar titers as the WT in vitro. 
 As previously noted, Wakai et al. showed decreased polymerase activity of 
these cap-binding mutants at 24 h and 37°C in the context of B/Shanghai/361/2002 
indicating that the mutations may be attenuated in mice as the body temperature of a 
mouse is 37°C (61). The results presented here, which show no decrease in 
polymerase activity of the cap-binding mutants compared to WT at 37°C and 
enhanced virulence of the cap-binding mutants in mice, are contrary to these findings, 
but they are consistent with the virulence seen in mice inoculated with the PB2/PB1 
mutant viruses in Chapter 3.  
There are several potential explanations for the discrepancy between the 
findings in Wakai et al. and those presented here including phylogenetic differences 
between B/Brisbane/60/2008 and B/Shanghai/361/2002 as well as potential temporal 
differences between the behaviors of these viruses. Influenza B viruses are subdivided 
into two HA antigenic lineages, B/Victoria and B/Yamagata, which differ from one 
another based on antigenicity and sequence (75). B/Brisbane/60/2008 is a B/Victoria-
like virus, while B/Shanghai/361/2002 is a B/Yamagata-like virus. These lineages are 
known to have different preferences for sialic acid receptors (alpha 2,3 versus alpha 
2,6) as well as dissimilarities in susceptibility of mice; therefore, given these known 
distinctions in behavior, it is also conceivable that the PB2_F406Y and PB2_W359F 
mutations could behave disparately in each lineage (234, 242, 331). Importantly, it is 
also possible that, had the polymerase assays with B/Shanghai/361/2002 been carried 




mutants relative to WT would have proven to be only temporal. 
 Although this study did not seek to identify a mechanism of the enhanced 
morbidity and mortality associated with the PB2_F406Y and PB2_W359F mutations, 
one possibility is that these mutations may alter polymerase interactions with mouse 
host factors, as the overall growth differences are relatively small but the difference in 
mortality is comparatively large. In influenza A, PB2 is known to be a major 
determinant of host range. For example, PB2 E627K is a marker of mammalian 
adaptation and has been shown to enhance replication in mammalian cells without 
altering tissue tropism (321, 339, 340). Given the strong degree of structural and 
sequence homology between the PB2 of IAV and IBV, it is conceivable that the 
influenza B cap-binding mutants described here could have similar effects, thus future 
studies on tissue tropism would address this question (61, 326). 
 To conclude, the findings presented here are consistent with other studies that 
have shown IBV adaptation in mice involves the backbone genes of the virus rather 
than the surface genes (234, 341). They are also consistent with another study, which 
showed that an IAV PB2 cap-binding mutant virus with a mutation at amino acid 
residue 357, analogous to position 359 of IBV, was more virulent in mice than the 
WT (320). Finally, these mutations are potential tools for the study of IBV 
pathogenesis and vaccine efficacy in mice. Since many IBV strains are not naturally 
virulent in mice, IBV studies have traditionally been performed in immunodeficient 
mice or with mouse-adapted viruses, but with the incorporation of the PB2 F406Y or 
PB2_W359F, studies could more easily be performed in mouse models, although the 













Chapter 5:  Development of Alternative Influenza B LAIV 
Vaccines based on three amino acid mutations and an C-





Influenza B virus (IBV) is a major cause of human respiratory illness and is 
such a significant cause of human disease that it is incorporated into the seasonal 
influenza vaccine. Traditionally, one strain of IBV was incorporated into a trivalent 
vaccine, which also contained two strains of influenza A virus (IAV); however, 
beginning in the early 2000s, this composition was sometimes associated with 
antigenic mismatch due to co-circulation of IBV HA antigenic lineages, B/Yamagata-
like and B/Victoria-like, and the lack of cross-reactivity between them. In response, a 
quadrivalent vaccine was developed which incorporates both HA antigenic lineages 
of IBV as well as two strains of IAV. While this has improved vaccine coverage 
against IBV, additional improvements could be made in both vaccine safety and 
efficacy. Previously, we showed that the incorporation of 391E, 581G, 661T and a C-
terminal HA tag in PB1 in addition to a 265S mutation in PB2 of A/guinea fowl/Hong 
Kong/WF10/99 (H9N2) and A/turkey/Ohio/313053/2004 (H3N2) viruses enhanced 
vaccine stability, safety and efficacy over similar but tag-less vaccine formulations. 
The study described here details efforts to develop a complementary strategy for IBV. 
The results show that an IBV carrying mutations in PB1 (K391E, E580G, S660A and 




demonstrate for the first time that a subset of mutations analogous to those found in 
the A/Ann Arbor cold-adapted licensed vaccine backbone can attenuate IBV and 
prove that 3 mutations rather than the licensed 7 found in the B/Ann Arbor cold-







Influenza B virus (IBV) is part of the Orthomyxoviridae family of viruses, 
which also includes influenza A virus (IAV) and influenza C virus (3). IBV is an 
enveloped, negative-sense, single-stranded RNA virus with a segmented genome (3). 
Each of the 8 RNA segments of its genome encodes 1 or 2 proteins, and the entire 
genome encodes a total of 11 proteins (44, 47, 48).  
Segments 1-3, 5, 7, and 8 comprise the virus backbone. Segments 1-3 and 5 
encode proteins that form the viral ribonucleoprotein complex (vRNP). The vRNP 
complex is comprised of the polymerase proteins, PB1, PB2 and PA, encoded from 
segments 1-3, respectively, as well as NP, a nucleoprotein, encoded from segment 5 
and bound to each vRNA segment (41, 42, 58, 60). The polymerase proteins work 
together to initiate viral mRNA, cRNA and vRNA transcription. To initiate viral 
mRNA transcription, the PB2 protein binds the host 5’ mRNA cap (61, 329). Then, 
PA cleaves the cap, and PB1, which contains the polymerase active site, initiates 
transcription of the viral genome (41, 42, 58, 59, 62, 344). The remaining backbone 
segments, 5 and 7, encode a variety of proteins including an innate immune response 
antagonist, a nuclear export protein, a matrix protein and an ion channel protein (47-
50, 69, 101, 126, 172, 194, 197, 198, 206, 235, 244, 245, 308, 345). 
Segments 4 and 6 encode surface proteins HA and NA, respectively, although 
HA is the major antigenic protein. In addition to being antigenic surface proteins, HA 
binds the host cell receptor, sialic acid, and NA is a neuraminidase responsible for 
cleaving sialic acid from the surface of the host cell to allow for release of newly 




alternate open reading frame (ORF), but unlike NA, NB is an ion channel that likely 
facilitates the acidification of the virion after endocytosis (44, 45, 85, 207).  
IBV causes respiratory disease in humans, is considered a major human 
pathogen and has a well-documented history of causing epidemics; however, IBV 
infections are seasonal, as infections peak in the winter due to the drier, colder 
conditions (30, 76, 180, 286, 287). Although IBV infects all age groups, infections 
are particularly severe in the very young and the elderly. For instance, from 2004-
2011 (excluding the 2009 pandemic), 22-44% of all pediatric influenza-related deaths 
in the U.S. were IBV-related (28). From 1979/80-2000/01, hospitalization rates for 
persons of all ages due to IBV-related illness occurred at a rate of 83.4/100,000 cases 
(4). Interestingly, influenza B hospitalization rates during this period were higher than 
seasonal influenza A H1N1 but lower than influenza A H3N2 (4).  
Each year, seasonal influenza vaccines are manufactured to confer protection 
against circulating strains of influenza A and B; nonetheless, the same backbone 
genes are always incorporated into the seasonal vaccine, while the surface genes are 
updated as needed to match circulating strains since immunity is associated primarily 
with the HA and NA surfaces proteins (35, 81, 309). Traditionally, the seasonal 
vaccine possessed three strains of influenza viruses, two IAV strains (an H1 and an 
H3) and one IBV strain; however, new for the 2013-14 influenza season, quadrivalent 
vaccines carrying two strains of IAV and two strains of IBV were made available (24, 
25, 37). The reason for the addition of a second strain of IBV is a result of the co-




have little cross-reactivity in that immunity to one lineage does not protect against 
exposure to the other (75, 76, 217, 346).  
Influenza vaccines come in two main platforms: killed virus (KV) and live-
attenuated (LAIV) (24). KV vaccines are grown and are then inactivated with 
formalin, a process that renders the component viruses non-replicative (24, 249). In 
contrast, the licensed LAIV vaccine contains a series of cold-adapted mutations that 
were identified by passing A/Ann Arbor/6/60 (H2N2) and B/Ann Arbor/1/66 viruses 
at progressively lower temperatures until these viruses grew well at 25°C, far below 
the optimum growth temperature of a wild-type (WT) virus of either type (220, 223, 
257, 319). Over the course of these passages, each virus accumulated a series of 
mutations enabling growth at lower temperatures. The mutations identified in both 
A/Ann Arbor/6/60 (H2N2) (A/Ann Arbor) and B/Ann Arbor/1/66 (B/Ann Arbor) are 
located primarily in the vRNP complex. The A/Ann Arbor mutations are PB2 265S, 
PB1 391E, PB1 581G, PB1 661T and NP 34G, while the B/Ann Arbor mutations are 
PB2 630R, PA 341M, NP 114A, NP 410H, NP 509T, M1 159Q and M1 183V (208, 
220, 222, 223, 257-259, 311, 319). The cold-adapted backbones of both of these 
viruses are incorporated into the LAIV seasonal vaccine each year as the presence of 
these mutations restricts virus replication of the vaccine to the upper respiratory tract, 
preventing severe vaccine-related influenza infection and ensuring vaccine safety 
(263). 
Live-attenuated vaccines have been shown to confer better coverage than KV 
vaccines due to the stimulation of a humoral (primarily IgG and IgA) and a T-cell 




simply the humoral (IgG) response associated with KV vaccines (347-349). In 
addition to an adaptive response, LAIV vaccines have also been shown to heighten 
the innate immune response, inducing increased IFN (170, 288, 350). Despite the 
enhanced protection conferred by LAIV vaccination, improvement is still needed, as 
LAIV vaccines can only be administered to healthy individuals of a select age group, 
ages 2-49 years old (24). Thus, the most at-risk populations, the very young, the 
elderly and those with pre-existing conditions, do not have access to the most 
immunogenic vaccine because of the potential risk that a replicative vaccine carries in 
those with altered immune status.  
Aside from the health and age-related restrictions associated with the LAIV 
vaccine, the outdated LAIV vaccine backbones present other limitations. These 
backbones potentially limit the amount of cross-protection elicited by the vaccine 
since cross-protection has been associated with an immune response to internal genes; 
however, they also limit the robustness of the immune response in individuals who 
have been repeatedly exposed, like elderly individuals (290, 292, 294-297). Elderly 
persons have been shown to respond less well to the LAIV vaccine than younger 
healthy individuals in part due to immune history and immunosenescence, so a 
possible resolution to this problem could be the use of a more contemporary vaccine 
backbone (267, 351). The limitations of the currently licensed LAIV vaccine based on 
A/Ann Arbor/6/60 (H2N2) and B/Ann Arbor/1/66 cold-adapted (ca) backbones have 
led to a concerted research effort to improve upon the current strategy in order to 
develop a more efficacious vaccine that can safely be administered to all, in particular 




A variety of strategies have been employed to develop alternative 
experimental LAIV influenza vaccines. Such strategies include, but are not limited to, 
whole and partial gene knockouts, the insertion of foreign sequences, and the 
manipulation of the HA cleavage site (176, 177, 239, 240, 248, 284, 352-355). 
Extensive work has been done on NS, M, NA and PB2 partial and full knockout 
vaccines, and while such vaccines have proven effective, there are drawbacks (239, 
240, 248, 352-354). For instance, the full knockout vaccines must be grown in cell 
lines which are not FDA approved that stably express the missing gene in order to 
achieve the level of growth required of a vaccine strain (354). The manipulated HA 
cleavage site strategy, which has been shown to limit virus growth to the presence of 
elastase, grows to high titers in approved cell lines but has shown some signs of 
instability in vitro (284, 355). Finally, while some of these strategies such as the 
elastase cleavage site have been shown to be effective in the context of IBV, most of 
these strategies have only been tested in the context of IAV (176, 248, 355).  
Our lab has developed an alternative IAV strategy, which incorporates the 
PB2 and PB1 mutations found in the A/Ann Arbor cold-adapted backbone (311, 319, 
356). Additionally, our strategy involves an in-frame introduction of an 8-amino acid 
HA tag derived from H3 at the C-terminus of PB1 (314). We have demonstrated 
safety and efficacy of our strategy in ovo as well as in mouse, chicken, ferret and 
swine models; furthermore, we have shown that it grows to high titers in approved 
cell lines and eggs (1, 314-316, 357). When compared to similar viruses differing 
only in the presence of the HA tag, the tagged virus has been proven to confer better 




shown that this strategy is a viable DIVA (Differentiating Infected from Vaccinated 
Animals) vaccine strategy, as the HA tag can be detected by RT-PCR and western 
blot (314). Indeed, our strategy has many advantages over other experimental 
vaccines including high growth titers, a DIVA vaccine element, enhanced stability 
and similarity to the currently licensed strategy, a fact that would likely expedite the 
FDA approval process.  
In order to develop a quadrivalent vaccine with our strategy that could better 
stimulate the immune response in immunosenescent individuals, we required a 
contemporary complementary IBV backbone. To this end, this study asked whether 
modifications in PB1 analogous to those found in our IAV strategy would be 
sufficient to attenuate B/Brisbane/60/2008 as our previous data suggested that the 
mutations primarily responsible for the temperature sensitive phenotype of our IAV 
strategy are located in PB1 (314). Thus, the following mutations were cloned into 
PB1 of the reverse genetics B/Brisbane/60/2008 (RG-B/Bris) system: K391E, E580G, 
and S660A. The subsequently rescued virus was called B/Brisbane/60/2008 ts (B/Bris 
ts). Another virus carrying these mutations as well as an HA tag at the C-terminus of 
PB1 was also generated and labeled B/Brisbane/60/2008 att. Here, the results show 
that both the B/Brisbane/60/2008 ts and att viruses are safe and immunogenic in the 
DBA/2 mouse model; however, B/Brisbane/60/2008 ts is unstable after just two 
passages in eggs. B/Brisbane/60/2008 att (B/Bris att), in contrast, is both stable and 
immunogenic, yet despite differences in stability, both viruses conferred protection 





5.3. Materials and Methods 
 
5.3.1. Cloning and confirmation of mutations 
 
Previously described bi-directional reverse genetics B/Brisbane/60/2008 (RG-
B/Bris) plasmids were used to clone the B/Brisbane/60/2008 ts and att constructs. 
First, four overlapping PCR fragments were generated. To generate the fragments, 
PCR using pDP-PB1 B/Bris as the template was performed with site-directed 
mutagenesis primers designed with the QuikChange Primer Design tool to generate 
forward and reverse primers for each mutation, K391E, E580G and S660A, (Agilent, 
Santa Clara, CA) and PB1 AarI cloning primers (described in 2.3.2). Then, 
overlapping PCR was performed to join all four fragments to obtain full-length PB1 
carrying all three mutations (PB1 ts). All PCR reactions were performed with Pfu 
Ultra Polymerase AD (Agilent, Santa Clara, CA) according to manufacturer 
recommendations. The full-length fragment was then digested with AarI (Agilent, 
Santa Clara, CA) while the pDP2002 vector was digested with BsmB1. Then, PB1 ts 
was ligated into pDP2002 using Quick Ligase (New England Biolabs, Ipswich, MA). 
Following the same procedure but using pDP-PB1HA (described in Chapter 3) as the 
template, pDP-PB1 att was also cloned. Both clones were sequenced using Sanger 
Sequencing on a Genetic Analyzer 3500xl (Applied Biosystems, Foster City, CA) 
following the Big Dye Terminator v3.1 kit and sequencing protocol (Life 
Technologies, Carlsbad, CA). All mutations were confirmed through sequencing and 




5.3.2. Virus rescue and stocks 
 
 Virus rescue was done via 8-plasmid reverse genetics as described in 2.3.4. 
Each of the PB1 mutant clones, pDP-PB1 ts and pDP-PB1 att, was paired with the 
corresponding 7 WT RG-B/Bris plasmids. Briefly, 1µg of each (10µL per plasmid at 
concentrations of 100ng/µL each) was mixed with 2µL/µg plasmid of Transit-LTI 
transfection reagent (Mirus Bio, Madison, WI) and serum free [OPTI-MEM] I (Life 
Technologies, Carlsbad, CA) up to 200µL. Following a 45-min incubation at room 
temperature, 800µL of serum free [OPTI-MEM] I (Life Technologies, Carlsbad, CA) 
was carefully added to each reaction. This solution was then overlaid on a co-culture 
of 293T/MDCK cells (8x105/5x105 cells/well) in a 6-well plate (Corning, Corning, 
NY). Plates were then placed at 33°C, and 24 h later, the media was changed, serum-
free [OPTI-MEM] I with 1µg/mL TPCK-trypsin (Worthington Biochemicals, 
Lakewood, NJ) containing Antibiotic/Antimycotic (10mL/L, Sigma-Aldrich, St. 
Louis, MO). Following virus rescue, tissue culture supernatant was used to infect 9-
day old specific pathogen free (SPF) hen eggs to grow virus stocks (33°C). All virus 
stocks were sequenced by Sanger Sequencing on a Genetic Analyzer 3500xl (Applied 
Biosystems, Foster City, CA) following the Big Dye Terminator v3.1 kit and 
sequencing protocol (Life Technologies, Carlsbad, CA) to confirm that the desired 






5.3.3. Virus titrations 
 
Virus stocks were titrated by both tissue culture infectious dose 50 (TICD50) 
and egg infectious dose 50 (EID50) (done in 9-day old SPF hen eggs, B&E Eggs, 
York Springs, PA). Animal samples were titrated by TCID50, and EID50 titers were 
used for the mouse safety and vaccine studies. Titrations were performed according to 
the protocol described in 2.3.5 at 33°C. Viral titers were determined by the Reed and 
Muench method (300). 
 
5.3.4. Mini-genome assays 
 
In order to assess polymerase activity, WT RG-B/Bris, B/Bris ts and B/Bris 
att polymerase complexes were transfected with the previously described NP Gaussia 
Luciferase (GLuc) reporter plasmid (described in Chapter 2) as well as a pCMV-
SEAP (secreted alkaline phosphatase) plasmid to control for transfection efficiency. 
Additionally, a no reporter control and a partial vRNP complex control that excluded 
pDP-PB2 B/Bris were included. Transfections were setup in 12-well plates (Corning, 
Corning, NY) as described in 2.3.7, and each polymerase complex was tested in 
triplicate at 33, 35, 37 and 39°C. At 6, 12, 24, 48 and 72 h post-transfection (hpt), 
tissue culture supernatant was collected in white high-binding 96-well microtiter 
plates (Corning, Corning, NY). At 24 hpt, additional supernatant was collected for 




 GLuc activity was assessed using the Biolux Gaussia Luciferase Assay Kit 
(New England Biolabs, Ipswich, MA) following the provided protocol, and 
expression was measured on a Victor x3 Multilabel Plate Reader (PerkinElmer, 
Waltham, MA). SEAP activity was assayed using Phospha-light SEAP Reporter Gene 
Assay System (Life Technologies, Carlsbad, CA) following the provided protocol. 
Then, like the GLuc measurements, SEAP activity was measured on a Victor x3 
Multilabel Plate Reader (PerkinElmer, Waltham, MA). In order to normalize for 
transfection efficiency, calculations were performed as described in 2.3.7.  
 
 5.3.5. Growth kinetics 
  
Growth kinetics for the WT RG-B/Bris, B/Bris att, and B/Bris ts viruses were 
evaluated at 33, 35, 37, and 39°C and 0.01 MOI. Assays were performed following 
the protocol described in 2.3.8. Briefly, each virus was tested in triplicate at each 
temperature in a 6-well plate (Corning, Corning, NY) seeded with 5x105 MDCK 
cells. Viruses were diluted to 0.01 MOI in serum free [OPTI-MEM] I (Life 
Technologies, Carlsbad, CA). Each well was infected with 1mL of virus. The plates 
were then placed at 4°C for 15 min to synchronize infection time. Next, the cells were 
placed at 37°C for 45 min to infect. At each time point, 6, 12, 24, 48 and 72 h post-
infection (hpi), 120µL of tissue culture supernatant was collected per well. The media 
was replenished after each sample was collected. After collection, all samples were 
placed at -80°C. Finally, the virus titer for each sample was determined by TCID50 




5.3.6. Western blot 
 
Prior to western blotting, MDCK cells were infected with 1 MOI of each 
virus: mock (serum free [OPTI-MEM] I, Life Technologies, Carlsbad, CA), WT RG-
B/Bris, B/Bris ts, B/Bris att, and 7malH7:WF10att described in Song et al. (317). To 
do this, 1 well of MDCK cells was first trypsinized and counted to determine the 
number of cells to be incorporated into the calculation of MOI. Then, each well was 
infected with 500µL of 1 MOI of each virus for 1-h at 37°C. Following incubation, 
the media was changed: 1mL of serum-free [OPTI-MEM] I (Life Technologies, 
Carlsbad, CA) with 1µg/mL of TPCK-trypsin (Worthington Biochemicals, 
Lakewood, NJ). The infected cells were then placed at 33°C for 20 h. At 20 hpi, 
tissue culture supernatant was aspirated, and 150µL of Laemilli Buffer (Bio-Rad, 
Berkeley, CA) and β-ME was added (10:1 ratio) to each well and swirled gently 
before collection. Then, each sample was heated for 7 min at 95°C to complete 
protein denaturation. Finally, samples were placed at -20°C.  
In order to perform the western blot, a gradient (4-20%) SDS-PAGE gel (Bio-
Rad, Berkeley, CA) carrying 5µL of protein ladder (Fermentas, Hanover, MD) and 
25µL of each sample was electrophoresed in a Mini-Protean Tetra Cell eletrophoresis 
chamber (Bio-Rad, Berkeley, CA) for 1 h at 130V. The gel was then removed from 
the electrophoresis chamber and placed with nitrocellulose paper (Bio-Rad, Berkeley, 
CA) and blotting paper (Bio-Rad, Berkeley, CA) into transfer buffer. This was then 
placed into a semi-dry transfer chamber (Bio-Rad, Berkeley, CA) at 16V for 1 h. The 




5mL of molecular grade non-fat dry milk (NFDM) (Bio-Rad, Berkeley, CA). 
Following blocking, the nitrocellulose paper was washed with TTBS. Each wash was 
5 min in length at room temperature on a rocker. In total, the nitrocellulose paper was 
washed 3 times. Finally, a 1:1000 dilution of mouse anti-HA-tag primary antibody 
(Cell Signaling Technologies, Danvers, MA) was prepared in 5mL of NFDM and 
TTBS (1g NFDM dissolved in 5mL TTBS) and allowed to incubate on a rocker at 
4°C overnight.  
The following day, the nitrocellulose paper was again washed with TTBS as 
described above. Then, goat anti-mouse secondary antibody (Southern Biotech, 
Birmingham, AL) was diluted 1:3000 in a 5mL NFDM/TTBS solution and incubated 
at room temperature on a rocker for 1 h. Next; the nitrocellulose paper was again 
washed 3 times with TTBS. Finally, Clarity Western ECL Substrate (Bio-Rad, 
Berkeley, CA), a chemiluminescent substrate, was applied to the nitrocellulose paper 
according to the supplied protocol, and the film was developed after a 30 sec 
exposure to the nitrocellulose paper in an exposure cassette.  
In order to control for overall protein expression, GAPDH expression was 
evaluated. First, stripping buffer (Thermo Scientific, Waltham, MA) was applied to 
the nitrocellulose membrane after development. Next, the membrane was washed 
with TTBS as described above. After washing, anti-GAPDH mouse primary antibody 
diluted in a 5mL NFDM/TTBS solution to a ratio of 1:3000 (Santa Cruz Biotech, 
Dallas, Texas) was applied to the membrane and allowed to incubate on a rocker for 2 
h at room temperature. The nitrocellulose paper was washed again following 




(using the same procedure as described above). After incubation with the secondary 
antibody, the nitrocellulose paper was washed 3 times, and the chemiluminescent 
substrate was applied (as described previously). Finally, the film was developed after 
a 15 sec exposure to the nitrocellulose paper.  
 
5.3.7. Assessing stability of vaccine candidates 
 
B/Bris ts and att viruses were passaged 10 times in 9-day-old SPF hen eggs 
(B&E Eggs, York Springs, PA). Serial dilutions were made of each virus prior to 
inoculating eggs. For every dilution, the allantoic cavities of 3 eggs were inoculated 
(200µL per egg). Following inoculation, eggs were placed at 33°C for 72 h. After 72 
h, the eggs were moved to 4°C to kill the embryos. The following day, HA assays 
were performed on the allantoic fluid (AF) of each egg, and the egg with the highest 
HA titer at the highest dilution was harvested, spun down at 1,000xg for 10 min at 
4°C and frozen at -80°C until further passaging. After 10 passages, the PB1 segment 
of each virus was sequenced as described below to determine whether or not the 
mutations were still present. To sequence the PB1 gene, RNA was extracted from AF 
using the QIAgen RNeasy mini-kit, following the provided protocol (QIAgen, 
Valencia, CA). Then, cDNA was prepared by the 2-step RT-PCR protocol described 
in 2.3.2.  
 Additionally, supernatant from nasal turbinates from day 3 post-vaccination, 
the peak titer day, was sequenced. RNA was extracted and cDNA was prepared as 




mice was sequenced. All sequencing was done by Sanger Sequencing using a Big 
Dye Terminator v3.1 kit and the corresponding sequencing protocol (Life 
Technologies, Carlsbad, CA) and then run on a Genetic Analyzer 3500xl (Applied 
Biosystems, Foster City, CA). 
 
5.3.8. Vaccine safety studies 
 
In order to assess the safety and immunogenicity of each vaccine candidate 
prior to the vaccine study, 5-6 week old female DBA/2 mice (Charles River, 
Frederick, MD), 4 mice/group, were inoculated with 50µL intranasally of 107, 106 and 
105 EID50/mL of B/Bris att, B/Bris ts or WT RG-B/Bris virus. Weight loss and signs 
of disease were monitored for 12 days post-inoculation (dpi), but mice were kept for 
3 weeks post-inoculation. After 3 weeks, immunogenicity was assessed at 106 EID50, 
as this dose was the designated vaccination dose. To assess immunogenicity, mice 
were exsanguinated via the mandibular vein, and blood was collected in 1.5mL tubes 
(USA Scientific, Orlando, FL) and left overnight at 4°C. The following day, the blood 
was spun down at 1,000xg for 10 min, and all sera was collected and frozen at -20°C. 
Then, immunogenicity was assessed by determining the hemagglutination inhibition 
titers (HI or HAI) against an egg grown stock of WT B/Brisbane/60/2008. The safety 
studies were performed with the approval of the University of Maryland, College 
Park IACUC (R-12-100) in BSL-2 containment. Mice that lost 20% or more of the 





5.3.9. Vaccine study 
 
The vaccine study was performed with 4 groups of 5-6 week old female 
DBA/2 mice (Charles River, Frederick, MD). The group names were assigned based 
on which vaccine virus was used for vaccination and whether or not the group was 
challenged (C, challenged; NC, not challenged), thus the groups were B/Bris ts/ C, 
B/Bris att/ C, PBS/ C, and PBS/ NC. Each group contained 8 mice to be monitored 
throughout the study for weight loss and disease signs as well as additional mice to be 
used for tissue harvest post-vaccination and post-challenge. Each group was 
vaccinated intranasally with 50µL of 1x106 EID50/mL of the appropriate vaccine or 
PBS. Weight loss and disease signs were monitored for days 1-12 post-vaccination. 
On days 1, 3 and 5 post-vaccination, 4 mice were euthanized per group (except the 
PBS groups in which only 3 mice/day were euthanized) for collection of trachea, 
nasal turbinates and lung tissues. On day 20 post-vaccination, all remaining mice 
were bled 10% of their body weight for serology, and on day 21 post-vaccination, all 
mice were challenged with 100 MLD50 of PB2_F406Y: B/Bris virus (described in 
Chapter 4). Post-challenge, mice were monitored for weight loss and disease signs for 
14 days. On days 3 and 5 post-challenge, 4 mice per group (except the PBS challenge 
group, 3 mice/day) were euthanized for tissue collection. Finally, three weeks post-
challenge, all remaining mice were euthanized and exsanguinated for serology. The 
University of Maryland, College Park IACUC approved this study under protocol R-
13-65. Once again, any mouse that lost 20% or more of its starting weight or scored a 




To process the tissues, the left lung lobe and trachea were preserved in 10% 
formalin for pathology while the remaining lung and nasal turbinates were 
homogenized in 500µL PBS per sample at 50Hz for 4 min using a QIAgen Tissue 
Lyser LT (QIAgen, Valencia, CA). Homogenized tissues were then spun down at 
1,000xg for 10 min before being frozen at -80°C to await titration. All tissue titrations 
were performed by TCID50 at 33°C as described in 2.3.5. Tissue titers for the nasal 
turbinate and trachea post-vaccination and post-challenge for each group were 
determined by the Reed and Muench method and graphed (301).  
 
5.3.10. Tissues for pathology 
 
Post-challenge tissues were sent to Histoserv, Inc. (Germantown, MD) for 
sectioning, staining and analysis (as described in Chapter 4). Two samples per group 
from days 3 and 5 post-challenge were scored by a board certified veterinary 
pathologist, who examined the bronchi/bronchioles, pulmonary vasculature, alveoli 
and overall/extent lung regions as well as trachea from each sample. Tissue damage 
was scored on a scale of 0-4, where 0 is normal and 4 indicates severe lesions. A total 
score/extent lung score of 4 signifies the involvement of the entire lung lobe. In 






5.3.11. Hemagglutination Inhibition assays 
 
In order to determine whether or not the vaccine candidates were 
immunogenic, hemagglutination inhibitions assays (HI or HAI) were performed as 
part of the safety and vaccine studies. Roughly 18 h prior to performing HI assays, 
50µL of each serum sample was added to 3 volumes of receptor destroying enzyme 
(RDE) (Fisher Scientific, Pittsburgh, PA) and incubated in a 37°C water bath to 
destroy non-specific inhibitors of hemagglutination. The following day, the sera were 
removed from the water bath, and 6 volumes of physiological saline (.85% NaCl) was 
mixed with each sample to yield a 1:10 dilution of serum per sample. Samples were 
then placed in a 56°C water bath for 30 min to inactivate the RDE. Following 
inactivation, 96-well v-bottom plates (Corning, Corning, NY) were filled with 25µL 
per well of PBS (wells B1-H1), and 50µL of serum was added to the first well (A1). 
The serum was then diluted down serially from A1-H1, transferring 25µL with each 
dilution. This process was repeated for each serum sample. Then, WT 
B/Brisbane/60/2008 was diluted to 4HAU (hemagglutination assay units) in PBS. 
Following confirmation of the HA titer by HA assay on the virus dilution, 25µL per 
well of the virus was overlaid on the diluted sera, and the plate was gently shaken and 
allowed to incubate for 15 min at room temperature.  After 15 min, 0.5% cRBC 
(50µL/well) was overlaid on the sera and virus in the 96-well plate. Finally, after a 
45-min incubation at room temperature, hemagglutination inhibition (HI) was 
recorded to determine the HI titer of each sample. Each assay was run with a PBS 




5.3.12. Statistical analyses 
 
All data analyses were performed using GraphPad Prism Software Version 
6.00 (GraphPad Software Inc., San Diego, CA).  All in vitro assays were performed a 
minimum of two times in triplicate. For multiple comparisons, two-way ANOVA was 







5.4.1. B/Bris ts and B/Bris att polymerase complexes have the highest GLuc 
expression at low temperatures  
 
Characterization of the B/Bris ts and B/Bris att vaccine candidates began by 
measuring GLuc expression of the polymerase complexes. These assays were aimed 
at determining whether the mutations incorporated in these complexes would result in 
a temperature sensitive phenotype consistent with LAIV vaccines, restriction at 37°C. 
To this end, the vRNP plasmids (pDP-PB2, pDP-PB1, pDP-PA and pDP-NP B/Bris) 
and the GLuc reporter plasmid were transfected in 293T cells. Transfections were 
done at 33, 35, 37 and 39°C, and samples were collected at 6, 12, 24, 48 and 72 h 
post-transfection (hpt) (Fig. 5.1A-F).  
Interestingly, the results showed that at 33°C both the B/Bris ts and att 
complexes display GLuc expression similar to that of WT, both in raw and 
normalized data (Fig. 5.1A and B). An increase of 2 degrees, however, resulted in a 
decrease in the luciferase expression from both the B/Bris ts and att polymerase 
complexes as compared to WT (Fig. 5.1C and D). At 35 and 37°C, the B/Bris ts and 
att complexes have roughly 1-2 logs lower raw GLuc expression than the WT and 
normalized activity is roughly 1 log lower (Fig. 5.1C- F). This is particularly 
noteworthy at 35°C, as GLuc expression of the WT polymerase complex is similar to 
the expression at 33°C even after normalization (Fig. 5.1C and D). At 37°C after 




WT normalized expression at 33 and 35°C (Fig. 5.1F), and at 39°C after 






   
Figure 5.1. Mini-genome assay results for B/Bris att and ts polymerase 
complexes. Assays were carried out at 33°C (A and B), 35°C (C and D) 
and 37°C (E and F). Supernatant was collected at 6, 12, 24, 48 and 72hpt. 
Left panels: raw GLuc Expression. Right panels: normalized GLuc 





Figure 5.2. Growth kinetics assay results for B/Bris att and ts vaccine 
candidates. Assays were carried out at 33°C (A), 35°C (B) and 37°C (C). 
Supernatant was collected at 6, 12, 24, 48 and 72hpi. Samples were titrated by 
TCID50. Red: WT, Green: B/Bris att, Black dashes: B/Bris ts. Asterisk 
indicates p<0.05, the color of the asterisk indicates that the corresponding virus 




5.4.2. B/Bris ts and att viral titers are undetectable at 37 and 39°C 
 
Next, growth kinetics of the B/Bris ts and att viruses were evaluated. MDCK 
cells were infected with 1mL of 0.01 MOI virus, and assays were performed at 33, 
35, 37 and 39°C. As with the polymerase assays, time points were collected at 6, 12, 
24, 48 and 72 h post-infection (hpi). Following completion of each assay, viral titers 
were determined by TCID50.  
 Overall, the results are consistent with the polymerase activity. At 33°C, the 
B/Bris ts and att viruses grew to similar titers as the WT, although at late time points 
the WT grew to significantly higher titers (Fig. 5.2A). Interestingly, in contrast to the 
mini-genome assay results, B/Bris ts and att viruses also grew to similar titers at 
35°C; however, at the 24, 48, and 72 h time points, the WT virus grew to significantly 
higher titers than both vaccine candidates (Fig. 5.2B). At 37°C, neither the B/Bris ts 
nor the att viruses grew to detectable viral titers, while the WT virus grew to low but 
detectable titers, reaching roughly 105 TCID50 by 48 hpi (Fig. 5.2C). None of the 
B/Bris viruses grew to detectable titers at 39°C, consistent with the polymerase data 
(data not shown). In all, viral growth of the B/Bris ts and att viruses was restricted to 






   
Figure 5.3. B/Bris att expression of HA tag. Using a mouse anti-HA-tag 
primary antibody, a western blot was performed to detect PB1HA proteins 
expressed by B/Bris att and the positive control virus, 1malH7: WF10att, lanes 4 
and 5 respectively. To control for overall protein expression, another western 
blot was done to assess GAPDH expression. Negative controls included a mock 
infected well, lane 1, WT RG-B/Bris, lane 2, and B/Bris ts, lane 3. MDCK cells 
were infected with 1MOI of each virus at 33°C. After 20 h, supernatant was 
aspirated, and samples were prepared for western blotting. The anti-HA tag film 
was developed after a 30 sec exposure while the anti-GAPDH film was 






Figure 5.4. Vaccine safety studies: weight loss of B/Bris ts and B/Bris att 
inoculated mice. Mice were inoculated intranasally with 50µL of 107 EID50 of 
each virus and monitored for weight loss and signs of disease for 12 days post-
inoculation. The skull and cross bones indicate a dead/euthanized mouse.  
B/Bris ts safety study (A) B/Bris att safety study (B) Individual weight loss of 
B/Bris att mice (C). Red: WT RG-B/Bris. Green: B/Bris att. Black dashes: 
B/Bris ts. Note that B/Bris ts and att safety studies were performed 
independently. Each group, n=4 
Table 5.1. B/Bris att and ts inoculated mice HI titers (21dpi). Mice were 
inoculated with 50µL of 106 EID50 virus. HI assays were performed against 
WT B/Brisbane/60/2008. Results are shown. Note that there was an extra 





5.4.3. B/Bris att expresses the HA tag 
 
To complete the in vitro characterization of the vaccine candidates, a western 
blot was performed to determine whether the B/Bris att virus expresses the HA tag 
from the PB1 ORF. First, MDCK cells were infected with 1 MOI of each virus: 
B/Bris ts, B/Bris att, WT RG-B/Bris and 1malH7: WF10 att (IAV positive control), 
and mock (314). After infection, the cells were placed at 33°C for 20 h.  
 The western blot clearly shows that the B/Bris att virus, not the B/Bris ts 
virus, expresses an HA tag from PB1. Notably, the B/Bris PB1 att protein ran lower 
than the IAV 1malH7: WF10 att positive control virus, as influenza B PB1 protein is 
smaller than that of influenza A (Fig. 5.3). Additionally, although it may appear as 
though protein expression from 1malH7:WF10 att virus was stronger than that of 
B/Bris att, this is not likely the case. Given the expression of GAPDH, this difference 
is more likely a result of greater overall protein expression in the 1malH7: WF10 att 






   
Figure 5.5. Weight loss post-vaccination. Mice were inoculated with 50µL 
intranasally of a vaccine candidate at a dose of 106 EID50/mL or with PBS. 
Weight changes are shown. Brown: PBS, Green: B/Bris att. Black dashes: 





Figure 5.6. Post-vaccination tissue titers. Nasal turbinates and lung 
tissues were harvested on days 1, 3 and 5 post-vaccination. Tissue was 
homogenized in PBS and titrated by TCID50. Results are shown. B/Bris 
att lung titers (A) B/Bris ts lung titers (B) B/Bris att nasal turbinate 
titers (C) B/Bris ts nasal turbinate titers (D). Green: B/Bris att. Black 




5.4.4. Vaccine safety studies show B/Bris ts and att viruses are safe and 
immunogenic in mice 
 
Prior to a vaccine study, the B/Bris ts and att viruses were evaluated for safety 
and immunogenicity in female 5-6 week old DBA/2 mice. Mice were inoculated 
intranasally with 50µL of 107, 106, or 105 EID50 of the B/Bris att, B/Bris ts or WT 
RG-B/Bris virus. Weight loss and signs of disease were monitored for 12 days post-
inoculation. On day 21, mice were exsanguinated for serology. 
 Both vaccine candidates were safe at all doses, while all WT inoculated mice 
in the 107 and 106 EID50 dosage groups either succumbed to infection or had to be 
humanely euthanized (Fig. 5.4, data not shown, respectively). It should be noted, 
however, that one mouse in the B/Bris att 107 EID50 inoculated group had to be 
euthanized due to weight loss late during the time course of infection (Fig. 5.4B). 
Also noteworthy, though, is that this mouse was the only mouse in its group to lose 
significant weight (Fig 5.4C). Importantly, at 106 EID50, the vaccine dose, neither 
vaccine candidate caused weight loss or death.  
To evaluate the immunogenicity of these vaccine candidates, HI titers were 
assessed against WT B/Brisbane/60/2008 on day 21 sera from the 106 EID50 dosage 
groups. Nearly all B/Bris att and ts mouse sera had HI titers of greater than or equal 
to 40, suggesting that nearly all mice developed an antibody response equivalent to or 





5.4.5. Vaccine study: no weight loss post-vaccination 
 
To assess efficacy of the vaccine candidates, 5-6 week old female DBA/2 
mice were vaccinated with 50µL intranasally of 106 EID50 of either the B/Bris att 
virus, the B/Bris ts virus or PBS. Each mouse was monitored for weight loss and 
signs of disease for 12 days post-vaccination. Consistent with the safety studies, none 
of the att or ts vaccinated mice showed any weight loss post-vaccination nor did any 
of the mice show signs of disease. Finally, all weight changes were comparable to 
those seen in the PBS group (Fig. 5.5).  
 
5.4.6. B/Bris att and ts vaccine replication is restricted to growth in nasal 
turbinates 
 
Viral tropism of the vaccine viruses was established in mice post-vaccination 
to determine if either the B/Bris att or ts viruses replicated in the lungs. On days 1, 3 
and 5 post-vaccination, nasal turbinates and lung tissues were harvested from 4 mice 
in each vaccine group and 3 mice in each PBS group. Tissues were then 
homogenized, clarified and titrated by TCID50.  
 The results showed that neither the B/Bris att nor ts vaccine viruses replicated 
in mouse lung, although 1 B/Bris att vaccinated mouse had a low but detectable viral 
titer in the lung on day 1 post-vaccination (Fig. 5.6A and B). These findings are 




no activity or growth at 37°C. In contrast, viral titers of both B/Bris att and ts 
vaccinated mice were detected in the nasal turbinates, also consistent with both the 






Figure 5.7. HI titers 20 days post-vaccination. Mice were bled 10% 
of their body weight on day 20 post-vaccination. HI assays were 
performed to determine pre-challenge HI titers. Brown: PBS. Green: 
B/Bris att. Black: B/Bris ts. Sera from 11 mice per group were 
assessed. 
Figure 5.8. Weight loss and survival post-challenge. Mice were challenged 
with 100 MLD50 of the challenge virus. A) Weight loss B) Survival. Brown: 





5.4.7. Pre-challenge HI assays reveal detectable HI titers in B/Bris att and ts 
vaccinated mice  
 
In order to assess pre-challenge HI titers, all mice were bled on day 20 post-
vaccination, and HI assays were then performed against WT B/Bris. The HI assay 
results were consistent with the HI results from the safety studies. Additionally, there 
was a trend towards higher HI titers in the B/Bris att vaccinated mice as compared to 
the B/Bris ts vaccinated mice (Fig. 5.7). Interestingly, some B/Bris att and ts 
vaccinated mice showed no seroconversion. There were insufficient mouse sera to 
perform HI assays on all mice bled; however, sera from the majority of mice (11/14) 
from each group were assessed, and equal numbers of samples were acquired for the 
B/Bris att and ts vaccinated groups.  
 
5.4.8. No weight loss in B/Bris att or ts vaccinated mice post-challenge 
 
All vaccinated and mock-vaccinated mice were challenged with 100 MLD50 
of a homologous B/Bris virus except for 1 group that was mock-challenged with PBS. 
Nearly all mock-vaccinated and challenged mice (PBS/ C) either succumbed to 
infection or had to be humanely euthanized by day 8 post-challenge, while all B/Bris 
att and B/Bris ts vaccinated mice survived challenge (Fig. 5.8B). Not only was no 




for the B/Bris att and ts vaccinated groups post-challenge was indistinguishable from 






Figure 5.9. Post-challenge tissue titers. Nasal turbinates and lungs were 
homogenized in PBS and titrated by TCID50. Results are shown. Lung titers (A) 
Nasal turbinate titers (B). Brown: PBS/ NC. Purple: PBS/ C. Green: B/Bris att/ C. 
Black: B/Bris ts/ C. Each group, n=4; PBS/ NC, n=3 
Figure 5.10. Post-challenge HI titers.  Mice were exsanguinated on day 
21 post-challenge. HI assays were performed to determine post-challenge 
HI titers. Brown: PBS/ NC. Purple: PBS/ C. Green: B/Bris att/ C. Black: 





5.4.9. No virus detected in tissues of B/Bris att or ts vaccinated mice post-
challenge, suggests sterilizing immunity 
 
Lung and nasal turbinates were harvested from the B/Bris att/C, B/Bris ts/C, 
PBS/C and PBS/NC groups on days 3 and 5 post-challenge and titrated by TCID50. 
No virus was detected in the B/Bris att or ts vaccinated mice on days 3 or 5 post-
challenge in either the lungs or the nasal turbinates, thus titers were indistinguishable 
from the PBS/NC group. In contrast, virus was detected in both the lungs and nasal 
turbinates of the PBS/C mice on days 3 and 5 post-challenge (Fig. 5.9). These results 
suggest sterilizing immunity in all vaccinated mice. 
 
5.4.10. Increased HI titers in vaccinated mice post-challenge 
 
In order to determine post-challenge HI titers of all remaining mice, mice 
were exsanguinated on day 21 post-challenge, and HI assays were performed on all 
sera against WT B/Bris. As anticipated, PBS/ NC had no detectable HI titers against 
B/Bris whereas HI titers were detected in B/Bris att/ C and ts/ C mice sera. Similar to 
the post-vaccination HI results, there was a trend towards higher HI titers in the 
B/Bris att vaccinated mice in comparison to the B/Bris ts vaccinated group. Overall, 
HI titers of all vaccinated mice were higher than those found pre-challenge, 
suggesting that all mice were properly challenged (Fig. 5.10). Finally, the only 





5.4.11. Increased pulmonary pathology in PBS/C group post-challenge 
 
Post-challenge tissue pathology was assessed by a board certified pathologist. 
Bronchiole, alveolar, vascular, total/extent lung and tracheal tissues were scored on a 
scale of 0-4 where a score of 4 indicated severe pathology. Overall, tissue pathology 
was similarly mild amongst the PBS/NC, B/Bris att/C and B/Bris ts/C groups. All 
PBS/NC tissue evaluated had a total/extent lung score of 1 on days 3 and 5 post-
challenge while nearly all vaccinated mice had a total lung score of 2 on the same 
days. The most severe pathology in the vaccinated mice was in the bronchioles 
(bronchiole score of 2 for nearly all mice) in which minimal epithelial lesions were 
observed. Mice of all groups, including PBS/C, scored either 0 or 1 in tracheal and 
vascular pathology; however, one B/Bris ts vaccinated mouse did have a vascular 
score of 3 (Table 5.2). 
The PBS/C mouse tissues showed more severe pathology than the vaccinated 
and mock-vaccinated groups. For instance, PBS/C mice had total lung scores of 3 on 
days 3 and 5 post-challenge, and the most severe pathology was found in the alveolar 
tissue. This tissue of mice in this group showed some necrosis, thickening of the 
alveolar walls and the presence inflammatory cells (Table 5.2).  
Finally, representative images of pulmonary pathology for each group on each 
day post-challenge were taken (Fig. 5.11). Consistent with the pathology scores, 




pathology in the PBS/C group, particularly on day 5 post-challenge, is visibly more 






Table 5.2. Tissue pathology post-challenge. Scores were assigned from 0-4, 4 
being severe pathology. Scores for days 3 and 5 post-challenge are shown. Days 
post-challenge: dpc. Scores from 2 mice per group per day are shown, except for the 





























Figure 5.11. Post-challenge representative pulmonary pathology 
images. Representative images are shown for each group on days 3 and 5 
post-challenge. Right column: 3 dpc. Left column: 5dpc. All images are 




5.4.12. Enhanced stability of B/Bris att virus over the B/Bris ts virus 
 
To assess the stability of the vaccine candidates, the B/Bris att and ts virus 
vaccines were passaged 10 times in eggs. After 10 passages, PB1 was sequenced to 
determine which mutations were present and whether any other mutations arose. 
Results showed that by egg passage 2 the K391E mutation reverted in the B/Bris ts 
vaccine, although no additional mutations were identified in subsequent passages. In 
stark contrast to these results, the B/Bris att mutations remained stable throughout all 
10-egg passages; nonetheless, an additional mutation at position 48 (E to K) was 
identified in egg passages 9 and 10. This E48K mutation will have to be investigated 
to determine if it affects safety. 
 In addition to testing the stability of the vaccine viruses in eggs, RNA 
extracted from B/Bris att and ts vaccinated mice nasal turbinates from day 3 post-
vaccination was sequenced. Consistent with the egg passage results, PB1 of B/Bris ts 
was unstable at position 391. Indeed, there was a mixed base causing a mixed amino 
acid, both K and E, at position 391. Once again, the B/Bris att virus was stable as all 
three mutations and the HA tag were confirmed present. No additional mutations 









This study described the development of two IBV vaccine candidates carrying 
PB1 mutations (K391E, E580G and S660A), B/Bris att and B/Bris ts, which differ 
only in the presence of an HA tag at the C-terminus of PB1 in B/Bris att. The data 
suggests that both vaccines are temperature sensitive, cold-adapted and attenuated. 
The temperature sensitive phenotype was evident in the absence of normalized GLuc 
expression and viral growth of B/Bris att and ts at 37°C while the high GLuc 
expression and growth of the B/Bris att and ts viruses at 33°C demonstrated that each 
is cold-adapted. Finally, the absence of B/Bris att and ts viral replication in the lungs 
of mice suggests that both viruses are attenuated. These growth characteristics are 
consistent with those of the currently licensed B/Ann Arbor cold-adapted backbone 
and are ideal for a safe LAIV vaccine (208, 259, 260, 263). 
Consistent with the temperature sensitive, cold-adapted and attenuated growth 
characteristics displayed by B/Bris att and ts, both vaccine candidates were safe in 
mice, causing virtually no weight loss even at a high dose of 107 EID50, and each 
virus was restricted to growth in the nasal turbinates. Upon a 100 MLD50 challenge, 
all vaccinated mice showed sterilizing immunity to the challenge virus as no virus 
was detected in the lungs or nasal turbinates of vaccinated mice on either of the days 
assayed; furthermore, no weight loss was seen in any vaccinated mice post-challenge. 
In contrast, all but 1 mouse of the mock-vaccinated/challenge group (PBS/C) 





Although the B/Bris att and ts vaccine candidates behaved similarly both in 
vitro and in vivo, there were differences in stability and immunogenicity; furthermore, 
given that the B/Bris att and ts viruses differ only in the presence of the HA tag, it is 
the likely cause of the dissimilarities that were observed. Previously, our lab showed 
that an HA tag in the context of IAV enhances stability, safety and efficacy of viruses 
carrying the PB2 and PB1 mutations found in A/Ann Arbor cold-adapted backbone, 
and similar to these findings, the B/Bris att and ts egg passage experiment 
demonstrated that the HA tag enhances stability of the PB1 mutations in ovo (1, 315-
317). No changes were seen in the B/Bris att PB1 segment through 8 passages in 
eggs, although a spurious mutation, E48K, was identified by passage 9; however, all 
the desired mutations were maintained (K391E, E580G, S660A and HA tag). In 
contrast, the B/Bris ts virus, absent an HA tag, was unstable after just 2 passages in 
eggs. Similar findings were made in sequencing virus from the nasal turbinates of 
vaccinated mice. Additionally, the HI results post-vaccination and post-challenge 
suggest that the presence of the HA tag may enhance immunogenicity of the vaccine. 
In each case, HI titers tended to be higher in the B/Bris att vaccinated mice, but 
notably, both the B/Bris att and ts vaccines were immunogenic.  
 The variation in stability between the B/Bris att and ts viruses offers some 
insight into which mutations are primarily responsible for attenuation. Despite the 
instability of the B/Bris ts vaccine in vivo, no weight loss, disease signs or viral 
replication in the lungs were observed which suggests that the stable E580G and 
S660A mutations were sufficient to attenuate the virus and prevent replication at 




temperature sensitive phenotype of the A/Ann Arbor cold-adapted backbone is 
determined primarily by the PB1 mutations, K391E and E581G, although A661T also 
contributes, yet the data presented here suggest that the K391E mutation may not be 
critical for attenuation of WT RG-B/Bris (310).   
This study shows that 3 mutations, rather than the licensed 7 mutations found 
in the B/Ann Arbor cold-adapted backbone, are sufficient to attenuate WT RG-B/Bris 
in the context of the mouse model. Importantly, the 3 mutations incorporated into the 
B/Bris att and ts vaccines (K391E, E580G and S660A) are analogous to a subset of 
the mutations present in the A/Ann Arbor cold-adapted backbone (310, 314, 356). 
Further studies must be done to evaluate the IgA an IgG responses to the B/Bris att 
vaccine as they relate to cross-protection in adult and aged mice. Aged mice could 
also be used to evaluate the efficacy of administering an alternative LAIV vaccine on 
a contemporary backbone, B/Bris att, after repeated exposure to the B/Ann Arbor 
backbone. This would give insight into the potential of enhancing the vaccine 
response in the elderly by using a more contemporary backbone. Finally, another 
possibility for future study is adapting the B/Bris att vaccine to other species such as 











The work described here sought to develop an alternative reverse genetics 
based live-attenuated (LAIV) influenza B virus (IBV) vaccine. To do this, a 
contemporary IBV isolate, B/Brisbane/60/2008 was cloned. In the process of 
developing the vaccine, a novel cloning strategy for IBV was developed and 
virulence factors of B/Brisbane/60/2008 were identified. 
The impetus for developing an alternative LAIV IBV vaccine based on a 
contemporary IBV isolate was three fold. Firstly, our lab required an IBV strategy, 
which complemented our alternative LAIV influenza A virus (IAV) vaccine in order 
to develop a quadrivalent vaccine (1, 315-317, 357). Secondly, there is a need for 
LAIV vaccines that enhance the immune response in immunosenescent individuals 
who have repeatedly been exposed to the currently licensed LAIV vaccine backbones 
which were originally isolated roughly 50 years ago (220, 223, 258, 290, 292, 294, 
295). Finally, vaccination of poultry against IAV is a significant problem as it is 
difficult to distinguish infected from vaccinated animals and administering standard 
IAV LAIV vaccines, which are considered to be the most efficacious, risks 
reassortment of the LAIV vaccine with virulent circulating strains; therefore, another 
strategy that could serve as a DIVA (Differentiating Infected form Vaccinated 




This dissertation describes several firsts in the field. For instance, to our 
knowledge, the wild-type (WT) reverse genetics (RG) B/Brisbane/60/2008 is the 
most modern B/Victoria-like reverse-genetics virus available, and the manner in 
which it was cloned, 2-step RT-PCR, is a novel cloning strategy for IBV. This 
dissertation also contains the first description of PB2 cap-binding mutants F406Y and 
W359F as virulence factors in mice. Finally, the B/Brisbane/60/2008 att vaccine 
strategy marks the first time that mutations analogous to those found in A/Ann Arbor 
cold-adapted have been shown to attenuate IBV; furthermore, this vaccine strategy 
shows that only 3 mutations rather than the licensed 7 mutations present in the IBV-
component of the LAIV seasonal vaccine are necessary to attenuate IBV (208, 220, 
310). 
 
6.1.2. Chapter 2 conclusions: A contemporary reverse genetics system for 
B/Brisbane/60/2008 grows to high titers and is virulent in mice 
 
 Chapter 2 described a reverse genetics RG-B/Brisbane/60/2008 (RG-B/Bris) 
virus generated by a 2-step RT-PCR system. In this 2-step system, “universal” reverse 
transcription primers are used to target specific segments of the IBV genome, and 
then, cloning primers are used to amplify individual segments. After generating RG-
B/Bris using this system, the virus was characterized. The results showed that this 
virus rescues efficiently, grows to high titers, behaves similarly to the WT 
B/Brisbane/60/2008 virus and is virulent in mice. Finally, phylogenetic analysis of 




same clade as all recent B/Victoria-like IBV sequences. The cloning of this reverse 
genetics virus permitted the development of a contemporary LAIV IBV platform 
vaccine that grows titers suitable for vaccine production and is testable in an animal 
model. 
 
6.1.3. Chapter 3 conclusions: PB2/PB1 mutant vaccine strategy is lethal in 
mice 
 
Chapter 3 describes a first attempt to develop an alternative IBV vaccine 
strategy that would complement our lab’s influenza A virus (IAV) HA tag strategy. In 
this study, 2 vaccine candidates, each carrying an HA tag at the C-terminus of PB1 
and a cap-binding mutation in PB2, were designed. While each of these vaccine 
candidates appeared to show signs of attenuation in vitro in comparison to the WT 
RG-B/Bris, both were lethal at the desired vaccine dose of 106 EID50 in a DBA/2 
mouse model. This was surprising given that cap-binding mutations have previously 
been shown to be attenuating and that the HA tag has been proven to enhance safety 
and efficacy in the context of our IAV strategy. The mortality seen in mice caused by 
the PB2/PB1 mutants precipitated the characterization of the PB2 cap-binding 





6.1.4. Chapter 4 conclusions: PB2_F406Y and PB2_W359F are virulence 
factors of B/Brisbane/60/2008 
 
 Chapter 4 sought to characterize PB2 F406Y and W359F cap-binding 
mutations in the context of WT RG-B/Bris. The results showed that each of these 
mutations had enhanced virulence and pathogenicity in comparison to WT RG-B/Bris 
in a DBA/2 mouse model. The cap-binding mutant viruses were shown to enhance 
virulence and pathogenicity early in infection in comparison to the WT virus, 
showing pathology as early as day 3 post-infection. Although there is some evidence 
that these viruses replicate better at 37°C, the enhanced virulence is likely related to 
host factors; however, more research is required to determine if this is the cause. 
Regardless of the means by which enhanced disease is achieved, these mutations 
present tools to facilitate the study of pathogenesis and vaccine efficacy in mice.  
 
6.1.5. Chapter 5 conclusions: B/Bris att is stable, safe and immunogenic in 
mice 
   
Chapter 5 describes the evaluation of two vaccine candidates, B/Bris att and 
ts, for safety, efficacy and immunogenicity in a DBA/2 mouse model. B/Bris att and 
B/Bris ts differ only in the presence of an HA tag at the C-terminus of PB1; each 
virus contains 3 amino acids mutations in PB1 analogous to those present in the PB1 
segment of the A/Ann Arbor cold-adapted backbone and our A/turkey/Ohio/2004 




growth kinetics assays confirmed that both vaccine candidates grow to high titers at 
low temperatures (33°C) but are temperature sensitive at high temperatures (37°C). 
Additionally, both vaccine candidates were safe, immunogenic and efficacious 
against a 100 MLD50 homologous challenge, and both induced sterilizing immunity. 
Despite the similar safety and efficacy findings, these viruses differed in stability and 
immunogenicity. B/Bris att was stable up to 10 passages in eggs and tended to 
generate greater serum immunity, while the B/Bris ts vaccine was unstable after just 2 
egg passages and tended to generate lower serum immunity compared to B/Bris att. 
The results clearly indicate that 3 mutations analogous to those found in the IAV-
component of the licensed LAIV vaccine rather than the 7 licensed IBV-component 







6.2. Future Directions 
 
6.2.1. Determine efficacy of the B/Bris att backbone in the context of a 
quadrivalent vaccine 
 
 Future work with the B/Bris att backbone must be done in the context of a 
quadrivalent vaccine which would incorporate our Ty/04 att influenza A platform 
carrying H1 and H3 surface genes as well as our B/Bris att platform carrying 
representative HAs from B/Yamagata-like and B/Victoria-like HA antigenic lineages. 
Given the phylogenetic analyses discussed in Chapter 2 of HA and NA IBV isolates 
which clearly show two NA lineages diverging with the HA antigenic lineages, NA 
segments corresponding to each lineage should also be incorporated to prevent IBV 
infection post-vaccination as a result of reassortment of the NA segment. This should 
first be done in a mouse model, and challenge viruses should include both 
homologous and heterologous challenges in order to test cross-protection of each 
strain represented in the vaccine.  
 
6.2.2. Assess IgG, IgA and innate responses to vaccination 
 
 In addition to evaluating the efficacy of the B/Bris and Ty/04 att backbones in 
the context of a quadrivalent vaccine, IgG, IgA and innate responses to vaccination 
should be assessed. Analysis of the immune response is particularly important 




response than KV formulations. This would most easily be done in a mouse model 
and should also be compared to a formalin-treated KV version of the quadrivalent 
vaccine. Additionally, IgA antibodies should be further evaluated for cross-reactivity 
with a panel of H1, H3, B/Victoria-like and B/Yamagata-like viruses, as IgA has been 
shown to be involved in cross-reactivity and heterologous protection (359). 
 
6.2.3. Evaluate the B/Bris att backbone in a quadrivalent vaccine for ferrets 
  
 After analyzing the immune response and cross-protection of the quadrivalent 
vaccine in the mouse model, the vaccine must then be evaluated in the ferret model, 
as ferrets are the best model for human influenza illness available and allow for the 
study of transmission. Cross-protection should be evaluated in a ferret study in a 
manner similar to the mouse studies in 6.2.1 and 6.2.2 with homologous and 
heterologous challenges using contemporary IAV and IBV strains. Naïve ferrets 
should be co-housed with vaccinated ferrets immediately following vaccination, and 
viral shedding should also be assessed by nasal washing all ferrets in the days post-
vaccination. Nasal washes should be titrated to ascertain if virus was shed, and the 
naïve ferrets should be bled for serology three weeks post-vaccination of their cage-
mate. In this manner, one could determine whether there is risk of spread of the 
vaccine viruses post-vaccination in addition to determining whether the vaccines are 






6.2.4. Analyze the immune response conferred by the B/Bris att vaccine in an 
aged mouse model 
 
The B/Bris att vaccine must also be evaluated in an aged mouse model to 
provide justification for the use of a more contemporary vaccine backbone as an 
alternative to adjuvants in immunosenescent individuals. This study must be carried 
out over a long period of time, possibly a year or more, to be done thoroughly as the 
immune history of an elderly individual must be simulated through repeated 
‘seasonal’ vaccinations with the B/Ann Arbor cold-adapted backbone. Then, once 
mice reach the appropriate age (18 months), they should be vaccinated with B/Bris att 
or B/Ann Arbor cold-adapted. IgA, IgG and T cell responses after vaccination in the 
now 18-month-old mice must be measured, and cross-reactivity of IgA and IgG with 
a panel of currently circulating influenza B viruses should also be analyzed to 
determine whether B/Bris att has enhanced heterologous reactivity in comparison to 
the B/Ann Arbor cold-adapted backbone. Differences in T cell responses between 
these groups should be closely evaluated since immunosenescence is associated with 
changing T cell immunity and it is important to discern whether B/Bris att induces a 
more robust T cell response.  Finally, each group should be challenged with 
homologous and heterologous challenge viruses to assess whether there is enhanced 
protection in the B/Bris att vaccinated group compared to the B/Ann Arbor 





 6.2.5. Adapt B/Bris att to birds for use as a DIVA vaccine 
 
 Adapting B/Bris att to birds would provide a vaccine vector for use in avian 
species that would carry no risk of becoming incorporated into the pool of circulating 
avian viruses, even if attenuating mutations were to revert, and would also function as 
a DIVA vaccine. IAV has been shown to be capable of tolerating the incorporation of 
IBV surface genes in cases where the IAV packaging signals have been maintained 
(360). Thus, provided the IBV packaging signals are maintained in HA and NA of 
B/Bris att, it is likely that IAV avian surface genes such as those from highly lethal 
avian H5N1 could be incorporated into B/Bris att, and then the B/Bris att-IAV virus 
could be adapted to birds such as chickens through serially passaging. Vaccinated 
chickens could then be distinguished from non-vaccinated via a standard RT-PCR 







1 1.5 ml self-standing screw cap tube, mixed color caps, USA Scientific, Orlando, 
FL, 1415-9799 
2 AarI, Thermo Scientific, ER1581 
3 AMV Reverse Transcriptase, Promega, Madison, WI, M5101 
4 Antibiotic/Antimycotic, Sigma-Aldrich, St. Louis, MO, A5955 
5 Anti-HA tag mouse monoclonal antibody (6E2), Cell Signaling Technologies, 
Beverly, MA, 2367S 
6 Anti-GAPDH mouse monoclonal antibody (65C), SantaCruz Biotech, Dallas, TX, 
sc-32233 
7 BioLux® Gaussia Luciferase Assay Kit, New England Biolabs, Ipswich, MA, 
E3300 
8 BigDye Terminator v3.1 Sequencing Kit, Applied Biosystems, Foster City, CA, 
4337455 
9 Blotting Grade Blocker, Bio-Rad, Berkeley, CA, 170-6404EDU 
10 BsmBI, New England Biolabs, Ipswich, MA, R0580S 
11 Chicken Blood in Alsevers, Lampire Biological Laboratories, Pipersville, PA 
12 Clarity Western ECL Substrate, Bio-Rad, Berkeley, CA, 170-5060 
13 Disposable Glass Pasteur Pipets, Fisher, Hampton, NH, 13-678-20D 





15 EB Buffer, QIAgen, Valencia, CA, 19086 
16 Expand High Fidelity PCR System, Roche, Indianapolis, IN, 11732641001 
17 Fetal Bovine Serum (FBS), heat inactivated, Sigma-Aldrich, St. Louis, MO, 
F4135 
18 FLSK 75CM W/MEMBRN CP 100/CS, Greiner Bio-One, Monroe, NC, 658175 
19 Goat anti-mouse secondary antibody, Southern Biotech, Birmingham, AL, 1010-
05 
20 HEPES Buffer, Sigma-Aldrich, St. Louis, MO, H0887 
21 Laemilli Buffer, Bio-Rad, Berkeley, CA, 161-0737 
22 L-Glutamine, Sigma-Aldrich, St. Louis, MO, G7513 
23 Mini-PROTEAN® TGX™ Gel (4-20%), Bio-Rad, Berkeley, CA, 456-1093 
24 OPTI-MEM I Reduced Serum Media, Life Technologies, Carlsbad, CA, 31985-
070 
25 PfuUltra High Fidelity DNA Polymerase Alternative Detergent, Agilent, Santa 
Clara, CA, 600385 
26 Plate 6-Well TC 50/CS, Corning, Corning, NY, 3516 
27 Plate 12-Well TC 6.9ML 50/CS, Corning, Corning, NY, 3513 
28 Plate 96-Well FLT BTM .365 50/CS, Greiner Bio-One, Monroe, NC, 658175 
29 PLT MICR 96WL V-BTM PVC 100/CS, Corning, Corning, NY 2897 
30 Page Ruler Plus Prestained Protein Ladder, Fermentas, SM1819 
31 Phospha-light SEAP Reporter Gene Assay System, Life Technologies, Carlsbad, 
CA, T1016 




33 Restore Plus Western Blot Stripping Buffer, Thermo Scientific, Waltham, MA, 
46430 
34 RNeasy Mini-kit, QIAgen, Valencia, CA, 74106 
35 RNasin Ribonuclease Inhibitor, Promega, Madison, WI, N2511 
36 Seal-Rite 1.5 ml microcentrifuge tube, natural, USA Scientific, Orlando, FL, 
1615-5500 
37 Specific pathogen free hen eggs, B&E Eggs, York Springs, PA 
38 Supported Nitrocellulose Membrane, Bio-Rad, Berkely, CA, 162-0097 
39 Trypsin, TPCK treated- Irradiated, Worthington Biochemical, Lakewood, NJ, 
TRTVMF 
40 Tungsten Carbide Beads (300mm), QIAgen, Valencia, CA, 69997 
41 QuickChange II XL Site-Directed Mutagenesis kit, Agilent, Santa Clara, CA, 
200521 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Accession	  #	   Virus	  Name	  
ACF10282	   (B/California/01/2008)	  
AFH58326	   	  (B/England/145/2008)	  
AGZ61741	   	  (B/Finland/282/2009)	  
ACG64219	   	  (B/Indiana/08/2008)	  
AGL05857	   	  (B/Iowa/01/2012)	  
AEA51387	   	  (B/Kol/1013/2007)	  
AEA51395	   	  (B/Kol/N-­‐140/2009)	  
AFJ91104	   	  (B/Malaysia/1919534/2008)	  
AGO05763	   	  (B/New	  Hampshire/02/2013)	  
AFF58918	   	  (B/Riyadh/02/2010)	  
AFG49012	   	  (B/Ulaanbaatar/1798/2008)	  
AFH57953	   	  (B/Wisconsin/01/2010)	  
ACB11749	   	  (B/Wisconsin/04/2008)	  
AGX23314	   	  (B/Brisbane/4/2006)	  
AEO80097	   (B/California/NHRC0001/2004)	  
AGX23578	   	  (B/Christchurch/18/2007)	  
ABL76628	   	  (B/Houston/B720/2004)	  
ABL76650	   	  (B/Houston/B756/2005)	  
ACA64910	   	  (B/Mississippi/UR060031/2007)	  
ACA33498	   	  (B/New	  Jersey/01/2008)	  
AEP20299	   	  (B/Texas/NHRC0001/2005)	  
AGX23391	   	  (B/Waikato/1/2006)	  
ABN50646	   	  (B/Alaska/03/1992)	  
ABL76991	   	  (B/Ann	  Arbor/1994)	  
ABN50525	   	  (B/Argentina/132/2001)	  
AGX21919	   	  (B/Auckland/1/2004)	  
ABN50624	   	  (B/Bangkok/163/1990)	  
AFH58304	   	  (B/Bangladesh/3333/2007)	  
AGX24095	   	  (B/Brisbane/29/2007)	  
ACJ53899	   	  (B/Cheongju/411/2008)	  
AGX22007	   	  (B/Christchurch/33/2004)	  
ABL77310	   	  (B/Connecticut/07/1993)	  
ABN50635	   	  (B/Cordoba/2979/1991)	  
ABL76749	   	  (B/Egypt/2040/2004)	  
ACF54246	   	  (B/Florida/4/2006)	  
ABN50437	   	  (B/Georgia/09/2005)	  
BAM37625	   	  (B/Hokkaido/FO/2012)	  
ABL77288	   	  (B/Hong	  Kong/03/1992)	  
ABL77266	   	  (B/Hong	  Kong/22/1989)	  
AAD42316	   (B/Houston/1/91)	  




ABN50701	   	  (B/Johannesburg/06/1994)	  
ACH53445	   	  (B/Kentucky/02/2006)	  
ABR15995	   	  (B/Lisbon/02/1994)	  
AFJ76323	   	  (B/Malaysia/1710547/2007)	  
ACR15699	   	  (B/Managua/4705.02/2008)	  
AAD42311	   	  (B/Memphis/18/95)	  
ABL77156	   	  (B/Moscow/16/2002)	  
AAU94697	   	  (B/Nashville/45/91)	  
ABN50657	   	  (B/New	  York/24/1993)	  
ABN51184	   	  (B/New	  York/39/1991)	  
ABL77299	   	  (B/Oita/15/1992)	  
AAU94696	   	  (B/Panama/45/90)	  
ABL77277	   	  (B/Singapore/04/1991)	  
ABN50712	   	  (B/Singapore/11/1994)	  
AGX16061	   	  (B/Sydney/3/2004)	  
AGX23655	   	  (B/Sydney/502/2007)	  
AGX19425	   	  (B/Sydney/55/2008)	  
ACD56577	   	  (B/Taiwan/125/2004)	  
ABN51195	   	  (B/Texas/14/1991)	  
AGX16193	   	  (B/Townsville/2/2005)	  
ABL77189	   	  (B/Ulan-­‐Ude/6/2003)	  
AGX21974	   	  (B/Victoria/109/2004)	  
AGX16160	   	  (B/Victoria/503/2005)	  
AGX16149	   	  (B/Waikato/1/2005)	  
AGZ59887	   	  (B/Wellington/7/2008)	  
ABL77255	   	  (B/Yamagata/16/1988)	  
ABL76705	   	  (B/Alaska/12/1996)	  
ABL76848	   	  (B/Alaska/16/2000)	  
ABL77035	   	  (B/Argentina/3640/1999)	  
ABN50668	   	  (B/Bangkok/141/1994)	  
ABL84340	   	  (B/Brazil/975/2000)	  
ABL77365	   	  (B/California/01/1995)	  
AEP20321	   	  (B/California/NHRC0004/2003)	  
AEP20387	   	  (B/California/NHRC0006/2006)	  
ABL76870	   	  (B/Canada/16188/2000)	  
ABN50569	   	  (B/Chile/3162/2002)	  
ABL76760	   	  (B/Florida/02/1998)	  
ABL77002	   	  (B/Georgia/04/1998)	  
ABL76837	   	  (B/Hawaii/11/2004)	  
AAK70482	   	  (B/Hong	  Kong/157/99)	  
AAO38870	   	  (B/Hong	  Kong/548/2000)	  
AAU94704	   	  (B/Houston/2/96)	  
ABL76353	   	  (B/Houston/B15/1999)	  




ABL76584	   	  (B/Houston/B84/2003)	  
ABN50459	   	  (B/Illinois/13/2005)	  
ABN50723	   	  (B/Indiana/01/1995)	  
AFJ80128	   	  (B/Malaysia/06535/1995)	  
AFJ80150	   	  (B/Malaysia/10928/1996)	  
ACR15732	   	  (B/Malaysia/2506/2004)	  
AFJ80803	   	  (B/Malaysia/30589/2005)	  
AFJ80869	   	  (B/Malaysia/33808/2006)	  
AAD42314	   	  (B/Memphis/12/97)	  
AAU94716	   	  (B/Memphis/3/01)	  
ABL76815	   	  (B/Mexico/84/2000)	  
ABL77332	   	  (B/Mie/01/1993)	  
AEP20233	   	  (B/Missouri/NHRC0001/2001)	  
AEP20277	   	  (B/Missouri/NHRC0001/2003)	  
AAU94699	   	  (B/Nanchang/195/94)	  
AAD44188	   	  (B/Nanchang/26/93)	  
AAD42326	   	  (B/Nashville/3/96)	  
AAU94717	   	  (B/Nebraska/1/01)	  
ACN32556	   	  (B/New	  York/347/1999)	  
AAA43702	   	  (B/Oregon/5/80)	  
ABL77024	   	  (B/Paris/549/1999)	  
ABN50734	   	  (B/Romania/318/1998)	  
ABL76936	   	  (B/Russia/22/1995)	  
ABL77057	   	  (B/Shizuoka/480/2000)	  
AAD42318	   	  (B/Sichuan/8/92)	  
CAA25425	   	  (B/Singapore/222/79)	  
ABL76980	   	  (B/Singapore/31/1998)	  
ABN50448	   	  (B/Singapore/35/1998)	  
ABN50580	   	  (B/South	  Carolina/04/2003)	  
AEP20211	   (B/South	  Carolina/NHRC0001/2000)	  
AEP20222	   (B/South	  Carolina/NHRC0001/2001)	  
AEP20288	   (B/South	  Carolina/NHRC0001/2004)	  
AEP20244	   (B/South	  Carolina/NHRC0002/2001)	  
AAK70485	   	  (B/Switzerland/4291/97)	  
AGX21732	   	  (B/Sydney/200/2002)	  
ACF54257	   	  (B/Taiwan/45/2001)	  
ABR15973	   	  (B/Temple/B1190/2001)	  
ABL76529	   	  (B/Temple/B21/2003)	  
ABL76331	   	  (B/Temple/B9/1999)	  
AAT69455	   	  (B/Victoria/504/2000)	  
ABL77101	   	  (B/Victoria/504/2000)	  
AAK70475	   Influenza	  B	  virus	  (B/Vienna/1/99)	  
AGX17620	   	  (B/Waikato/6/2005)	  




ABN50503	   	  (B/Yamanashi/166/1998)	  
ABL77134	   	  (B/Akita/27/2001)	  
ACA33483	   	  (B/Alaska/01/2007)	  
AGI64373	   	  (B/Alaska/01/2011)	  
AGX16962	   	  (B/Auckland/16/2002)	  
AGX19480	   	  (B/Auckland/23/2008)	  
AFH58447	   	  (B/Bangladesh/5945/2009)	  
CAA37262	   	  (B/Beijing/1/1987)	  
AGX20129	   	  (B/Brisbane/1/2010)	  
AGX20745	   	  (B/Brisbane/13/2011)	  
AGX16599	   	  (B/Brisbane/2/2002)	  
AGX15662	   	  (B/Brisbane/33/2008)	  
AGI63978	   	  (B/California/01/2011)	  
AFX68905	   	  (B/Cambodia/V0112324/2011)	  
AGI64011	   	  (B/Colorado/01/2011)	  
ABN58661	   	  (B/Czechoslovakia/69/1990)	  
AGL05756	   	  (B/Delaware/01/2012)	  
ADY16757	   	  (B/Denmark/11/2011)	  
AGI64004	   	  (B/Florida/02/2011)	  
ACU12701	   	  (B/Florida/04/2009)	  
AFH58348	   	  (B/Fujian-­‐Gulou/1272/2008)	  
AET80614	   	  (B/Georgia/01/2011)	  
AET21680	   	  (B/Georgia/02/2010)	  
ABN50470	   	  (B/Hawaii/10/2001)	  
ABL77321	   	  (B/Hong	  Kong/02/1993)	  
ABL77123	   	  (B/Hong	  Kong/167/2002)	  
AFH57964	   	  (B/Hong	  Kong/259/2010)	  
ABL77112	   	  (B/Hong	  Kong/310/2004)	  
ABL76958	   	  (B/Hong	  Kong/70/1996)	  
ACA96563	   	  (B/Illinois/UR06-­‐0016/2007)	  
AET21612	   	  (B/Iowa/01/2010)	  
AFB77681	   	  (B/Kenya/104/2011)	  
AEG21020	   	  (B/Kol/1373/2008)	  
AEG21029	   	  (B/Kol/273/2010)	  
AEG21014	   	  (B/Kol/515/2006)	  
AEG21026	   	  (B/Kol/N-­‐2121/2010)	  
AAU94719	   	  (B/Los	  Angeles/1/02)	  
AFJ80238	   	  (B/Malaysia/15048/1998)	  
AEQ39315	   	  (B/Managua/3323.01/2010)	  
AET22082	   	  (B/Massachusetts/01/2010)	  
AAD42309	   	  (B/Memphis/3/89)	  
AAU94720	   	  (B/Memphis/7/03)	  
AGI64344	   	  (B/Michigan/01/2011)	  




ACA64976	   	  (B/Mississippi/UR06-­‐0340/2007)	  
AAU94702	   	  (B/Nanchang/3/95)	  
AAD44192	   	  (B/Nanchang/5/97)	  
AAD44191	   	  (B/Nanchang/6/96)	  
AAU94710	   	  (B/Nanchang/6/98)	  
AGG86691	   	  (B/Nanjing/1521/2011)	  
AGI63971	   	  (B/Nebraska/01/2011)	  
ABL76925	   	  (B/Nepal/1331/2005)	  
ACA33492	   	  (B/New	  Jersey/02/2007)	  
AGL05234	   	  (B/New	  Mexico/01/2012)	  
AGR34013	   	  (B/Novosibirsk/05/2011)	  
AGR34018	   	  (B/Novosibirsk/74/2012)	  
AET80607	   	  (B/Ohio/01/2011)	  
ABL76969	   	  (B/Osaka/547/1997)	  
ABL77200	   	  (B/Paraguay/636/2003)	  
AET10074	   	  (B/Sao	  Paulo/09-­‐949/2011)	  
AGB08299	   	  (B/Sao	  Paulo/10977/2012)	  
AFG48978	   	  (B/Selenge/1099/2012)	  
AGX20800	   	  (B/South	  Auckland/3/2011)	  
AEO80067	   	  (B/South	  Carolina/NHRC0001/2006)	  
ABL76738	   	  (B/St.	  Petersburg/14/2006)	  
AGX15808	   	  (B/Sydney/1/2009)	  
AGX20195	   	  (B/Sydney/202/2010)	  
AGX15940	   	  (B/Sydney/47/2011)	  
AEO80216	   	  (B/Taiwan/14/2007)	  
ACR15655	   	  (B/Taiwan/202/2005)	  
ACR15677	   	  (B/Taiwan/2643/2002)	  
ACF54334	   	  (B/Taiwan/70690/2006)	  
ACU12699	   	  (B/Tennessee/03/2009)	  
ACA64943	   	  (B/Tennessee/UR06-­‐0263/2007)	  
AGO05472	   	  (B/Texas/02/2013)	  
AGZ61728	   (B/Texas/23/2009)	  
ABN50602	   	  (B/Texas/37/1988)	  
AFR45694	   	  (B/Thailand/CU-­‐243/2006)	  
AFR45683	   	  (B/Thailand/CU-­‐364/2008)	  
AFR45881	   	  (B/Thailand/CU-­‐B2372/2010)	  
AFR45804	   	  (B/Thailand/CU-­‐B4585/2011)	  
AFR45672	   	  (B/Thailand/CU-­‐H1400/2010)	  
ADD01312	   	  (B/Ulaanbaatar/289/2010)	  
ABL77244	   	  (B/Victoria/02/1987)	  
AGX19304	   	  (B/Victoria/210/2007)	  
AGX18633	   	  (B/Victoria/307/2006)	  
AGX20140	   	  (B/Victoria/503/2010)	  




AGX15984	   	  (B/Waikato/7/2011)	  
ACV69972	   	  (B/Washington/01/2009)	  
AGX18622	   	  (B/Wellington/1/2006)	  
AGX15596	   	  (B/Wellington/85/2006)	  
AFU34595	   	  (B/Wuhan/4/2009)	  
ABF21279	   	  (B/Ann	  Arbor/1/1986)	  
BG85167	   	  (B/Lee/40)	  
ABQ81842	   	  (B/Russia/69)	  
	   	  
	   	  
  
Table 2. HA Accession numbers for phylogenetic tree. Accession numbers 
and corresponding virus names are listed for the HA phylogenetic tree presented 




Accession	  #	   Virus	  Name	  
AGO05311	   	  (B/Alabama/01/2013)	  
AGX21919	   	  (B/Auckland/1/2004)	  
AFH58304	   	  (B/Bangladesh/3333/2007)	  
AGX24095	   	  (B/Brisbane/29/2007)	  
AGX23314	   	  (B/Brisbane/4/2006)	  
ACF10282	   	  (B/California/01/2008)	  
AGO05592	   	  (B/California/01/2013)	  
AEO80097	   	  (B/California/NHRC0001/2004)	  
AEQ39440	   	  (B/California/NHRC0006/2005)	  
ACJ53899	   	  (B/Cheongju/411/2008)	  
AGX23578	   	  (B/Christchurch/18/2007)	  
AGX22007	   	  (B/Christchurch/33/2004)	  
ABL76749	   	  (B/Egypt/2040/2004)	  
AFH58326	   	  (B/England/145/2008)	  
AGZ61741	   	  (B/Finland/282/2009)	  
AGL09843	   	  (B/Florida/3277/2013)	  
ACF54246	   	  (B/Florida/4/2006)	  
ABN50437	   	  (B/Georgia/09/2005)	  
BAM37625	   	  (B/Hokkaido/FO/2012)	  
ABL76628	   	  (B/Houston/B720/2004)	  
ABL76650	   	  (B/Houston/B756/2005)	  
ABL76672	   	  (B/Houston/B846/2005)	  
ACG64219	   	  (B/Indiana/08/2008)	  
AGL05857	   	  (B/Iowa/01/2012)	  
ACF54180	   	  (B/Jilin/20/2003)	  
ACH53445	   	  (B/Kentucky/02/2006)	  
AEA51387	   	  (B/Kol/1013/2007)	  
AEA51395	   	  (B/Kol/N-­‐140/2009)	  
AFJ76323	   	  (B/Malaysia/1710547/2007)	  
AFJ91104	   	  (B/Malaysia/1919534/2008)	  
ACR15699	   	  (B/Managua/4705.02/2008)	  
ACA64910	   	  (B/Mississippi/UR06-­‐0031/2007)	  
AGL05763	   	  (B/New	  Hampshire/01/2012)	  
AGO05763	   	  (B/New	  Hampshire/02/2013)	  
ACA33498	   	  (B/New	  Jersey/01/2008)	  
AGL09864	   	  (B/Oklahoma/3298/2013)	  
AFF58918	   	  (B/Riyadh/02/2010)	  
AGX16061	   	  (B/Sydney/3/2004)	  
AGX23655	   	  (B/Sydney/502/2007)	  
AGX19425	   	  (B/Sydney/55/2008)	  
ACD56577	   	  (B/Taiwan/125/2004)	  
AEP20299	   	  (B/Texas/NHRC0001/2005)	  




AGX16193	   	  (B/Townsville/2/2005)	  
AFG49012	   	  (B/Ulaanbaatar/1798/2008)	  
AGX21974	   	  (B/Victoria/109/2004)	  
AGX16160	   	  (B/Victoria/503/2005)	  
AGX16149	   	  (B/Waikato/1/2005)	  
AGX23391	   	  (B/Waikato/1/2006)	  
AGZ59887	   	  (B/Wellington/7/2008)	  
AFH57953	   	  (B/Wisconsin/01/2010)	  
ACB11749	   	  (B/Wisconsin/04/2008)	  
ABL77134	   	  (B/Akita/27/2001)	  
ABN50646	   	  (B/Alaska/03/1992)	  
ABL76991	   	  (B/Ann	  Arbor/1994)	  
ABN50525	   	  (B/Argentina/132/2001)	  
AGX16962	   	  (B/Auckland/16/2002)	  
ABN50624	   	  (B/Bangkok/163/1990)	  
CAA37262	   	  (B/Beijing/1/1987)	  
AGX16599	   	  (B/Brisbane/2/2002)	  
AFX68905	   	  (B/Cambodia/V0112324/2011)	  
ABL77310	   	  (B/Connecticut/07/1993)	  
ABN50635	   	  (B/Cordoba/2979/1991)	  
ABN58661	   	  (B/Czechoslovakia/69/1990)	  
AFH58348	   	  (B/Fujian-­‐Gulou/1272/2008)	  
ABN50470	   	  (B/Hawaii/10/2001)	  
ABL77321	   	  (B/Hong	  Kong/02/1993)	  
ABL77288	   	  (B/Hong	  Kong/03/1992)	  
ABL77123	   	  (B/Hong	  Kong/167/2002)	  
ABL77266	   	  (B/Hong	  Kong/22/1989)	  
ABL76958	   	  (B/Hong	  Kong/70/1996)	  
AAD42316	   	  (B/Houston/1/91)	  
ABN50701	   	  (B/Johannesburg/06/1994)	  
ABR15995	   	  (B/Lisbon/02/1994)	  
AAU94719	   	  (B/Los	  Angeles/1/02)	  
AFJ80238	   	  (B/Malaysia/15048/1998)	  
AAD42311	   	  (B/Memphis/18/95)	  
AAD42309	   	  (B/Memphis/3/89)	  
AAU94720	   	  (B/Memphis/7/03)	  
ABL77156	   	  (B/Moscow/16/2002)	  
AAU94702	   	  (B/Nanchang/3/95)	  
AAD44192	   	  (B/Nanchang/5/97)	  
AAD44191	   	  (B/Nanchang/6/96)	  
AAU94710	   	  (B/Nanchang/6/98)	  
AAU94697	   	  (B/Nashville/45/91)	  
ABL76925	   	  (B/Nepal/1331/2005)	  




ABN51184	   	  (B/New	  York/39/1991)	  
ABL77299	   	  (B/Oita/15/1992)	  
AAA43702	   	  (B/Oregon/5/80)	  
ABL76969	   	  (B/Osaka/547/1997)	  
AAU94696	   	  (B/Panama/45/90)	  
ABL77200	   	  (B/Paraguay/636/2003)	  
ABL77277	   	  (B/Singapore/04/1991)	  
ABN50712	   	  (B/Singapore/11/1994)	  
CAA25425	   	  (B/Singapore/222/79)	  
ACR15677	   	  (B/Taiwan/2643/2002)	  
ABN51195	   	  (B/Texas/14/1991)	  
ABN50602	   	  (B/Texas/37/1988)	  
AFR45804	   	  (B/Thailand/CU-­‐B4585/2011)	  
ABL77189	   	  (B/Ulan-­‐Ude/6/2003)	  
ABL77244	   	  (B/Victoria/02/1987)	  
ABL77255	   	  (B/Yamagata/16/1988)	  
ABL76705	   	  (B/Alaska/12/1996)	  
ABL76848	   	  (B/Alaska/16/2000)	  
ABF21279	   	  (B/Ann	  Arbor/1/1986)	  
ABL77035	   	  (B/Argentina/3640/1999)	  
ABN50668	   	  (B/Bangkok/141/1994)	  
ABL84340	   	  (B/Brazil/975/2000)	  
ABL77365	   	  (B/California/01/1995)	  
AEP20387	   	  (B/California/NHRC0006/2006)	  
ABL76870	   	  (B/Canada/16188/2000)	  
ABN50569	   	  (B/Chile/3162/2002)	  
ABL76760	   	  (B/Florida/02/1998)	  
ABL77002	   	  (B/Georgia/04/1998)	  
AAK70482	   	  (B/Hong	  Kong/157/99)	  
AAO38870	   	  (B/Hong	  Kong/548/2000)	  
AAU94704	   	  (B/Houston/2/96)	  
ABL76353	   	  (B/Houston/B15/1999)	  
ABL76254	   	  (B/Houston/B56/1997)	  
ABN50723	   	  (B/Indiana/01/1995)	  
ABG85167	   	  (B/Lee/40)	  
AFJ80128	   	  (B/Malaysia/06535/1995)	  
AFJ80150	   	  (B/Malaysia/10928/1996)	  
AAD42314	   	  (B/Memphis/12/97)	  
AAU94716	   	  (B/Memphis/3/01)	  
ABL76815	   	  (B/Mexico/84/2000)	  
ABL77332	   	  (B/Mie/01/1993)	  
AEP20233	   	  (B/Missouri/NHRC0001/2001)	  
AEP20277	   	  (B/Missouri/NHRC0001/2003)	  




AAD44188	   	  (B/Nanchang/26/93)	  
AAD42326	   	  (B/Nashville/3/96)	  
AAU94717	   	  (B/Nebraska/1/01)	  
ACN32556	   	  (B/New	  York/347/1999)	  
ABL77024	   	  (B/Paris/549/1999)	  
ABN50734	   	  (B/Romania/318/1998)	  
ABL76936	   	  (B/Russia/22/1995)	  
ABQ81842	   	  (B/Russia/69)	  
ABL77057	   	  (B/Shizuoka/480/2000)	  
AAD42318	   	  (B/Sichuan/8/92)	  
ABL76980	   	  (B/Singapore/31/1998)	  
ABN50448	   	  (B/Singapore/35/1998)	  
ABN50580	   	  (B/South	  Carolina/04/2003)	  
AEP20211	   	  (B/South	  Carolina/NHRC0001/2000)	  
AEP20222	   	  (B/South	  Carolina/NHRC0001/2001)	  
AEP20244	   	  (B/South	  Carolina/NHRC0002/2001)	  
AAK70485	   	  (B/Switzerland/4291/97)	  
AGX21732	   	  (B/Sydney/200/2002)	  
ACF54257	   	  (B/Taiwan/45/2001)	  
ABR15973	   	  (B/Temple/B1190/2001)	  
ABL76331	   	  (B/Temple/B9/1999)	  
AAT69455	   	  (B/Victoria/504/2000)	  
ABL77101	   	  (B/Victoria/504/2000)	  
AAK70475	   	  (B/Vienna/1/99)	  
ABL77354	   	  (B/Wellington/01/1994)	  
ABN50503	   	  (B/Yamanashi/166/1998)	  
ACA33483	   	  (B/Alaska/01/2007)	  
AGI64373	   	  (B/Alaska/01/2011)	  
AGX19480	   	  (B/Auckland/23/2008)	  
AFH58447	   	  (B/Bangladesh/5945/2009)	  
AGX20129	   	  (B/Brisbane/1/2010)	  
AGX20745	   	  (B/Brisbane/13/2011)	  
AGX15662	   	  (B/Brisbane/33/2008)	  
AGI63978	   	  (B/California/01/2011)	  
AEP20321	   	  (B/California/NHRC0004/2003)	  
AGI64011	   	  (B/Colorado/01/2011)	  
AGL05756	   	  (B/Delaware/01/2012)	  
ADY16757	   	  (B/Denmark/11/2011)	  
AGI64004	   	  (B/Florida/02/2011)	  
ACU12701	   	  (B/Florida/04/2009)	  
AET80614	   	  (B/Georgia/01/2011)	  
AET21680	   	  (B/Georgia/02/2010)	  
ABL76837	   	  (B/Hawaii/11/2004)	  




ABL77112	   	  (B/Hong	  Kong/310/2004)	  
ABL76584	   	  (B/Houston/B84/2003)	  
ABN50459	   	  (B/Illinois/13/2005)	  
ACA96563	   	  (B/Illinois/UR06-­‐0016/2007)	  
AET21612	   	  (B/Iowa/01/2010)	  
AFB77681	   	  (B/Kenya/104/2011)	  
AEG21020	   	  (B/Kol/1373/2008)	  
AEG21029	   	  (B/Kol/273/2010)	  
AEG21014	   	  (B/Kol/515/2006)	  
AEG21026	   	  (B/Kol/N-­‐2121/2010)	  
ACR15732	   	  (B/Malaysia/2506/2004)	  
AFJ80803	   	  (B/Malaysia/30589/2005)	  
AFJ80869	   	  (B/Malaysia/33808/2006)	  
AEQ39315	   	  (B/Managua/3323.01/2010)	  
AET22082	   	  (B/Massachusetts/01/2010)	  
AGI64344	   	  (B/Michigan/01/2011)	  
AET80612	   	  (B/Minnesota/01/2011)	  
ACA64976	   	  (B/Mississippi/UR06-­‐0340/2007)	  
AGG86691	   	  (B/Nanjing/1521/2011)	  
AGI63971	   	  (B/Nebraska/01/2011)	  
ACA33492	   	  (B/New	  Jersey/02/2007)	  
AGL05234	   	  (B/New	  Mexico/01/2012)	  
AGR34013	   	  (B/Novosibirsk/05/2011)	  
AGR34018	   	  (B/Novosibirsk/74/2012)	  
AET80607	   	  (B/Ohio/01/2011)	  
AET10074	   	  (B/Sao	  Paulo/09-­‐949/2011)	  
AGB08299	   	  (B/Sao	  Paulo/10977/2012)	  
AFG48978	   	  (B/Selenge/1099/2012)	  
AGX20800	   	  (B/South	  Auckland/3/2011)	  
AEP20288	   	  (B/South	  Carolina/NHRC0001/2004)	  
AEO80067	   	  (B/South	  Carolina/NHRC0001/2006)	  
ABL76738	   	  (B/St.	  Petersburg/14/2006)	  
AGX15808	   	  (B/Sydney/1/2009)	  
AGX20195	   	  (B/Sydney/202/2010)	  
AGX15940	   	  (B/Sydney/47/2011)	  
AEO80216	   	  (B/Taiwan/14/2007)	  
ACR15655	   	  (B/Taiwan/202/2005)	  
ACF54334	   	  (B/Taiwan/70690/2006)	  
ABL76529	   	  (B/Temple/B21/2003)	  
ACU12699	   	  (B/Tennessee/03/2009)	  
ACA64943	   	  (B/Tennessee/UR06-­‐0263/2007)	  
AGO05472	   	  (B/Texas/02/2013)	  
AGZ61728	   	  (B/Texas/23/2009)	  




AFR45683	   	  (B/Thailand/CU-­‐364/2008)	  
AFR45881	   	  (B/Thailand/CU-­‐B2372/2010)	  
AFR45672	   	  (B/Thailand/CU-­‐H1400/2010)	  
ADD01312	   	  (B/Ulaanbaatar/289/2010)	  
AGX19304	   	  (B/Victoria/210/2007)	  
AGX18633	   	  (B/Victoria/307/2006)	  
AGX20140	   	  (B/Victoria/503/2010)	  
ACU12724	   	  (B/Virginia/02/2009)	  
AGX17620	   	  (B/Waikato/6/2005)	  
AGX15984	   	  (B/Waikato/7/2011)	  
ACV69972	   	  (B/Washington/01/2009)	  
AGX18622	   	  (B/Wellington/1/2006)	  
AGX15596	   	  (B/Wellington/85/2006)	  






Table 2. NA Accession numbers for phylogenetic tree. Accession numbers 
and corresponding virus names are listed for the NA phylogenetic tree presented 
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